WO2011041461A2 - Polycyclic compounds as lysophosphatidic acid receptor antagonists - Google Patents

Polycyclic compounds as lysophosphatidic acid receptor antagonists Download PDF

Info

Publication number
WO2011041461A2
WO2011041461A2 PCT/US2010/050786 US2010050786W WO2011041461A2 WO 2011041461 A2 WO2011041461 A2 WO 2011041461A2 US 2010050786 W US2010050786 W US 2010050786W WO 2011041461 A2 WO2011041461 A2 WO 2011041461A2
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
isoxazol
compound
biphenyl
cyclopropanecarboxylic acid
Prior art date
Application number
PCT/US2010/050786
Other languages
French (fr)
Other versions
WO2011041461A3 (en
Inventor
Ryan Clark
Brian Andrew Stearns
Lucy Zhao
Thomas Jon Seiders
Deborah Volkots
Jeannie M. Arruda
David Nathan Zalatan
Original Assignee
Amira Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43128100&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2011041461(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CN201080054537.6A priority Critical patent/CN102656168B/en
Priority to MX2012003723A priority patent/MX2012003723A/en
Priority to EA201270467A priority patent/EA201270467A1/en
Priority to BR112012007102A priority patent/BR112012007102A2/en
Priority to JP2012532286A priority patent/JP2013506679A/en
Application filed by Amira Pharmaceuticals, Inc. filed Critical Amira Pharmaceuticals, Inc.
Priority to CA2776779A priority patent/CA2776779A1/en
Priority to EP10821201.0A priority patent/EP2483269A4/en
Priority to IN2702DEN2012 priority patent/IN2012DN02702A/en
Priority to AU2010300594A priority patent/AU2010300594A1/en
Publication of WO2011041461A2 publication Critical patent/WO2011041461A2/en
Publication of WO2011041461A3 publication Critical patent/WO2011041461A3/en
Priority to TNP2012000126A priority patent/TN2012000126A1/en
Priority to IL218962A priority patent/IL218962A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • R D is H or Ci-C 6 alkyl
  • L 4 is absent, or a substituted or unsubstituted C 1 -C4 alkylene, where if L 4 is
  • ring A is a substituted or unsubstituted 5-membered monocyclic Ci-C 4 heteroarylene containing 1-4 N atoms, 0 or 1 O atoms and 0 or 1 S atoms, where if ring A is substituted, then ring A is substituted with 1 or 2 R 14 .
  • the compound of Formula (I) is an antagonist of LPA 3 .
  • presented herein are compounds selected from active metabolites, tautomers, solvates, pharmaceutically acceptable salts or prodrugs of a compound of Formula (I).
  • the one or more additional therapeutically active agents other than a compound of Formula (I) are selected from: corticosteroids, immunosuppresants, analgesics, anti-cancer agent, anti-inflammatories, chemokine receptor antagonists, bronchodilators, leukotriene receptor antagonists, leukotriene formation inhibitors, monoacylglycerol kinase inhibitors, phospholipase A 1 inhibitors, phospholipase A 2 inhibitors, and lysophospholipase D (lysoPLD) inhibitors, autotaxin inhibitors,
  • NASH steatohepatitis
  • biliary duct injury primary biliary cirrhosis
  • infection induced liver fibrosis viral induced liver fibrosis
  • autoimmune hepatitis corneal scarring
  • scleroderma spinal cord injury/fibrosis; myelofibrosis; vascular restenosis; atherosclerosis; arteriosclerosis; Wegener's granulomatosis; Peyronie's disease, chronic lymphocytic leukemia, tumor metastasis, transplant organ rejection, endometreosis, neonatal respiratory distress syndrome and neuropathic pain.
  • compounds disclosed herein are used to treat post-transplant fibrosis associated with chronic rejection in a mammal: Bronchiolitis obliterans for lung transplant.
  • the mammal is a human.
  • LPA and LPAi are involved in the etiology of kidney fibrosis.
  • LPAi LPAi receptor
  • UUO animal model of renal fibrosis mice treated with the LPA receptor antagonist Ki 16425 closely resembled the LPAi ( ⁇ / ⁇ ) mice.
  • a mammal suffering from one of the following non-limiting exemplary diseases, disorders, or conditions will benefit from therapy with a compound of Formula (I): atherosclerosis, thrombosis, heart disease, vasculitis, formation of scar tissue, restenosis, phlobitis, COPD (chronic obstructive pulmonary disease), pulmonary hypertension, pulmonary fibrosis, pulmonary inflammation, bowel adhesions, bladder fibrosis and cystitis, fibrosis of the nasal passages, sinusitis, inflammation mediated by neutrophils, and fibrosis mediated by fibroblasts.
  • atherosclerosis atherosclerosis, thrombosis, heart disease, vasculitis, formation of scar tissue, restenosis, phlobitis, COPD (chronic obstructive pulmonary disease), pulmonary hypertension, pulmonary fibrosis, pulmonary inflammation, bowel adhesions, bladder fibrosis and cystitis, fibrosis of the nasal passages, sinusitis
  • the nervous system is a major locus for LPAi expression.
  • a compound of Formula (I) for use in the treatment or prevention of a nervous system disorder in a mammal.
  • the term "nervous system disorder,” as used herein includes, but is not limited to, Alzheimer's Disease, cerebral edema, cerebral ischemia, stroke, multiple sclerosis, neuropathies, Parkinson's Disease, multiple sclerosis, retinal ischemia, postsurgical cognitive dysfunction, migraine, peripheral neuropathy/neuropathic pain, spinal cord injury, cerebral edema and head injury.
  • LPA-dependent conditions or diseases include those wherein an absolute or relative excess of LPA is present and/or observed.
  • the LPA-dependent or LPA-mediated diseases or conditions include, but are not limited to, organ fibrosis, asthma, allergic disorders, chronic obstructive pulmonary disease, pulmonary hypertension, lung or pleural fibrosis, peritoneal fibrosis, arthritis, allergy, cancer, cardiovascular disease, aldult respiratory distress syndrome, myocardial infarction, aneurysm, stroke, and cancer.
  • R E is Ci-C 6 alkyl or a substituted or unsubstituted phenyl
  • r is 1 or 2. In some embodiments, r is 1.
  • ring A is a substituted or unsubstituted phenyl, or a substituted or unsubstituted monocyclic Ci-Csheteroarylene, where if ring A is substituted, then ring A is substituted with 1 or 2 R 14 .
  • ring A is a substituted or unsubstituted monocyclic Ci- Csheteroarylene containing 1-4 N atoms, 0 or 1 O atoms and 0 or 1 S atoms, where if ring A is substituted, then ring A is substituted with 1 or 2 R 14 .
  • compounds described herein may coordinate with an organic base, such as, but not limited to, ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, dicyclohexylamine, tris(hydroxymethyl)methylamine.
  • compounds described herein may form salts with amino acids such as, but not limited to, arginine, lysine, and the like.
  • Acceptable inorganic bases used to form salts with compounds that include an acidic proton include, but are not limited to, aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like.
  • a sodium salt of the compound of Formula (I) is prepared.
  • the effective amount of the compound of Formula (I) is: (a) systemically administered to the mammal; and/or (b) administered orally to the mammal; and/or (c) intravenously administered to the mammal; and/or (d) administered by inhalation to the mammal; and/or (e) administered by nasal administration to the mammal; or and/or (f) administered by injection to the mammal; and/or (g) administered topically to the mammal; and/or (h) administered by ophthalmic administration; and/or (i) administered rectally to the mammal; and/or (j) adminstered non- systemically or locally to the mammal.
  • compounds of Formula (I) are prepared as transdermal dosage forms.
  • Step 9 l-[4-(4,4,5,5-Tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]- cyclopropanecarboxylic acid ethyl ester: l-(4-Bromo-phenyl)-cyclopropanecarboxylic acid ethyl ester (3.6 g, 13.4 mmol), bis(pinacolato)diboron (3.37 g, 16.1 mmol), and potassium acetate (2.8 g, 29.0 mmol) were combined in 1,4-dioxane (30 mL) under N 2 atmosphere.
  • Step 10 l-[4'-(4-tei"i-Butoxycarbonylamino-3-methyl-isoxazol-5-yl)-biphenyl-4- yl]-cyclopropanecarboxylic acid ethyl ester: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4- yl]-carbamic acid tert-butyl ester (2.0 g, 5.6 mmol), l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester (1.78 g, 5.6 mmol), tetrakis(triphenylphosphine)palladium(0) (0.65 g, 0.56 mmol), and sodium bicarbonate (1.4 g, 16.8 mmol) were combined in DME (30 ).
  • Step 2 l-(4'- ⁇ 3-Methyl-4-[(5-phenyl-[l,3,4]oxadiazol-2-ylamino)-methyl]- isoxazol-5-yl ⁇ -biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using [5-(4-bromo-phenyl)-3- methyl-isoxazol-4-ylmethyl]-(5-phenyl-[l,3,4]oxadiazol-2-yl)-amine and l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
  • Step 3 The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 3.
  • Step 2 l-[4'-(4- ⁇ [l-(4-Chloro-benzyl)-lH-[l,2,3]triazol-4-yl]-hydroxy-methyl ⁇ - 3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester:
  • Step 1 ((S)-l-Bromo-ethyl)-benzene: Bromine (3.2 g, 20.0 mmol) was added to a suspension of triphenylphosphine (5.2 g, 19.8 mmol) stirring in ACN at -15 °C. The reaction was warmed to room temperature and stirred for 50 mintues then cooled to -35 °C and (Pv)-(+)-l-phenylethanol (1.6 g, 13.1 mmol) was added. The reaction was allowed to warm to -10 °C over 70 minutes and was then quenched with H 2 0 and submitted to standard aqueous workup to afford the title compound which was used without further purification.
  • Step 2 (6-Benzyl-pyridin-2-yl)-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]- methanol: Prepared according to the procedure described in Example 34, Step 3, using 5- (4-bromo-phenyl)-3-methyl-isoxazole-4-carbaldehyde and 2-benzyl-6-bromo-pyridine.
  • Step 2 l-[4'-(4- ⁇ Hydroxy-[l-(2-methyl-benzyl)-lH-[l,2,3]triazol-4-yl]-methyl ⁇ - 3-methyl-isoxazol-5-yl)-biphenyl-4-yl] -cyclopropanecarboxylic acid ethyl ester:
  • Step 1 2-Bromo-6-phenyl-pyrazine: Prepared according to the procedure described in Example 1, Step 10, using 2,6-dibromo-pyrazine and phenylboronic acid. Additionally, (l, -bis(diphenylphosphino)ferrocene)-dichloropalladium(II) was used as the catalyst in place of tetrakis(triphenylphosphine)palladium(0).
  • Step 2 l- ⁇ 4'-[3-Methyl-4-(6-phenyl-pyrazin-2-ylamino)-isoxazol-5-yl]-biphenyl- 4-yl ⁇ -cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)-biphenyl-4- yl]-cyclopropanecarboxylic acid ethyl ester and 2-bromo-6-phenyl-pyrazine.
  • Step 3 l- ⁇ 4'-[4-(5-Benzyl-[l,3,4]oxadiazol-2-ylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl ⁇ -cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using (5-benzyl-[l,3,4]oxadiazol-2-yl)-[5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-amine and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
  • Step 3 l-(4'- ⁇ 4-[6-(2-Fluoro-benzyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5- yl ⁇ -biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 2-bromo-6-(2-fluoro-benzyl)- pyridine.
  • Step 3 l-(4'- ⁇ 4-[6-(3-Fluoro-benzyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5- yl ⁇ -biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 2-bromo-6-(3-fluoro-benzyl)- pyridine.
  • Step 3 l-(4'- ⁇ 4-[6-(4-Fluoro-benzyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5- yl ⁇ -biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 2-bromo-6-(4-fluoro-benzyl)- pyridine.
  • Step 1 l- ⁇ 4'-[4-(3-Benzyl-phenylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl ⁇ - cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester and l-benzyl-3-bromo-benzene.
  • Step 3 The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 3.
  • Step 1 l-[4'-(4- ⁇ Hydroxy-[5-(3-trifluoromethyl-phenyl)-pyridin-3-yl]-methyl ⁇ - 3-methyl-isoxazol-5-yl)-biphenyl-4-yl] -cyclopropanecarboxylic acid ethyl ester:
  • Step 1 l- ⁇ 4'-[3-Methyl-4-(6-phenylethynyl-pyridin-2-ylamino)-isoxazol-5-yl]- biphenyl-4-yl ⁇ -cyclopropanecarboxylic acid ethyl ester: l- ⁇ 4'-[4-(6-Bromo-pyridin-2- ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl ⁇ -cyclopropanecarboxylic acid ethyl ester (0.200 g, 0.386 mmol) was dissolved in toluene along with phenylacetylene (0.051 mL, 0.46 mmol), copper(I) iodide (0.367 g, 1.93 mmol), triethylamine (0.269 mL, 1.93 mmol) and bis(triphenylphosphine)pal
  • Step 2 The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
  • Step 2 The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
  • Step 3 The ester from Step 2 was hydrolyzed to the acid according to the procedure described in Example 3.
  • Example 103 Synthesis of l-(4'- ⁇ 4-[5-(2,5-Difluoro-phenyl)-pyridin-3-ylamino]-3- methyl-isoxazol-5-yl ⁇ -biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 89)
  • Step 1 l-(4'- ⁇ 4-[6-(3-Chloro-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5- yl ⁇ -biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using l- ⁇ 4'-[4-(6-bromo-pyridin-2-ylamino)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl ⁇ -cyclopropanecarboxylic acid ethyl ester and 3- chlorophenylboronic acid. (1,1 '-bis(diphenylphosphino)ferrocene)-dichloropalladium(II) was used in place of tetrakis(triphenylphosphine)palladium(0).
  • Step 7 l-[4'-(4-Amino-3-ethyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 11, using l-[4'-(4-tert-butoxycarbonylamino-3-ethyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester.
  • Example 109 Establishment of a CHO Cell Line Stably Expressing Human LPA 3
  • the full-length cDNA fragment for human LP A3 was obtained by PCR from the vector.
  • the nucleotide sequence of the cloned human LPA 3 was determined by sequencing and confirmed to be identical to the published human LP A3 sequence (NCBI accession number NM 012152).
  • the cDNA was cloned into the pCDNA5/FRT expression plasmid and transfected in CHO cells using lipofectamine 2000 (Invitrogen Corp., USA). Clones stably expressing human LPA 3 were selected using hygromycin and identified as cells that show Ca-influx in response to LPA.
  • A less than 0.3 ⁇
  • B greater than 0.3 ⁇ and less than 1 ⁇
  • mice are returned to their cages and monitored daily for the duration of the experiment.
  • Test compound or vehicle is delivered po, ip or sc daily. The route and frequency of dosing is based on previously determined
  • BALF is centrifuged for 10 min at 800 x g to pellet the cells and the cell supernatant removed and frozen at -80 °C for subsequent protein analysis using the DC protein assay kit (Biorad, Hercules, CA.) and soluble collagen analysis using Sircol (Biocolor Ltd, UK).
  • BALF is analyzed for concentrations of inflammatory, pro-fibrotic and tissue injury biomarkers including transforming growth factor ⁇ , hyaluronic acid, tissue inhibitor of metalloproteinase-1, matrix matelloproteinase- 7, connective tissue growth factor and lactate dehydrogenase activity, using commercially available ELISA.
  • the cell pellet is re-suspended in PBS.
  • kidneys are harvested and one half of the kidney is frozen at -80°C and the other half is fixed in 10% neutral buffered formalin for histological assessment of kidney fibrosis using light microscopy (lOx magnification).
  • Kidney tissue homogenates are analyzed for collagen levels using Sircol (Biocolor Ltd, UK). Fixed kidney tissue is also stained using hematoxylin and eosin (H&E) and trichrome and kidney fibrosis is determined by quantitative, computer-assisted densitometry of collagen in liver tissue sections using light microscopy and collagen content in kidney lysate.
  • H&E hematoxylin and eosin
  • Plasma and kidney tissue lysates are also analyzed for concentrations of inflammatory, pro-fibrotic and tissue injury biomarkers including transforming growth factor ⁇ , hyaluronic acid, tissue inhibitor of metalloproteinase-1, and plasminogen activator inhibitor -1, using commercially available ELISA.
  • the resulting data are plotted using Graphpad prism and statistical differences between groups determined.
  • a pharmaceutical composition for oral delivery 100 mg of a compound of Formula (I) is mixed with 750 mg of starch. The mixture is incorporated into an oral dosage unit for, such as a hard gelatin capsule, which is suitable for oral administration.
  • Example 121 Sublingual (Hard Lozenge) Pharmaceutical Composition
  • a pharmaceutical composition for buccal delivery such as a hard lozenge
  • a pharmaceutical composition for buccal delivery such as a hard lozenge
  • the mixture is gently blended and poured into a mold to form a lozenge suitable for buccal administration.
  • a pharmaceutical opthalmic solution composition 100 mg of a compound of Formula (I) is mixed with 0.9 g of NaCl in 100 mL of purified water and filterd using a 0.2 micron filter. The resulting isotonic solution is then incorporated into ophthalmic delivery units, such as eye drop containers, which are suitable for ophthalmic administration.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Description

POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR
ANTAGONISTS
RELATED APPLICATIONS
[0001] This application claims benefit of U.S. Provisional Application No. 61/247,877, entitled "POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS" filed on October 1, 2009, which is herein incorporated by reference.
FIELD OF THE INVENTION
[0002] Described herein are compounds, methods of making such compounds,
pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders or conditions associated with one or more of the lysophosphatidic acid (LPA) receptors.
BACKGROUND OF THE INVENTION
[0003] Lysophospholipids are membrane-derived bioactive lipid mediators.
Lysophospholipids affect fundamental cellular functions that include proliferation, differentiation, survival, migration, adhesion, invasion, and morphogensis. These functions influence many biological processes that include, but are not limited to, neurogensis, angiogenesis, wound healing, fibrosis, immunity, and carcinogenesis.
[0004] Lysophosphatidic acid (LPA) is a lysophospholipid that has been shown to act through sets of specific G protein-coupled receptors (GPCRs) in an autocrine and paracrine fashion. LPA binding to its cognate GPCRs (LPAi, LPA2, LPA3, LPA4, LPA5, LPA6) activates intracellular signaling pathways to produce a variety of biological responses. Antagonists of the LPA receptors find use in the treatment of diseases, disorders or conditions in which LPA plays a role.
SUMMARY OF THE INVENTION
[0005] In one aspect, presented herein are compounds of Formula (I) that inhibit the physiological activity of lysophosphatidic acid (LPA), and therefore, are useful as agents for the treatment or prevention of diseases in which inhibition of the physiological activity of LPA is useful, such as diseases in which an LPA receptor participates, is involved in the etiology or pathology of the disease, or is otherwise associated with at least one symptom of the disease. [0006] In one aspect, the compounds of Formula (I) are useful for the treatment of fibrosis of organs (liver, kidney, lung, heart and the like), liver diseases (acute hepatatis, chronic hepatitis, liver fibrosis, liver cirrhosis, portal hypertension, regenerative failure, nonalcoholic steatohepatitis (NASH), liver hypofunction, hepatic blood flow disorder, and the like), cell proliferative disease (cancer (solid tumor, solid tumor metastasis, vascular fibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leukemia, chronic lymphocytic leukemia (CLL) and the like) and invasive metastasis of cancer cell, and the like), inflammatory disease (psoriasis, nephropathy, pneumonia and the like), gastrointestinal tract disease (irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), abnormal pancreatic secretion, and the like), renal disease, urinary tract-associated disease (benign prostatic hyperplasia or symptoms associated with neuropathic bladder disease, spinal cord tumor, hernia of intervertebral disk, spinal canal stenosis, symptoms derived from diabetes, lower urinary tract disease (obstruction of lower urinary tract, and the like), inflammatory disease of lower urinary tract, dysuria, frequent urination, and the like), pancreas disease, abnormal angiogenesis-associated disease (arterial obstruction and the like), scleroderma, brain-associated disease (cerebral infarction, cerebral hemorrhage, and the like),
neuropathic pain, peripheral neuropathy, and the like, ocular disease (age-related macular degeneration (AMD), diabetic retinopathy, proliferative vitreoretinopathy (PVR), cicatricial pemphigoid, glaucoma filtration surgery scarring, and the like). In one aspect, the compounds of Formula (I) are used in the treatment of fibrotic diseases or conditions.
[0007] In one aspect, described herein are compounds of Formula (I), pharmaceutically acceptable salts, solvates, and prodrugs thereof. Compounds of Formula (I) are antagonists of at least one of the LPA receptors selected from LPAi, LPA2, LPA3, LPA4, LPA5 and LPA6. In one embodiment, compounds of Formula (I) are antagonists of LPAi. In one embodiment, compounds of Formula (I) are antagonists of LPAi and/or LPA3. In some embodiments, compounds of Formula (I) are antagonists of LPAi and/or LPA2. In some embodiments, compounds of Formula (I) are selective antagonists for one of the LPA receptors relative to the other LPA receptors. In some embodiments, such a selective antagonist is selective for the LPAi receptor. In some embodiments, such a selective antagonist is selective for the LPA2 receptor. In some embodiments, such a selective antagonist is selective for the LPA3 receptor.
[0008] Compounds of Formula (I) are used in the treatment of diseases, disorders, or conditions in which activation of at least one LPA receptor by LPA contributes to the symptomology or progression of the disease, disorder or condition. In one aspect, the methods, compounds, pharmaceutical compositions, and medicaments described herein comprise antagonists of LP A receptor(s). In one aspect, the methods, compounds, pharmaceutical compositions, and medicaments described herein comprise antagonists of LPAi, LPA2, or LP A3, or combinations thereof.
[0009] In one aspect, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof:
Figure imgf000005_0001
Formula (I)
wherein,
ft1 is -C02PvD,
Figure imgf000005_0002
-C(=0)N(RD)2, -CN, or tetrazolyl;
RD is H or Ci-C6 alkyl;
REis Ci-C6 alkyl or a substituted or unsubstituted phenyl;
L2 is absent, -C(=0)-, -N(RD)-, substituted or unsubstituted C1-C4 alkylene, or
substituted or unsubstituted C1-C4 heteroalkylene, where if L2 is substituted, then L2 is substituted with R12, where R12 is F, Ci-C4alkyl, -OH, or -ORD; ring A is a substituted or unsubstituted phenyl, or a substituted or unsubstituted monocyclic Ci-Csheteroarylene, where if ring A is substituted, then ring A is substituted with 1 or 2 R14, each R14 is independently selected from halogen, - CN, -OH, Ci-C4alkyl, Ci-C4fluoroalkyl, Ci-C4fluoroalkoxy, Ci-C4alkoxy, and Ci-C4heteroalkyl;
L4 is absent, or a substituted or unsubstituted C1-C4 alkylene, where if L4 is
substituted then L4 is substituted with R13, where R13 is F, Ci-C4alkyl, -OH, or -ORD;
R5 is H or C C4 alkyl;
each RA is independently selected from halogen, -CN, -OH, Ci-C4alkyl, Ci- C4fluoroalkyl, Ci-C4fluoroalkoxy, Ci-C4alkoxy, and Ci-C4heteroalkyl; each R is independently selected from halogen, -CN, -OH, Ci-C4alkyl, Ci- C4fluoroalkyl, Ci-C4fluoroalkoxy, Ci-C4alkoxy, and Ci-C4heteroalkyl;
each R is independently selected from halogen, -CN, -OH, Ci-C4alkyl, Ci- C4fluoroalkyl, Ci-C4fluoroalkoxy, Ci-C4alkoxy, and Ci-C4heteroalkyl;
m is 0, 1 or 2; n is 0, 1 or 2; p is 0, 1 or 2; r is 1 , 2, 3, or 4.
[0010] For any and all of the embodiments, substituents are selected from among from a subset of the listed alternatives. For example, in some embodiments, R1 is -C02RD or - C(=0)NHS02RE In some embodiments, R1 is -C02RD. In some embodiments, R1 is - C02H. In some embodiments, R1 is -C(=0)NHS02RE In some embodiments, R is Ci-C6 alkyl. In some embodiments, RE is -CH3 or -CH2CH3. In some embodiments, RD is -CH3 or -CH2CH3.
[0011] In some embodiments, R1 is -C02RD, or -C(=0)NHS02RE; L2 is absent, -C(=0)-, - NH-, -N(CH3)-, -CH2-, -CH2CH2-, -CH(CH3)-, -CH2CH(CH3)-, -CH(CH3)CH2-, -CH(OH)-, -CH(ORD)-, -CH2CH(OH)-, -CH2CH(ORD)-, -CH(OH)CH2-, -CH(ORD)CH2-, -CH2NH-, - CH(CH3)NH-, -NHCH2- or -NHCH(CH3)-; L4 is absent, -CH2-, -CH(CH3)-, -CH(OH)-, - CH2CH2-, -CH2CH(CH3)-, -CH(CH3)CH2-, -CH2CH(OH)-, or -CH(OH)CH2-; R5 is -H, - CH3 or -CH2CH3; m is 0 or 1 ; n is 0 or 1 ; r is 1 , 2, or 3.
[0012] In some embodiments, L2 is -NH-, -CH2-, -CH2CH2-, -CH(CH3)-, -CH2CH(CH3)-, - CH(CH3)CH2-, -CH(OH)-, -CH2CH(OH)-, -CH(OH)CH2-, -CH2NH-, -CH(CH3)NH-, - NHCH2- or -NHCH(CH3)-; ring A is a substituted or unsubstituted phenyl, or a substituted or unsubstituted monocyclic Ci-Csheteroarylene containing 1-4 N atoms, 0 or 1 O atoms and 0 or 1 S atoms, where if ring A is substituted, then ring A is substituted with 1 or 2 R14; L4 is absent, -CH2-, or -CH(CH3)-; R5 is -CH3; r is 1.
[0013] In some embodiments, ring A is a substituted or unsubstituted phenyl, where if ring A is substituted, then ring A is substituted with 1 or 2 R14.
[0014] In some embodiments, ring A is a substituted or unsubstituted monocyclic Ci- Csheteroarylene containing 1-4 N atoms, 0 or 1 O atoms and 0 or 1 S atoms, where if ring A is substituted, then ring A is substituted with 1 or 2 R14.
[0015] In some embodiments, ring A is a substituted or unsubstituted 5-membered monocyclic Ci-C4heteroarylene containing 1-4 N atoms, 0 or 1 O atoms and 0 or 1 S atoms, where if ring A is substituted, then ring A is substituted with 1 or 2 R14.
[0016] In some embodiments, ring A is a substituted or unsubstituted furanyl, a substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted pyrazolyl, substituted or unsubstituted triazolyl, substituted or unsubstituted tetrazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted isothiazolyl, substituted or unsubstituted oxadiazolyl, or substituted or unsubstituted
Figure imgf000007_0001
[0018] In some embodiments, ring A is a substituted or unsubstituted 6-membered monocyclic Cs-Csheteroarylene containing 1-3 N atoms, where if ring A is substituted, then ring A is substituted with 1 or 2 R
Figure imgf000007_0002
Figure imgf000008_0001
[0020] In some embodiments, the compound of Formula (I) has the structure of Formula (II):
Figure imgf000008_0002
Formula (II).
[0021] In some embodiments, R1 is -C02RD, or -C(=0)NHS02RE; RD is H or Ci-C4 alkyl; RE is Ci-C4 alkyl; L2 is -CH2-, -CH(CH3)-, or -CH(OH)-; ring A is a substituted or unsubstituted 5-membered monocyclic Ci-C4heteroarylene containing 1-4 N atoms and 0 or 1 O atoms, where if ring A is substituted, then ring A is substituted with R14; L4 is -CH2- or -CH(CH3)-; p is 0 or 1.
[0022] In some embodiments, R1 is -C02RD, or -C(=0)NHS02RE; RD is H or Ci-C4alkyl;
RE is Ci-C4alkyl; L2 is -NH-, -CH2-, -CH(CH3)-, -CH(OH)-, -NHCH2- or -NHCH(CH3)-; ring A is a substituted or unsubstituted pyridinylene, where if ring A is substituted, then ring
A is substituted with R14; L4 is absent, -CH2-, or -CH(CH3)-; p is 0 or 1.
[0023] Any combination of the groups described above for the various variables is contemplated herein. Throughout the specification, groups and substituents thereof are chosen by one skilled in the field to provide stable moieties and compounds.
[0024] In one aspect, provided are compounds presented in Tables 1 to 3 and Figures 1 to
11.
[0025] Compounds of Formula (I) are antagonists of at least one LPA receptor. In some embodiments, the compound of Formula (I) is an antagonist of LPAi. In some
embodiments, the compound of Formula (I) is an antagonist of LPA2. In some
embodiments, the compound of Formula (I) is an antagonist of LPA3. [0026] In some embodiments, presented herein are compounds selected from active metabolites, tautomers, solvates, pharmaceutically acceptable salts or prodrugs of a compound of Formula (I).
[0027] In some embodiments, provided is a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I). In some embodiments, the pharmaceutical composition also contains at least one pharmaceutically acceptable inactive ingredient.
[0028] In some embodiments, provided is a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable inactive ingredient. In one aspect, the pharmaceutical composition is formulated for intravenous injection, subcutaneous injection, oral administration, inhalation, nasal administration, topical administration, ophthalmic administration or otic administration. In some embodiments, the pharmaceutical composition is a tablet, a pill, a capsule, a liquid, an inhalant, a nasal spray solution, a suppository, a suspension, a gel, a colloid, a dispersion, a suspension, a solution, an emulsion, an ointment, a lotion, an eye drop or an ear drop.
[0029] In some embodiments, the pharmaceutical composition further comprises one or more additional therapeutically active agents other than a compound of Formula (I).
[0030] In some embodiments, provided is a method comprising administering a compound of Formula (I) to a human with a LPA-dependent or LPA-mediated disease or condition. In some embodiments, the human is already being administered one or more additional therapeutically active agents other than a compound of Formula (I). In some embodiments, the method further comprises administering one or more additional therapeutically active agents other than a compound of Formula (I).
[0031] In some embodiments, the one or more additional therapeutically active agents other than a compound of Formula (I) are selected from: corticosteroids, immunosuppresants, analgesics, anti-cancer agent, anti-inflammatories, chemokine receptor antagonists, bronchodilators, leukotriene receptor antagonists, leukotriene formation inhibitors, monoacylglycerol kinase inhibitors, phospholipase A1 inhibitors, phospholipase A2 inhibitors, and lysophospholipase D (lysoPLD) inhibitors, autotaxin inhibitors,
decongestants, antihistamines, mucolytics, anticholinergics, antitussives, expectorants, and β-2 agonists. [0032] In another aspect is the use of a compound of Formula (I) in the treatment of a disease, disorder or condition in which the activity of at least one LPA receptor contributes to the pathology and/or symptoms of the disease or condition. In one embodiment of this aspect, the LPA receptor is selected from LPAi, LPA2, LPA3, LPA4, LPA5 and LPA6. In some embodiments, the LPA receptor is LPAi or LPA2 or LPA3. In some embodiments, the disease or condition is any of the diseases or conditions specified herein.
[0033] Also provided is a method of inhibiting the physiological activity of LPA in a mammal comprising administering a therapuetically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof to the mammal in need thereof.
[0034] In one aspect, is a method for treating or preventing a LPA-dependent or LPA- mediated disease or condition in a mammal comprising administering a therapuetically effective amount of a compound of Formula (I).
[0035] In one aspect, LPA-dependent or LPA-mediated diseases or conditions include, but are not limited to, fibrosis of organs or tissues, scarring, liver diseases, dermatological conditions, cancer, cardiovascular disease, respiratory diseases or conditions, inflammatory disease, gastrointestinal tract disease, renal disease, urinary tract-associated disease, inflammatory disease of lower urinary tract, dysuria, frequent urination, pancreas disease, arterial obstruction, cerebral infarction, cerebral hemorrhage, pain, peripheral neuropathy, and fibromyalgia.
[0036] In some embodiments, the LPA-dependent or LPA-mediated disease or condition is selected from idiopathic pulmonary fibrosis; other diffuse parenchymal lung diseases of different etiologies including iatrogenic drug-induced fibrosis, occupational and/or environmental induced fibrosis, granulomatous diseases (sarcoidosis, hypersensitivity pneumonia), collagen vascular disease, alveolar proteinosis, langerhans cell granulomatosis, lymphangioleiomyomatosis, inherited diseases (Hermansky-Pudlak Syndrome, tuberous sclerosis, neurofibromatosis, metabolic storage disorders, familial interstitial lung disease); radiation induced fibrosis; chronic obstructive pulmonary disease (COPD); scleroderma; bleomycin induced pulmonary fibrosis; chronic asthma; silicosis; asbestos induced pulmonary fibrosis; acute respiratory distress syndrome (ARDS); kidney fibrosis;
tubulointerstitium fibrosis; glomerular nephritis; focal segmental glomerular sclerosis; IgA nephropathy; hypertension; Alport; gut fibrosis; liver fibrosis; cirrhosis; alcohol induced liver fibrosis; toxic/drug induced liver fibrosis; hemochromatosis; nonalcoholic
steatohepatitis (NASH); biliary duct injury; primary biliary cirrhosis; infection induced liver fibrosis; viral induced liver fibrosis; and autoimmune hepatitis; corneal scarring;
hypertrophic scarring; Duputren disease, keloids, cutaneous fibrosis; cutaneous
scleroderma; spinal cord injury/fibrosis; myelofibrosis; vascular restenosis; atherosclerosis; arteriosclerosis; Wegener's granulomatosis; Peyronie's disease, chronic lymphocytic leukemia, tumor metastasis, transplant organ rejection, endometreosis, neonatal respiratory distress syndrome and neuropathic pain.
[0037] In one aspect, is a method for treating or preventing cancer in a mammal comprising administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof to the mammal in need thereof.
[0038] In one aspect, is a method for treating or preventing fibrosis in a mammal comprising administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof to the mammal in need thereof.
[0039] In one aspect, is a method for treating or preventing lung fibrosis, asthma, chronic obstructive pulmonary disease (COPD), renal fibrosis, acute kidney injury, chronic kidney disease, liver fibrosis, skin fibrosis, fibrosis of the gut, breast cancer, pancreatic cancer, ovarian cancer, prostate cancer, glioblastoma, bone cancer, colon cancer, bowel cancer, head and neck cancer, melanoma, multiple myeloma, chronic lymphocytic leukemia, cancer pain, tumor metastasis, transplant organ rejection, scleroderma, ocular fibrosis, age related macular degeneration (AMD), diabetic retinopathy, collagen vascular disease,
atherosclerosis, Raynaud's phenomenom, or neuropathic pain in a mammal comprising administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof to the mammal in need thereof.
[0040] In one aspect, provided is a method for the treatment or prevention of organ fibrosis in a mammal comprising administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof to a mammal in need thereof. In some embodiments, the organ fibrosis comprises lung fibrosis, renal fibrosis, or hepatic fibrosis.
[0041] In one aspect, provided is a method of improving lung function in a mammal comprising administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof to the mammal in need thereof. In one aspect, the mammal has been diagnosed as having lung fibrosis.
[0042] In one aspect, compounds disclosed herein are used to treat idiopathic pulmonary fibrosis (usual interstitial pneumonia) in a mammal. [0043] In one aspect, compounds disclosed herein are used to treat Raynaud's phenomenon. Raynaud's phenomenon comprises both Raynaud's disease (where the phenomenon is idiopathic) and Raynaud's syndrome, where it is caused by some other instigating factor.
[0044] In some embodiments, compounds disclosed herein are used to treat diffuse parenchymal interstitial lung diseases in mammal: iatrogenic drug induced,
occupational/environmental (Farmer lung), granulomatous diseases (sarcoidosis, hypersensitivity pneumonia), collagen vascular disease (scleroderma and others), alveolar proteinosis, langerhans cell granulonmatosis, lymphangioleiomyomatosis, Hermansky- Pudlak Syndrome, Tuberous sclerosis, neurofibromatosis, metabolic storage disorders, familial interstitial lung disease.
[0045] In some embodiments, compounds disclosed herein are used to treat post-transplant fibrosis associated with chronic rejection in a mammal: Bronchiolitis obliterans for lung transplant.
[0046] In some embodiments, compounds disclosed herein are used to treat cutaneous fibrosis in a mammal: cutaneous scleroderma, Dupuytren disease, keloids.
[0047] In one aspect, compounds disclosed herein are used to treat hepatic fibrosis with or without cirrhosis in a mammal: toxic/drug induced (hemochromatosis), alcoholic liver disease, viral hepatitis (hepatitis B virus, hepatitis C virus, HCV), nonalcoholic liver disease (NASH), metabolic and auto-immune.
[0048] In one aspect, compounds disclosed herein are used to treat renal fibrosis in a mammal: tubulointerstitium fibrosis, glomerular sclerosis.
[0049] In any of the aforementioned aspects involving the treatment of LP A dependent diseases or conditions are further embodiments comprising administering at least one additional agent in addition to the administartion of a compound having the structure of Formula (I). In various embodiments, each agent is administered in any order, including simultaneously.
[0050] In any of the embodiments disclosed herein, the mammal is a human.
[0051] In some embodiments, compounds provided herein are administered to a human. In some embodiments, compounds provided herein are orally administered to a human.
[0052] In some embodiments, compounds provided herein are used as antagonists of at least one LPA receptor. In some embodiments, compounds provided herein are used for inhibiting the activity of at least one LPA receptor or for the treatment of a disease or condition that would benefit from inhibition of the activity of at least one LPA receptor. In one aspect, the LPA receptor is LPAi.
[0053] In other embodiments, compounds provided herein are used for the formulation of a medicament for the inhibition of LPAi activity.
[0054] Other objects, features and advantages of the compounds, methods and compositions described herein will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments, are given by way of illustration only, since various changes and modifications within the spirit and scope of the instant disclosure will become apparent to those skilled in the art from this detailed description
BRIEF DESCRIPTION OF THE FIGURES
[0055] Figure 1. Illustrative examples of compounds described herein.
[0056] Figure 2. Illustrative examples of compounds described herein.
[0057] Figure 3. Illustrative examples of compounds described herein.
[0058] Figure 4. Illustrative examples of compounds described herein.
[0059] Figure 5. Illustrative examples of compounds described herein.
[0060] Figure 6. Illustrative examples of compounds described herein.
[0061] Figure 7. Illustrative examples of compounds described herein.
[0062] Figure 8. Illustrative examples of compounds described herein.
[0063] Figure 9. Illustrative examples of compounds described herein.
[0064] Figure 10 . Illustrative examples of compounds described herein.
[0065] Figure 11 . Illustrative examples of compounds described herein.
DETAILED DESCRIPTION OF THE INVENTION
[0066] Lysophospholipids (such as lysophosphatidic acid (LPA)) affect fundamental cellular functions that include cellular proliferation, differentiation, survival, migration, adhesion, invasion, and morphogensis. These functions influence many biological processes that include neurogensis, angiogenesis, wound healing, immunity, and carcinogenesis.
[0067] LPA acts through sets of specific G protein-coupled receptors (GPCRs) in an autocrine and paracrine fashion. LPA binding to its cognate GPCRs (LPAi, LPA2, LPA3, LPA4, LPA5, LPA6) activates intracellular signaling pathways to produce a variety of biological responses. [0068] LPA has a role as a biological effector molecule, and has a diverse range of physiological actions such as, but not limited to, effects on blood pressure, platelet activation, and smooth muscle contraction, and a variety of cellular effects, which include cell growth, cell rounding, neurite retraction, and actin stress fiber formation and cell migration. The effects of LPA are predominantly receptor mediated.
[0069] Activation of the LPA receptors with LPA mediates a range of downstream signaling cascades. The actual pathway and realized end point are dependent on a range of variables that include receptor usage, cell type, expression level of a receptor or signaling protein, and LPA concentration. Nearly all mammalian cells, tissues and organs co-express several LPA-receptor subtypes, which indicates that LPA receptors signal in a cooperative manner. LPAi, LPA2, and LPA3 share high amino acid sequence similarity.
[0070] LPA regulates many important functions of fibroblasts in wound healing, including proliferation, migration, differentiation and contraction. Fibroblast proliferation is required in wound healing in order to fill an open wound. In contrast, fibrosis is characterized by intense proliferation and accumulation of myofibroblasts that actively synthesize ECM and proinflammatory cytokines. LPA can either increase or suppress the proliferation of cell types important in wound healing.
[0071] Tissue injury initiates a complex series of host wound-healing responses; if successful, these responses restore normal tissue structure and function. If not, these responses can lead to tissue fibrosis and loss of function.
[0072] A number of muscular dystrophies are characterized by a progressive weakness and wasting of musculature, and by extensive fibrosis. It has been shown that LPA treatment of cultured myoblasts induced significant expression of connective tissue growth factor (CTGF). CTGF subsequently induces collagen, fibronectin and integrin expression and induces dedifferentiation of these myoblasts. Treatment of a variety of cell types with LPA induces reproducible and high level induction of CTGF. CTGF is a profibrotic cytokine, signaling down-stream and in parallel with TGFp.
[0073] LPA and LPAi play key pathogenic roles in pulmonary fibrosis. Fibroblast chemoattractant activity plays an important role in the lungs in patients with pulmonary fibrosis. Profibrotic effects of LPAi -receptor stimulation is explained by LPAi -receptor- mediated vascular leakage and increased fibroblast recruitment, both profibrotic events. The LPA-LPAi pathway has a role in mediating fibroblast migration and vascular leakage in IPF. The end result is the aberrant healing process that characterises this fibrotic condition. [0074] The LPA-LPA2 pathway contributes to the activation of the TGF-β pathway in pulmonary fibrosis. In some embodiments, compounds that inhibit LPA2 show efficacy in the treatment of lung fibrosis. In some embodiments, compounds that inhibit both LPAI and LPA2 show improved efficacy in the treatment of lung fibrosis compared to compounds which inhibit only LPAI or LPA2.
[0075] LPA and LPAi are involved in the etiology of kidney fibrosis. In mice invalidated for the LPAi receptor (LPAi (_/_), the development of renal fibrosis was significantly attenuated. Unilateral ureteral obstruction (UUO; animal model of renal fibrosis) mice treated with the LPA receptor antagonist Ki 16425 closely resembled the LPAi (~/~) mice.
[0076] LPA is implicated in liver disease and fibrosis. Plasma LPA levels and serum autotoxin are elevated in hepatitis patients and animal models of liver injury in correlation with increased fibrosis. LPA also regulates liver cell function. LPAi and LPA2 receptors are expressed by mouse hepatic stellate cells and LPA stimulates migration of hepatic myofibroblasts.
[0077] LPA is in involved in wound healing in the eye. LPAi and LPA3 receptors are detectable in the normal rabbit corneal epithelial cells, keratocytes and endothelial cells and LPAi and LPA3 expression are increased in corneal epithelial cells following injury.
[0078] LPA is present in the aqueous humor and the lacrimal gland fluid of the rabbit eye and these levels are increased in a rabbit corneal injury model.
[0079] LPA induces actin stress fiber formation in rabbit corneal endothelial and epithelial cells and promotes contraction corneal fibroblasts. LPA also stimulates proliferation of human retinal pigmented epithelial cells.
[0080] LPA is implicated in myocardial infarction and cardiac fibrosis. Serum LPA levels are increased in patients following mycocardial infarction (MI) and LPA stimulates proliferation and collagen production (fibrosis) by rat cardiac fibroblasts. Both LPAI and LPA3 receptors are highly expressed in human heart tissue.
[0081] In one aspect, compounds of Formula (I) are used to treat or prevent fibrosis in a mammal. In one aspect, compounds of Formula (I) are used to treat or prevent fibrosis of an organ or tissue in a mammal.
[0082] The terms "fibrosis" or "fibrosing disorder," as used herein, refers to conditions that are associated with the abnormal accumulation of cells and/or fibronectin and/or collagen and/or increased fibroblast recruitment and include but are not limited to fibrosis of individual organs or tissues such as the heart, kidney, liver, joints, lung, pleural tissue, peritoneal tissue, skin, cornea, retina, musculoskeletal and digestive tract.
[0083] Exemplary diseases, disorders, or conditions that involve fibrosis include, but are not limited to: Lung diseases associated with fibrosis, e.g., idiopathic pulmonary fibrosis, pulmonary fibrosis secondary to systemic inflammatory disease such as rheumatoid arthritis, scleroderma, lupus, cryptogenic fibrosing alveolitis, radiation induced fibrosis, chronic obstructive pulmonary disease (COPD), scleroderma, chronic asthma, silicosis, asbestos induced pulmonary or pleural fibrosis, acute lung injury and acute respiratory distress (including bacterial pneumonia induced, trauma induced, viral pneumonia induced, ventilator induced, non-pulmonary sepsis induced, and aspiration induced); Chronic nephropathies associated with injury/fibrosis (kidney fibrosis), e.g., glomerulonephritis secondary to systemic inflammatory diseases such as lupus and scleroderma, diabetes, glomerular nephritis, focal segmental glomerular sclerosis, IgA nephropathy, hypertension, allograft and Alport; Gut fibrosis, e.g., scleroderma, and radiation induced gut fibrosis; Liver fibrosis, e.g., cirrhosis, alcohol induced liver fibrosis, nonalcoholic steatohepatitis (NASH), biliary duct injury, primary biliary cirrhosis, infection or viral induced liver fibrosis (e.g., chronic HCV infection), and autoimmune hepatitis; Head and neck fibrosis, e.g., radiation induced; Corneal scarring, e.g., LASIK (laser-assisted in situ keratomileusis), corneal transplant, and trabeculectomy; Hypertrophic scarring and keloids, e.g., burn induced or surgical; and other fibrotic diseases, e.g., sarcoidosis, scleroderma, spinal cord injury/fibrosis, myelofibrosis, vascular restenosis, atherosclerosis, arteriosclerosis,
Wegener's granulomatosis, mixed connective tissue disease, and Peyronie's disease.
[0084] In one aspect, a mammal suffering from one of the following non-limiting exemplary diseases, disorders, or conditions will benefit from therapy with a compound of Formula (I): atherosclerosis, thrombosis, heart disease, vasculitis, formation of scar tissue, restenosis, phlobitis, COPD (chronic obstructive pulmonary disease), pulmonary hypertension, pulmonary fibrosis, pulmonary inflammation, bowel adhesions, bladder fibrosis and cystitis, fibrosis of the nasal passages, sinusitis, inflammation mediated by neutrophils, and fibrosis mediated by fibroblasts.
[0085] In one aspect, compounds of Formula (I) are used to treat a dermatological disorders in a mammal. Dermatological disorders include, but are not limited to, proliferative or inflammatory disorders of the skin such as, atopic dermatitis, bullous disorders,
collagenoses, psoriasis, psoriatic lesions, dermatitis, contact dermatitis, eczema, urticaria, rosacea, wound healing, scarring, hypertrophic scarring, keloids, Kawasaki Disease, rosacea, Sjogren-Larsso Syndrome, urticaria.
[0086] LPA is released following tissue injury. LPAi plays a role in the initiation of neuropathic pain. In one aspect, compounds of Formula (I) are used in the treatment of pain in a mammal. In one aspect, the pain is acute pain or chronic pain. In another aspect, the pain is neuropathic pain. In another aspect, the pain is cancer pain. In one aspect, compounds of Formula (I) are used in the treatment of fibromylagia.
[0087] Lysophospholipid receptor signaling plays a role in the etiology of cancer.
Lysophosphatidic acid (LPA) and its G protein-coupled receptors (GPCRs) LPAi, LPA2, and/or LPA3 play a role in the development of several types of cancers.
[0088] LPA contributes to tumorigenesis by increasing motility and invasiveness of cells. LPA has been implicated in the initiation or progression of ovarian cancer. LPA is present at significant concentrations (2-80 μΜ) in the ascitic fluid of ovarian cancer patients. LPA receptors (LPA2 and LPA3) are also overexpressed in ovarian cancer cells as compared to normal ovarian surface epithelial cells. LPA has also been implicated in the initiation or progression of prostate cancer, breast cancer, melanoma, head and neck cancer, bowel cancer (colorectal cancer), thyroid cancer, glioblastoma, and other cancers.
[0089] LPA receptors mediate both migration of and invasion by pancreatic cancer cell lines: ΚΪ16425 and LPAi-specific siRNA effectively blocked in vitro migration in response to LPA and peritoneal fluid (ascites) from pancreatic cancer patients; in addition, Ki 16425 blocked the LPA-induced and ascites-induced invasion activity of a highly peritoneal metastatic pancreatic cancer cell line (Yamada et al, J. Biol. Chem., 279, 6595-6605, 2004).
[0090] Colorectal carcinoma cell lines show significant expression of LPAi mRNA and respond to LPA by cell migration and production of angiogenic factors. Overexpression of LPA receptors has a role in the pathogenesis of thyroid cancer. LPA3 was originally cloned from prostate cancer cells, concordant with the ability of LPA to induce autocrine proliferation of prostate cancer cells.
[0091] LPA has stimulatory roles in cancer progression in many types of cancer. LPA is produced from and induces proliferation of prostate cancer cell lines. LPA induces human colon carcinoma DLD1 cell proliferation, migration, adhesion, and secretion of angiogenic factors through LPAi signalling. In other human colon carcinoma cells lines (HT29 and WiDR), LPA enhances cell proliferation and secretion of angiogenic factors. In other colon cancer cell lines, LPA2 and LPA3 receptor activation results in proliferation of the cells. LPAi is implicated in bone metastasis (Boucharaba et al., Proc. Natl. Acad. Sci USA, 103, 9643-9648, 2006).
[0092] In one aspect, a compound of Formula (I) is used in the treatment of cancer. In one aspect, compounds of Formula (I) are used in the treatment of malignant and benign proliferative disease. In one aspect, compounds of Formula (I) are used to prevent or reduce proliferation of tumor cells, invasion and metastasis of carcinomas, pleural mesothelioma or peritoneal mesothelioma, cancer pain, bone metastases. In one aspect is a method of treating cancer in a mammal, the method comprising administering to the mammal a compound of Formula (I) and a second therapeutic agent, wherein the second therapeutic agent is an anti- cancer agent. In some embodiments, radiation therapy is also used.
[0093] The types of cancer include, but is not limited to, solid tumors (such as those of the bladder, bowel, brain, breast, endometrium, heart, kidney, lung, lymphatic tissue
(lymphoma), ovary, pancreas or other endocrine organ (thyroid), prostate, skin (melanoma or basal cell cancer) or hematological tumors (such as the leukemias) at any stage of the disease with or without metastases.
[0094] In one aspect, LPA is a contributor to the pathogenesis of respiratory diseases.
Proinflammatory effects of LPA include degranulation of mast cells, contraction of smooth- muscle cells and release of cytokines from dendritic cells. LPA induces the secretion of IL-8 from human bronchial epithelial cells. IL-8 is found in increased concentrations in BAL fluids from patients with asthma, chronic obstructive lung disease, pulmonary sarcoidosis and acute respiratory distress syndrome and 11-8 has been shown to exacerbate airway inflammation and airway remodeling of asthmatics. LPAI, LPA2 and LPA3 receptors have all been shown to contribute to the LPA-induced IL-8 production.
[0095] Administration of LPA in vivo induces airway hyper-responsiveness, itch-scratch responses, infiltration and activation of eosinophils and neutrophils, vascular remodeling, and nociceptive flexor responses. LPA also induces histamine release from mouse and rat mast cells. In one aspect, the effects of LPA are mediated through LPAi and/or LPA3. In one aspect, compounds of Formula (I) are used in the treatment of various allergic disorders in a mammal. In one aspect, compounds of Formula (I) are used in the treatment of respiratory diseases, disorders or conditions in a mammal. In one aspect, compounds of
Formula (I) are used in the treatment of asthma in a mammal. In one aspect, compounds of Formula (I) are used in the treatment of chronic asthma in a mammal. [0096] The term "respiratory disease," as used herein, refers to diseases affecting the organs that are involved in breathing, such as the nose, throat, larynx, eustachian tubes, trachea, bronchi, lungs, related muscles (e.g., diaphram and intercostals), and nerves. Respiratory diseases include, but are not limited to, asthma, adult respiratory distress syndrome and allergic (extrinsic) asthma, non-allergic (intrinsic) asthma, acute severe asthma, chronic asthma, clinical asthma, nocturnal asthma, allergen-induced asthma, aspirin-sensitive asthma, exercise-induced asthma, isocapnic hyperventilation, child-onset asthma, adult- onset asthma, cough-variant asthma, occupational asthma, steroid-resistant asthma, seasonal asthma, seasonal allergic rhinitis, perennial allergic rhinitis, chronic obstructive pulmonary disease, including chronic bronchitis or emphysema, pulmonary hypertension, interstitial lung fibrosis and/or airway inflammation and cystic fibrosis, and hypoxia.
[0097] In one aspect, presented herein is the use of compounds of Formula (I) in the treatment or prevention of chronic obstructive pulmonary disease in a mammal comprising administering to the mammal at least once an effective amount of at least one compound of Formula (I). In addition, chronic obstructive pulmonary disease includes, but is not limited to, chronic bronchitis or emphysema, pulmonary hypertension, interstitial lung fibrosis and/or airway inflammation, and cystic fibrosis.
[0098] The nervous system is a major locus for LPAi expression. In one aspect, provided is a compound of Formula (I) for use in the treatment or prevention of a nervous system disorder in a mammal. The term "nervous system disorder," as used herein includes, but is not limited to, Alzheimer's Disease, cerebral edema, cerebral ischemia, stroke, multiple sclerosis, neuropathies, Parkinson's Disease, multiple sclerosis, retinal ischemia, postsurgical cognitive dysfunction, migraine, peripheral neuropathy/neuropathic pain, spinal cord injury, cerebral edema and head injury.
[0099] Angiogenesis, the formation of new capillary networks from pre-existing
vasculature, is normally invoked in wound healing, tissue growth and myocardial angiogenesis after ischemic injury. Peptide growth factors and lysophospholipids control coordinated proliferation, migration, adhesion, differentiation and assembly of vascular endothelial cells (VECs) and surrounding vascular smooth-muscle cells (VSMCs). In one aspect, dysregulation of the processes mediating angiogenesis leads to atherosclerosis, hypertension, tumor growth, rheumatoid arthritis and diabetic retinopathy.
[00100] In one aspect, compounds of Formula (I) are used to treat or prevent cardiovascular disease in mammal, including but not limited to: arrhythmia (atrial or ventricular or both); atherosclerosis and its sequelae; angina; cardiac rhythm disturbances; myocardial ischemia; myocardial infarction; cardiac or vascular aneurysm; vasculitis, stroke; peripheral obstructive arteriopathy of a limb, an organ, or a tissue; reperfusion injury following ischemia of the brain, heart, kidney or other organ or tissue; endotoxic, surgical, or traumatic shock; hypertension, valvular heart disease, heart failure, abnormal blood pressure; shock; vasoconstriction (including that associated with migraines); vascular abnormality, inflammation, insufficiency limited to a single organ or tissue.
[00101] In one aspect, provided herein are methods for preventing or treating
vasoconstriction, atherosclerosis and its sequelae myocardial ischemia, myocardial infarction, aortic aneurysm, vasculitis and stroke comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I) or pharmaceutical composition or medicament which includes a compound of Formula (I). In some embodiments, provided herein are methods for preventing or treating Raynaud's
phenomenon.
[00102] In one aspect, provided herein are methods for reducing cardiac reperfusion injury following myocardial ischemia and/or endotoxic shock comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I).
[00103] In one aspect, provided herein are methods for reducing the constriction of blood vessels in a mammal comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I).
[00104] In one aspect, provided herein are methods for lowering or preventing an increase in blood pressure of a mammal comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I).
[00105] LPA is associated with various inflammatory/immune diseases. In one aspect, compounds of Formula (I) are used to treat or prevent inflammation in a mammal. In one aspect, antagonists of LPAi and/or LPA3 find use in the treatment or prevention of inflammatory/immune disorders in a mammal.
[00106] Examples of inflammatory/immune disorders include psoriasis, rheumatoid arthritis, vasculitis, inflammatory bowel disease, dermatitis, osteoarthritis, asthma, inflammatory muscle disease, allergic rhinitis, vaginitis, interstitial cystitis, scleroderma, eczema, allogeneic or xenogeneic transplantation (organ, bone marrow, stem cells and other cells and tissues) graft rejection, graft- versus-host disease, lupus erythematosus, inflammatory disease, type I diabetes, pulmonary fibrosis, dermatomyositis, Sjogren's syndrome, thyroiditis (e.g., Hashimoto's and autoimmune thyroiditis), myasthenia gravis, autoimmune hemolytic anemia, multiple sclerosis, cystic fibrosis, chronic relapsing hepatitis, primary biliary cirrhosis, allergic conjunctivitis and atopic dermatitis.
[00107] In accordance with one aspect, are methods for treating, preventing, reversing, halting or slowing the progression of LPA-dependent or LPA-mediated diseases or conditions once it becomes clinically evident, or treating the symptoms associated with or related to LPA-dependent or LPA-mediated diseases or conditions, by administering to the mammal a compound of Formula (I). In certain embodiments, the subject already has a LPA-dependent or LPA-mediated disease or condition at the time of administration, or is at risk of developing a LPA-dependent or LPA-mediated disease or condition.
[00108] In certain aspects, are methods for preventing or treating eosinophil and/or basophil and/or dendritic cell and/or neutrophil and/or monocyte and/or T-cell recruitment comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I).
[00109] In certain aspects, are methods for the treatment of cystitis, including, e.g., interstitial cystitis, comprising administering at least once to the mammal a therapeutically effective amount of at least one compound of Formula (I).
[00110] In accordance with one aspect, methods described herein include the diagnosis or determination of whether or not a patient is suffering from a LPA-dependent or LPA- mediated disease or condition by administering to the subject a therapeutically effective amount of a compound of Formula (I) and determining whether or not the patient responds to the treatment.
[00111] In one aspect provided herein are compounds of Formula (I), pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically acceptable solvates thereof, which are antagonists of at least one LPA receptor (e.g. LPAi, LPA2, LPA3) and are used to treat patients suffering from one or more LPA-dependent or LPA- mediated conditions or diseases, including, but not limited to, lung fibrosis, kindney fibrosis, liver fibrosis, scarring, asthma, rhinitis, chronic obstructive pulmonary disease, pulmonary hypertension, interstitial lung fibrosis, arthritis, allergy, psoriasis, inflammatory bowel disease, adult respiratory distress syndrome, myocardial infarction, aneurysm, stroke, cancer, pain, proliferative disorders and inflammatory conditions. In some embodiments, LPA-dependent conditions or diseases include those wherein an absolute or relative excess of LPA is present and/or observed. [00112] In any of the aforementioned aspects the LPA-dependent or LPA-mediated diseases or conditions include, but are not limited to, organ fibrosis, asthma, allergic disorders, chronic obstructive pulmonary disease, pulmonary hypertension, lung or pleural fibrosis, peritoneal fibrosis, arthritis, allergy, cancer, cardiovascular disease, aldult respiratory distress syndrome, myocardial infarction, aneurysm, stroke, and cancer.
[00113] In one aspect, compounds of Formula (I) are used to improve the corneal sensitivity decrease caused by corneal operations such as laser-assisted in situ keratomileusis (LASIK) or cataract operation, corneal sensitivity decrease caused by corneal degeneration, and dry eye symptom caused thereby.
[00114] In one aspect, presented herein is the use of compounds of Formula (I) in the treatment or prevention of ocular inflammation and allergic conjunctivitis, vernal keratoconjunctivitis, and papillary conjunctivitis in a mammal comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I).
[00115] In one aspect, presented herein is the use of compounds of Formula (I) in the treatment or prevention of Sjogren disease or inflammatory disease with dry eyes in a mammal comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I).
[00116] In one aspect, LPA and LPA receptors (e.g. LPAi) are involved in the pathogenesis of osteoarthritis. In one aspect, presented herein is the use of compounds of Formula (I) in the treatment or prevention of osteoarthritis in a mammal comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I).
[00117] In one aspect, LPA receptors (e.g. LPAi, LPA3) contribute to the pathogenesis of rheumatoid arthritis. In one aspect, presented herein is the use of compounds of Formula (I) in the treatment or prevention of rheumatoid arthritis in a mammal comprising
administering at least once to the mammal an effective amount of at least one compound of Formula (I).
[00118] In one aspect, LPA receptors (e.g. LPAi) contribute to adipogenesis. In one aspect, presented herein is the use of compounds of Formula (I) in the promotion of adipose tissue formation in a mammal comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I).
Compounds
[00119] In one aspect, provided herein is a compound having the structure of Formula (I) or a pharmaceutically acceptable salt thereof:
Figure imgf000023_0001
Formula (I)
wherein,
R1 is -C02RD, -C(=0)NHS02RE, -C(=0)N(RD)2, -CN, or tetrazolyl;
RD is H or Ci-C6 alkyl;
REis Ci-C6 alkyl or a substituted or unsubstituted phenyl;
L2 is absent, -C(=0)-, -N(RD)-, substituted or unsubstituted C1-C4 alkylene, or
substituted or unsubstituted C1-C4 heteroalkylene, where if L2 is substituted, then L2 is substituted with R12, where R12 is F, C C4alkyl, -OH, or -ORD; ring A is a substituted or unsubstituted phenyl, or a substituted or unsubstituted monocyclic Ci-Csheteroarylene, where if ring A is substituted, then ring A is substituted with 1 or 2 R14, each R14 is independently selected from halogen, - CN, -OH, Ci-C4alkyl, Ci-C4fluoroalkyl, Ci-C4fluoroalkoxy, Ci-C4alkoxy, and Ci-C4heteroalkyl;
L4 is absent, or a substituted or unsubstituted C1-C4 alkylene, where if L4 is
substituted then L4 is substituted with R13, where R13 is F, Ci-C4alkyl, -OH, or -ORD;
R5 is H or Ci-C4 alkyl;
each RA is independently selected from halogen, -CN, -OH, Ci-C4alkyl, Ci- C4fluoroalkyl, Ci-C4fluoroalkoxy, Ci-C4alkoxy, and Ci-C4heteroalkyl;
each RB is independently selected from halogen, -CN, -OH, Ci-C4alkyl, Ci- C4fluoroalkyl, Ci-C4fluoroalkoxy, Ci-C4alkoxy, and Ci-C4heteroalkyl;
each R is independently selected from halogen, -CN, -OH, Ci-C4alkyl, Ci- C4fluoroalkyl, Ci-C4fluoroalkoxy, Ci-C4alkoxy, and Ci-C4heteroalkyl;
m is 0, 1 or 2; n is 0, 1 or 2; p is 0, 1 or 2; r is 1, 2, 3, or 4.
[00120] For any and all of the embodiments, substituents are selected from among from a subset of the listed alternatives. For example, in some embodiments, R1 is -C02RD or - C(=0)NHS02RE. In some embodiments, R1 is -C02RD. In some embodiments, R1 is - CO2H. In some embodiments, R1 is -C(=0)NHS02RE In some embodiments, R is Ci-C6 alkyl. In some embodiments, RE is -CH3 or -CH2CH3. In some embodiments, RD is H, - CH3 or -CH2CH3. In some embodiments, RD is H.
[00121] In some embodiments, R5 is Ci-C4alkyl. In some embodiments, R5 is H, -CH3, or - CH2CH3. In some embodiments, R5 is -CH3, or -CH2CH3. In some embodiments, R5 is - CH3. In some embodiments, R5 is H.
[00122] In some embodiments, L2 is absent, -C(=0)-, -N(RD)-, substituted or unsubstituted C1-C4 alkylene, or substituted or unsubstituted C1-C4 heteroalkylene, where if L2 is substituted, then L2 is substituted with R12. In some embodiments, L2 is -N(RD)-, substituted or unsubstituted Ci-C2 alkylene, or substituted or unsubstituted Ci-C2 heteroalkylene, where if L2 is substituted, then L2 is substituted with R12. In some embodiments, L2 is -N(H)-, -N(CH3)-, substituted or unsubstituted methylene, or substituted or unsubstituted ethylene, where if L2 is substituted, then L2 is substituted with R12. In some embodiments, L2 is -N(H)-. In some embodiments, L2 is substituted or unsubstituted methylene, where if L2 is substituted, then L2 is substituted with R12.
[00123] In some embodiments, L2 is selected from a bond, C1-C4 alkylene, -C(=0)-, - CH(OH)-, -CH(ORD)-, -CH2CH(OH)-, - CH2CH(ORD)-, -CH2S-, -CH2S(0)-, -CH2S(0)2-, - SCH2-, - S(0)CH2-, -S(0)2CH2-, -CH20-, -OCH2-, -S(0)2CH2-, -N(H)-, -CH2N(H)-, or - N(H)CH2-.
[00124] In some embodiments, L2 is absent, -C(=0)-, -NH-, -N(CH3)-, -CH2-, -CH2CH2-, - CH(CH3)-, -CH2CH(CH3)-, -CH(CH3)CH2-, -CH(OH)-, -CH(ORD)-, -CH2CH(OH)-, - CH2CH(ORD)-, -CH(OH)CH2-, -CH(ORD)CH2-, -CH2NH-, -CH(CH3)NH-, -NHCH2- or - NHCH(CH3)-. In some embodiments, L2 is -NH-, -N(CH3)-, -CH2-, -CH(CH3)-, -CH(OH)-, -CH(ORD)-, -CH2NH-, -CH(CH3)NH-, -NHCH2- or -NHCH(CH3)-. In some embodiments, L2 is -NH-, -N(CH3)-, -CH2NH-, -CH(CH3)NH-, -NHCH2- or -NHCH(CH3)-. In some embodiments, L2 is -NH-. In some embodiments, L2 is -CH2-, -CH(CH3)-, -CH(OH)-, - CH(ORD)-, -CH2NH-, -CH(CH3)NH-, -NHCH2- or -NHCH(CH3)-. In some embodiments, L2 is -CH2-, -CH(CH3)-, -CH(OH)-, or -CH(ORD)-. In some embodiments, L2 is -CH2- or - CH(OH)-. In some embodiments, L2 is -CH(OH)-. In some embodiments, L2 is -CH2-.
[00125] In some embodiments, R12 is F, -CH3, -CH2CH3, -OH, -OCH3, or -OCH2CH3. In some embodiments, R12 is -CH3, or -OH.
[00126] In some embodiments, R1 is -C02RD, or -C(=0)NHS02RE; L2 is absent, -C(=0)-, - NH-, -N(CH3)-, -CH2-, -CH2CH2-, -CH(CH3)-, -CH2CH(CH3)-, -CH(CH3)CH2-, -CH(OH)-, -CH(ORu)-, -CH2CH(OH)-, -CH2CH(ORu)-, -CH(OH)CH2-, -CH(ORu)CH2-, -CH2NH-, - CH(CH3)NH-, -NHCH2- or -NHCH(CH3)-; L4 is absent, -CH2-, -CH(CH3)-, -CH(OH)-, - CH2CH2-, -CH2CH(CH3)-, -CH(CH3)CH2-, -CH2CH(OH)-, or -CH(OH)CH2-; R5 is -H, - CH3 or -CH2CH3.
[00127] In some embodiments, each RA is independently selected from halogen, -OH, -CH3, -CH2CH3, -CF3, -OCF3, -OCH3 and -OCH2CH3. In some embodiments, each RA is halogen, -OH, -CH3, -CH2CH3, -CF3, -OCF3, -OCH3 or -OCH2CH3.
[00128] In some embodiments, each RB is independently selected from halogen, -OH, -CH3, -CH2CH3, -CF3, -OCF3, -OCH3 and -OCH2CH3. In some embodiments, each RB is halogen, -OH, -CH3, -CH2CH3, -CF3, -OCF3, -OCH3 or -OCH2CH3.
[00129] In some embodiments, each Rc is halogen, -OH, -CH3, -CH2CH3, -CF3, -OCF3, - OCH3, -OCH2CH3, -CH2OCH3, -CH2OCH2CH3, or -CH2N( CH3)2. In some embodiments, each Rc is independently selected from halogen, -OH, -CH3, -CH2CH3, -CF3, -OCF3, -OCH3 and -OCH2CH3.
[00130] In some embodiments, m is 0 or 1 ; n is 0 or 1 ; r is 1 , 2, or 3.
[00131] In some embodiments, m is 0 or 1. In some embodiments, m is 0. In some embodiments, n is 0 or 1. In some embodiments, n is 0. In some embodiments, r is 1 , 2, or
3. In some embodiments, r is 1 or 2. In some embodiments, r is 1.
[00132] In some embodiments, ring A is a substituted or unsubstituted phenyl, or a substituted or unsubstituted monocyclic Ci-Csheteroarylene, where if ring A is substituted, then ring A is substituted with 1 or 2 R14.
[00133] In some embodiments, ring A is a substituted or unsubstituted phenyl, or a substituted or unsubstituted monocyclic Ci-Csheteroarylene containing 1-4 N atoms, 0 or 1 O atoms and 0 or 1 S atoms, where if ring A is substituted, then ring A is substituted with 1 or 2 R14.
[00134] In some embodiments, ring A is a substituted or unsubstituted monocyclic Ci- Csheteroarylene containing 1-4 N atoms, 0 or 1 O atoms and 0 or 1 S atoms, where if ring A is substituted, then ring A is substituted with 1 or 2 R14.
[00135] In some embodiments, ring A is a substituted or unsubstituted 5-membered monocyclic Ci-C4heteroarylene containing 1-4 N atoms, 0 or 1 O atoms and 0 or 1 S atoms, where if ring A is substituted, then ring A is substituted with 1 or 2 R14. [00136] In some embodiments, ring A is a substituted or unsubstituted 6-membered monocyclic Cs-Csheteroarylene containing 1-3 N atoms, where if ring A is substituted, then ring A is substituted with 1 or 2 R14.
[00137] In some embodiments, ring A is a substituted or unsubstituted monocyclic ring wherein the groups -L2- and -L4- are in a 1 ,2-relationship on ring A (i.e. an ortho relationship).
[00138] In some embodiments, ring A is a substituted or unsubstituted monocyclic ring wherein the groups -L2- and -L4- are in a 1 ,3 -relationship on ring A (i.e. a meta
relationship).
[00139] In some embodiments, ring A is a substituted or unsubstituted monocyclic ring wherein the groups -L2- and -L4- are in a 1 ,4-relationship on ring A (i.e. a para
relationship).
[00140] In some embodiments, ring A is unsubstituted or monosubstituted with R14. In some embodiments, ring A is unsubstituted. In some embodiments, ring A is monosubstituted with R14.
[00141] In some embodiments, L4 is absent, or a substituted or unsubstituted methylene, or substituted or unsubstituted ethylene, where if L4 is substituted, then L4 is substituted with R13. In some embodiments, L4 is absent. In some embodiments, L4 is a substituted or unsubstituted methylene, where if L4 is substituted, then L4 is substituted with R13. In some embodiments, L4 is a substituted or unsubstituted ethylene, where if L4 is substituted, then L4 is substituted with R13.
[00142] In some embodiments, R13 is F, -CH3, -CH2CH3, -OH, -OCH3, or -OCH2CH3. In some embodiments, R13 is -CH3.
[00143] In some embodiments, L4 is absent, -CH2-, or -CH(CH3)-.
[00144] In some embodiments, L2 is -NH-, -CH2-, -CH2CH2-, -CH(CH3)-, -CH2CH(CH3)-, - CH(CH3)CH2-, -CH(OH)-, -CH2CH(OH)-, -CH(OH)CH2-, -CH2NH-, -CH(CH3)NH-, - NHCH2- or -NHCH(CH3)-; ring A is a substituted or unsubstituted phenyl, or a substituted or unsubstituted monocyclic Ci-Csheteroarylene containing 1-4 N atoms, 0 or 1 O atoms and 0 or 1 S atoms, where if ring A is substituted, then ring A is substituted with 1 or 2 R14; L4 is absent, -CH2-, or -CH(CH3)-; R5 is -CH3; r is 1.
[00145] In some embodiments, ring A is a substituted or unsubstituted phenyl, where if ring A is substituted, then ring A is substituted with 1 or 2 R14. [00146] In some embodiments, ring A is a substituted or unsubstituted monocyclic Ci- Csheteroarylene containing 1-4 N atoms, 0 or 1 O atoms and 0 or 1 S atoms, where if ring A is substituted, then ring A is substituted with 1 or 2 R14.
[00147] In some embodiments, ring A is a substituted or unsubstituted 5-membered monocyclic Ci-C4heteroarylene containing 1-4 N atoms, 0 or 1 O atoms and 0 or 1 S atoms, where if ring A is substituted, then ring A is substituted with 1 or 2 R14.
[00148] In some embodiments, ring A is a substituted or unsubstituted furanyl, a substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted pyrazolyl, substituted or unsubstituted triazolyl, substituted or unsubstituted tetrazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted isothiazolyl, substituted or unsubstituted oxadiazolyl, or substituted or unsubstituted thiadiazolyl, where if ring A is substituted, then ring A is substituted with 1 or 2 R14.
[00149] In some embodiments, each R14 is independently selected from halogen, -CN, -OH, - CH3, -CH2CH3, -CF3, -OCF3, -OCH3 and -OCH2CH3. In some embodiments, each R14 is halogen, -CN, -OH, -CH3, -CH2CH3, -CF3, -OCF3, -OCH3 or -OCH2CH3. In some embodiments, each R14 is independently selected from halogen, -OH, and -CH3. . In some embodiments, R14 is halogen, -OH, or -CH3. In some embodiments, each R14 is
independently selected from halogen and -CH3.
Figure imgf000027_0001
Figure imgf000028_0001
[00151] In some embodiments, ring A is a substituted or unsubstituted 6-membered monocyclic Cs-Csheteroarylene containing 1-3 N atoms, where if ring A is substituted, then ring A is substituted with 1 or 2 R14.
[00152] In some embodiments, ring A is a substituted or unsubstituted pyridinylene, a substituted or unsubstituted pyridazinylene, a substituted or unsubstituted pyrimidinylene, a substituted or unsubstituted pyrazinylene, or a substituted or unsubstituted triazinylene, where if ring A is substituted, then ring A is substituted with 1 or 2 R14.
[00153] In some embodiments, ring A is a substituted or unsubstituted pyridinylene, where if
Figure imgf000028_0002
In some embodiments, the compound of Formula (I) has the structure of Formula
Figure imgf000028_0003
[00156] In some embodiments, R1 is -C02RD, or -C(=0)NHS02RE; RD is H or C1-C4 alkyl; RE is C1-C4 alkyl; L2 is -CH2-, -CH(CH3)-, or -CH(OH)-; ring A is a substituted or unsubstituted 5-membered monocyclic Ci-C4heteroarylene containing 1-4 N atoms and 0 or 1 O atoms, where if ring A is substituted, then ring A is substituted with R14, R14 is halogen, -CN, -OH, -CH3, -CH2CH3, -CF3, -OCF3, -OCH3 or -OCH2CH3; L4 is -CH2- or -CH(CH3)-; p is 0 or 1.
[00157] In some embodiments, R1 is -C02RD, or -C(=0)NHS02RE; RD is H or Ci-C4alkyl; RE is Ci-C4alkyl; L2 is -NH-, -CH2-, -CH(CH3)-, -CH(OH)-, -NHCH2- or -NHCH(CH3)-; ring A is a substituted or unsubstituted pyridinylene, where if ring A is substituted, then ring A is substituted with R14, R14 is halogen, -CN, -OH, -CH3, -CH2CH3, -CF3, -OCF3, -OCH3 or -OCH2CH3; L4 is absent, -CH2-, or -CH(CH3)-; p is 0 or 1.
[00158] In some embodiments, p is 0, 1 or 2. In some embodiments, p is 0 or 1. In some embodiments, p is 0. In some embodiments, p is 1.
[00159] In some embodiments,
Figure imgf000029_0001
is phenyl, 2-fluorophenyl, 2,3- difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 2-chlorophenyl, 2,6-dichlorophenyl, 2-bromophenyl, 3-bromophenyl, 2,4-dichlorophenyl, 2-hydroxyphenyl, 3- hydroxyphenyl, 4- hydroxyphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4- methoxyphenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-fluoro-4-methoxyphenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2- cyanophenyl, 3-cyanophenyl, or 4-cyanophenyl.
[00160] In some embodiments, -L2- is as described in Table(s) 1, 2 and/or 3.
[00161] In some embodiments, -L4- is as described in Table(s) 1, 2 and/or 3.
[00162] In some embodiments, ring A is as described in Table(s) 1, Table 2 and/or 3.
Figure imgf000029_0002
[00163] In some embodiments, is R as defined in Table(s) 1, 2 and/or 3.
[00164] Any combination of the groups described above for the various variables is contemplated herein. Throughout the specification, groups and substituents thereof are chosen by one skilled in the field to provide stable moieties and compounds.
[00165] In some embodiments, compounds of Formula (I) include, but are not limited to, those described in Tables 1 to 3 and Figures 1 to 11.
Table 1 :
Figure imgf000030_0001
25 1 -CH(OH)- lH-[l ,2,3]Triazol- -CH2- 3-Chloro-phenyl 541
Figure imgf000031_0001
Figure imgf000032_0001
* mass spectrometric data
Table 2:
Figure imgf000033_0001
mass spectrometric data
Table 3:
Figure imgf000033_0002
mass spectrometric data
Synthesis of Compounds
[00166] Compounds of Formula (I) described herein are synthesized using standard synthetic techniques or using methods known in the art in combination with methods described herein. In additions, solvents, temperatures and other reaction conditions presented herein may vary.
[00167] The starting material used for the synthesis of the compounds of Formula (I) are either synthesized or obtained from commercial sources, such as, but not limited to, Sigma- Aldrich, Fluka, Acros Organics, Alfa Aesar, and the like. The compounds described herein, and other related compounds having different substituents are synthesized using techniques and materials described herein or otherwise known, including those found in March, ADVANCED ORGANIC CHEMISTRY 4th Ed., (Wiley 1992); Carey and Sundberg, ADVANCED ORGANIC CHEMISTRY 4th Ed., Vols. A and B (Plenum 2000, 2001), and Green and Wuts, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS 3 Ed., (Wiley 1999). General methods for the preparation of compounds can be modified by the use of appropriate reagents and conditions for the introduction of the various moieties found in the formulae as provided herein.
[00168] In some embodiments, the synthesis of compounds of Formula (I) begins with the synthetic steps outlined in Scheme 1.
Scheme 1
Figure imgf000034_0001
[00169] In one aspect, the synthesis of compounds of Formula (I) described herein begins with the reaction of an alkyl acetoacetate with methylamine to provide a compound of structure l-II. Compounds of structure l-II are reacted with a substituted or unsubstituted 4-halo-benzoyl chloride (structure l-III) to provide compounds of structure 1-IV.
Treatment of compounds of structure 1-IV with hydroxyl amine and acetic acid provides isoxazoles of structure 1-V. Hydrolysis of the ester group of isoxazoles of structure 1-V provides carboxylic acids of structure 1-VI. A Curtius rearrangement of carboxylic acids of structure 1-VI in the presence of hydroxy compounds of structure 1-VII provides carbamate compounds of structure 1-VIII. Deprotection of the tert-butoxycarbonyl group provides amines of structure 1-IX which are further functionalized into compounds of Formula (I). In some embodiments, compounds of 1-V are reduced to the alcohol and then further functionalized into compounds of Formula (I). [00170 In some embodiments, compounds are prepared as outlined in Scheme 2.
Figure imgf000035_0001
[00171] In some embodiments, compounds of structure 2-1 are subjected to a palladium- catalyzed coupling with boronic acid deriviatives 3-III to provide compounds of structure
2-II. In some embodiments, R is -NH2, -NHC02alkyl, -C02alkyl, -CH2OH, -CH2CN, - CH2Br, -C(=0)H, -CH2N3, -C02NHNH2, -CH2C02NHNH2 or any other suitable group that can be transformed to provide L2 as described herein. Compounds of structure 2-II are then utilized to provide compounds of structure 2-III. Alternatively, compounds of structure 2-1 are derivatized to provide compounds of structure 2-IV, which are subsequently coupled with compound 3-III to provide compounds of structure 2-III. R2 in scheme 2 is a substituted or unsubstituted phenyl.
[00172] Suitable reactions for transforming 2-1 to 2-IV or 2-II to 2-III include, but are not limited to, nucleophilic displacement reactions (where R includes a suitable leaving group), organometallic chemical reactions, reductive amination reactions, cycloaddition reactions (e.g. Huisgen-Sharpless cycloaddition), and the like.
[00173] In some embodiments, compounds of Formula (I) are synthesized as outlined in the Examples.
[00174] Throughout the specification, groups and substituents thereof are chosen by one skilled in the field to provide stable moieties and compounds. [00175] A detailed description of techniques applicable to the creation of protecting groups and their removal are described in Greene and Wuts, Protective Groups in Organic
Synthesis, 3rd Ed., John Wiley & Sons, New York, NY, 1999, and Kocienski, Protective Groups, Thieme Verlag, New York, NY, 1994, which are incorporated herein by reference for such disclosure.
Further Forms of Compounds
[00176] In one aspect, compounds of Formula (I) possess one or more stereocenters and each stereocenter exists independently in either the R or S configuration. The compounds presented herein include all diastereomeric, and enantiomeric forms. Stereoisomers are obtained, if desired, by methods such as, stereoselective synthesis and/or the separation of stereoisomers by chiral chromatographic columns.
[00177] The methods and formulations described herein include the use of N-oxides (if appropriate), crystalline forms (also known as polymorphs), amorphous phases, and/or pharmaceutically acceptable salts of compounds having the structure of Formula (I), as well as metabolites and active metabolites of these compounds having the same type of activity. In some situations, compounds may exist as tautomers. All tautomers are included within the scope of the compounds presented herein. In specific embodiments, the compounds described herein exist in solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In other embodiments, the compounds described herein exist in unsolvated form.
[00178] In some embodiments, compounds described herein are prepared as prodrugs. A "prodrug" refers to an agent that is converted into the parent drug in vivo. In certain embodiments, upon in vivo administration, a prodrug is chemically converted to the biologically, pharmaceutically or therapeutically active form of the compound. In certain embodiments, a prodrug is enzymatically metabolized by one or more steps or processes to the biologically, pharmaceutically or therapeutically active form of the compound.
[00179] In some embodiments, sites on the aromatic ring portion of compounds of Formula (I) are susceptible to various metabolic reactions. Incorporation of appropriate substituents on the aromatic ring structures will reduce, minimize or eliminate this metabolic pathway. In specific embodiments, the appropriate substituent to decrease or eliminate the susceptibility of the aromatic ring to metabolic reactions is, by way of example only, a deuterium, a halogen, or an alkyl group. [00180] In another embodiment, the compounds described herein are labeled isotopically or by another other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.
[00181] In one aspect, substitution with isotopes such as deuterium affords certain therapeutic advantages resulting from greater metabolic stability, such as, for example, increased in vivo half-life or reduced dosage requirements.
[00182] "Pharmaceutically acceptable," as used herein, refers a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively nontoxic, i.e., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
[00183] In some embodiments, pharmaceutically acceptable salts are obtained by reacting a compound of Formula (I) with acids. Pharmaceutically acceptable salts are also obtained by reacting a compound of Formula (I) with a base to form a salt.
[00184] Compounds described herein may be formed as, and/or used as, pharmaceutically acceptable salts. The type of pharmaceutical acceptable salts, include, but are not limited to: (1) acid addition salts, formed by reacting the free base form of the compound with a pharmaceutically acceptable inorganic acid (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, and the like); or with an organic acid (e.g. acetic acid, propionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, trifluoroacetic acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1 ,2- ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, 2-naphthalenesulfonic acid, salicylic acid, stearic acid, muconic acid, butyric acid, phenylacetic acid, phenylbutyric acid, valproic acid, and the like); (2) salts formed when an acidic proton present in the parent compound is replaced by a metal ion, e.g., an alkali metal ion (e.g. lithium, sodium, potassium), an alkaline earth ion (e.g. magnesium, or calcium), or an aluminum ion. In some cases, compounds described herein may coordinate with an organic base, such as, but not limited to, ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, dicyclohexylamine, tris(hydroxymethyl)methylamine. In other cases, compounds described herein may form salts with amino acids such as, but not limited to, arginine, lysine, and the like. Acceptable inorganic bases used to form salts with compounds that include an acidic proton, include, but are not limited to, aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like. In some embodiments, a sodium salt of the compound of Formula (I) is prepared.
[00185] It should be understood that a reference to a pharmaceutically acceptable salt includes the solvent addition forms or crystal forms thereof, particularly solvates or polymorphs. Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and may be formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. In addition, the compounds provided herein can exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.
[00186] Compounds described herein, such as compounds of Formula (I), may be in various forms, including but not limited to, amorphous forms, milled forms and nano-particulate forms. In addition, compounds described herein include crystalline forms, also known as polymorphs. Polymorphs include the different crystal packing arrangements of the same elemental composition of a compound.
Certain Terminology
[00187] Unless otherwise stated, the following terms used in this application, including the specification and claims, have the definitions given below. It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Unless otherwise indicated, conventional methods of mass spectroscopy, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA techniques and pharmacology are employed. In this application, the use of "or" or "and" means "and/or" unless stated otherwise. Furthermore, use of the term "including" as well as other forms, such as "include", "includes," and "included," is not limiting. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[00188] An "alkyl" refers to an aliphatic hydrocarbon. The alkyl may be saturated or unsaturated. The alkyl, whether saturated or unsaturated, is a branched alkyl or straight chain alkyl. Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tertiary butyl, pentyl, neopentyl, hexyl, allyl, but-2-enyl, but-3-enyl, and the like. [00189] The term "alkylene" refers to a divalent alkyl radical. Any of the above mentioned monovalent alkyl groups may be an alkylene by abstraction of a second hydrogen atom from the alkyl. In one aspect, an alkelene is a Ci-Cealkylene. In another apsect, an alkylene is a Ci-C4alkylene. Typical alkylene groups include, but are not limited to, methylene, ethylene, propylene and butylene. Typical alkylene groups include, but are not limited to, - CH2-, -CH(CH3)-, -C(CH3)2-, -CH2CH2-, -CH2CH(CH3)-, -CH2C(CH3)2-, -CH2CH2CH2-, - CH2CH2CH2CH2-, and the like.
[00190] An "alkoxy" group refers to a (alkyl)O- group, where alkyl is as defined herein.
[00191] "Cycloalkyl" refers to cyclopropyl, cyclopropenyl, cyclobutyl,
cyclobutenyl,cyclopentyl, cyclopentenyl, cyclohexyl, or cyclohexenyl.
[00192] The term "halo" or, alternatively, "halogen" or "halide" means fluoro, chloro, bromo or iodo.
[00193] The term "fluoroalkyl" refers to an alkyl in which one or more hydrogen atoms are replaced by a fluorine atom.
[00194] The term "heteroalkyl" refers to an alkyl group in which one or more skeletal atoms of the alkyl are selected from an atom other than carbon, e.g., oxygen, nitrogen (e.g. NH or Nalkyl), sulfur, or combinations thereof. In some embodiments, one aspect, heteroalkyl refers to an alkyl group in which one of the skeletal atoms of the alkyl is oxygen. In some embodiments, one aspect, heteroalkyl refers to an alkyl group in which one of the skeletal atoms of the alkyl is NH or Nalkyl.
[00195] The term "heteroalkylene" refers to an alkylene group in which one or more skeletal atoms of the alkyl are selected from an atom other than carbon, e.g. , oxygen, nitrogen (e.g. NH or Nalkyl), sulfur, or combinations thereof. In one aspect, a heteroalkylene is a Ci- Ceheteroalkylene. In another aspect, a heteroalkylene is a Ci-C4heteroalkylene. Examplary heteroalkylenes include, but are not limited to, -OCH2-, -OCH(CH3)-, -OC(CH3)2-, -
OCH2CH2-, -CH20-, -CH(CH3)0-, -C(CH3)20-, -CH2CH20-, -CH2OCH2-, -CH2OCH2CH2- , -CH2CH2OCH2-, -SCH2-, -SCH(CH3)-, -SC(CH3)2-, -SCH2CH2-, -CH2S-, -CH(CH3)S-, - C(CH3)2S-, -CH2CH2S-, -CH2SCH2-, -CH2SCH2CH2-, -CH2CH2SCH2-, -S02CH2-, - S02CH(CH3)-, -S02C(CH3)2-, -S02CH2CH2-, -CH2S02-, -CH(CH3)S02-, -C(CH3)2S02-, - CH2CH2S02-, -CH2S02CH2-, -CH2S02CH2CH2-, -CH2CH2S02CH2-, -NHCH2-, -
NHCH(CH3)-, -NHC(CH3)2-, -NHCH2CH2-, -CH2NH-, -CH(CH3)NH-, -C(CH3)2NH-, - CH2CH2NH-, -CH2NHCH2-, -CH2NHCH2CH2-, -CH2CH2NHCH2-, and the like. [00196] The terms "heteroaryl" or, alternatively, "heteroaromatic" refers to an aryl group that includes one or more ring heteroatoms selected from nitrogen, oxygen and sulfur.
Monocyclic heteroaryls include, but are not limited to, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, or triazinyl. In one aspect, a heteroaryl contains 0-4 N atoms. In another aspect, a heteroaryl contains 1-3 N atoms. In another aspect, a heteroaryl contains 0-3 N atoms, 0-1 O atoms, and 0-1 S atoms. In one aspect, monocyclic heteroaryl is a Ci-Csheteroaryl. In one aspect, monocyclic heteroaryl is a 5-membered or 6-membered heteroaryl. Depending on the structure, a heteroaryl group can be a monoradical or a diradical (i.e., a heteroarylene group).
[00197] The term "heteroarylene" refers to a divalent heteroaryl radical. Any of the above mentioned monovalent heteroaryl groups may be a heteroarylene by abstraction of a second hydrogen atom from the heteroaryl group. The divalent heteroaryl radical may be attached through two carbon atoms, or through one carbon atom and one heteroatom, or through two heteroatoms.
[00198] The term "optionally substituted" or "substituted" means that the referenced group may be substituted with one or more additional group(s) individually and independently selected from halogen, -CN, -NH2, -OH, -NH(CH3), -N(CH3)2, alkyl, cycloalkyl, fluoroalkyl, heteroalkyl, alkoxy, fluoroalkoxy, -S-alkyl, or -S(=0)2alkyl. In some embodiments, an optional substituent is selected from halogen, -CN, -NH2, -OH, -NH(CH3), -N(CH3)2, -CH3, -CH2CH3, -CF3, -CH2CF3, -OCH3, -OCH2CH3, -OCF3 and - OCH2CF3. In some embodiments, substituted groups are substituted with one or two of the preceding groups. In some embodiments, substituted groups are substituted with one of the preceding groups.
[00199] The term "acceptable" with respect to a formulation, composition or ingredient, as used herein, means having no persistent detrimental effect on the general health of the subject being treated.
[00200] The term "modulate," as used herein, means to interact with a target either directly or indirectly so as to alter the activity of the target, including, by way of example only, to enhance the activity of the target, to inhibit the activity of the target, to limit the activity of the target, or to extend the activity of the target.
[00201] The term "modulator," as used herein, refers to a molecule that interacts with a target either directly or indirectly. The interactions include, but are not limited to, the interactions of an agonist, partial agonist, an inverse agonist and antagonist. In one embodiment, a modulator is an antagonist.
[00202] The term "agonist," as used herein, refers to a molecule such as a compound, a drug, an enzyme activator or a hormone modulator that binds to a specific receptor and triggers a response in the cell. An agonist mimics the action of an endogenous ligand (such as LP A, prostaglandin, hormone or neurotransmitter) that binds to the same receptor.
[00203] The term "antagonist," as used herein, refers to a molecule such as a compound, which diminishes, inhibits, or prevents the action of another molecule or the activity of a receptor site. Antagonists include, but are not limited to, competitive antagonists, non- competitive antagonists, uncompetitive antagonists, partial agonists and inverse agonists.
[00204] The term "LPA-dependent", as used herein, refers to conditions or disorders that would not occur, or would not occur to the same extent, in the absence of LPA.
[00205] The term "LPA-mediated", as used herein, refers to refers to conditions or disorders that might occur in the absence of LPA but can occur in the presence of LPA.
[00206] The terms "co-administration" or the like, as used herein, are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are administered by the same or different route of administration or at the same or different time.
[00207] The terms "effective amount" or "therapeutically effective amount," as used herein, refer to a sufficient amount of an agent or a compound being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. The result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an "effective amount" for therapeutic uses is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in disease symptoms. An appropriate "effective" amount in any individual case may be determined using techniques, such as a dose escalation study.
[00208] The term "pharmaceutical combination" as used herein, means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients. The term "fixed combination" means that the active ingredients, e.g. a compound of Formula (I) and a co-agent, are both administered to a patient simultaneously in the form of a single entity or dosage. The term "non- fixed combination" means that the active ingredients, e.g. a compound of Formula (I) and a co-agent, are administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific intervening time limits, wherein such administration provides effective levels of the two compounds in the body of the patient. The latter also applies to cocktail therapy, e.g. the administration of three or more active ingredients.
[00209] The term "subject" or "patient" encompasses mammals. Examples of mammals include, but are not limited to, humans, chimpanzees, apes, monkey, cattle, horses, sheep, goats, swine, rabbits, dogs, cats, rodents, rats, mice guinea pigs, and the like. In one embodiment, the mammal is a human.
[00210] The terms "treat," "treating" or "treatment," as used herein, include alleviating, abating or ameliorating at least one symptom of a disease disease or condition, preventing additional symptoms, inhibiting the disease or condition, e.g., arresting the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition either prophylactically and/or therapeutically.
Pharmaceutical Compositions/Formulations and Routes of Administration
[00211] In some embodiments, the compounds described herein are formulated into pharmaceutical compositions. Pharmaceutical compositions are formulated in a
conventional manner using one or more pharmaceutically acceptable inactive ingredients that facilitate processing of the active compounds into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. A summary of pharmaceutical compositions described herein can be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A. and Lachman, L., Eds.,
Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams &
Wilkinsl999), herein incorporated by reference for such disclosure.
[00212] A pharmaceutical composition, as used herein, refers to a mixture of a compound of Formula (I) with other chemical components (i.e. pharmaceutically acceptable inactive ingredients), such as carriers, excipients, binders, filling agents, suspending agents, flavoring agents, sweetening agents, disintegrating agents, dispersing agents, surfactants, lubricants, colorants, diluents, solubilizers, moistening agents, plasticizers, stabilizers, penetration enhancers, wetting agents, anti-foaming agents, antioxidants, preservatives, or one or more combination thereof. The pharmaceutical composition facilitates administration of the compound to an organism.
[00213] Pharmaceutical formulations described herein are administerable to a subject in a variety of ways by multiple administration routes, including but not limited to, oral, parenteral (e.g., intravenous, subcutaneous, intramuscular, intramedullary injections, intrathecal, direct intraventricular, intraperitoneal, intralymphatic, intranasal injections), intranasal, buccal, topical or transdermal administration routes. The pharmaceutical formulations described herein include, but are not limited to, aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate and controlled release formulations.
[00214] In some embodiments, the compounds of Formula (I) are administered orally.
[00215] In some embodiments, the compounds of Formula (I) are administered topically. In such embodiments, the compound of Formula (I) is formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, shampoos, scrubs, rubs, smears, medicated sticks, medicated bandages, balms, creams or ointments. In one aspect, the compounds of Formula (I) are administered topically to the skin.
[00216] In another aspect, the compounds of Formula (I) are administered by inhalation.
[00217] In another aspect, the compounds of Formula (I) are formulated for intranasal adminstration. Such formulations include nasal sprays, nasal mists, and the like.
[00218] In another aspect, the compounds of Formula (I) are formulated as eye drops.
[00219] In any of the aforementioned aspects are further embodiments in which the effective amount of the compound of Formula (I) is: (a) systemically administered to the mammal; and/or (b) administered orally to the mammal; and/or (c) intravenously administered to the mammal; and/or (d) administered by inhalation to the mammal; and/or (e) administered by nasal administration to the mammal; or and/or (f) administered by injection to the mammal; and/or (g) administered topically to the mammal; and/or (h) administered by ophthalmic administration; and/or (i) administered rectally to the mammal; and/or (j) adminstered non- systemically or locally to the mammal. [00220] In any of the aforementioned aspects are further embodiments comprising single administrations of the effective amount of the compound, including further embodiments in which (i) the compound is administered once; (ii) the compound is administered to the mammal multiple times over the span of one day; (iii) continually; or (iv) continuously.
[00221] In any of the aforementioned aspects are further embodiments comprising multiple administrations of the effective amount of the compound, including further embodiments in which (i) the compound is administered continuously or intermittently: as in a a single dose; (ii) the time between multiple administrations is every 6 hours; (iii) the compound is administered to the mammal every 8 hours; (iv) the compound is administered to the mammal every 12 hours; (v) the compound is administered to the mammal every 24 hours. In further or alternative embodiments, the method comprises a drug holiday, wherein the administration of the compound is temporarily suspended or the dose of the compound being administered is temporarily reduced; at the end of the drug holiday, dosing of the compound is resumed. In one embodiment, the length of the drug holiday varies from 2 days to 1 year.
[00222] In certain embodiments, a compound as described herein is administered in a local rather than systemic manner.
[00223] In some embodiments, the compound described herein is administered topically. In some embodiments, the compound described herein is administered systemically.
[00224] In some embodiments, the pharmaceutical formulation is in the form of a tablet. In other embodiments, pharmaceutical formulations of the compounds of Formula (I) are in the form of a capsule.
[00225] In one aspect, liquid formulation dosage forms for oral administration are in the form of aqueous suspensions or solutions selected from the group including, but not limited to, aqueous oral dispersions, emulsions, solutions, elixirs, gels, and syrups.
[00226] For administration by inhalation, a compound of Formula (I) is formulated for use as an aerosol, a mist or a powder.
[00227] For buccal or sublingual administration, the compositions may take the form of tablets, lozenges, or gels formulated in a conventional manner.
[00228] In some embodiments, compounds of Formula (I) are prepared as transdermal dosage forms.
[00229] In one aspect, a compound of Formula (I) is formulated into a pharmaceutical composition suitable for intramuscular, subcutaneous, or intravenous injection. [00230] In some embodiments, the compounds described herein may be administered topically and can be formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams or ointments.
[00231] In some embodiments, the compounds of Formula (I) are formulated in rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas.
Methods of Dosing and Treatment Regimens
[00232] In one embodiment, the compounds of Formula (I) are used in the preparation of medicaments for the treatment of LPA-dependent or LPA-mediated diseases or conditions. In addition, a method for treating any of the diseases or conditions described herein in a subject in need of such treatment, involves administration of pharmaceutical compositions that include at least one compound of Formula (I) or a pharmaceutically acceptable salt, active metabolite, prodrug, or solvate thereof, in therapeutically effective amounts to said subject.
[00233] In certain embodiments, the compositions containing the compound(s) described herein are administered for prophylactic and/or therapeutic treatments. In certain therapeutic applications, the compositions are administered to a patient already suffering from a disease or condition, in an amount sufficient to cure or at least partially arrest at least one of the symptoms of the disease or condition. Amounts effective for this use depend on the severity and course of the disease or condition, previous therapy, the patient's health status, weight, and response to the drugs, and the judgment of the treating physician. Therapeutically effective amounts are optionally determined by methods including, but not limited to, a dose escalation clinical trial.
[00234] In prophylactic applications, compositions containing the compounds described herein are administered to a patient susceptible to or otherwise at risk of a particular disease, disorder or condition.
[00235] In certain embodiments, the dose of drug being administered may be temporarily reduced or temporarily suspended for a certain length of time (i.e., a "drug holiday").
[00236] Doses employed for adult human treatment are typically in the range of 0.0 lmg- 5000 mg per day or from about lmg to about 1000 mg per day. In one embodiment, the desired dose is conveniently presented in a single dose or in divided doses.
Patient Selection [00237] In any of the aforementioned aspects involving the prevention or treatment of LPA- mediated diseases or conditions are further embodiments comprising identifying patients by screening for LP A receptor gene SNPs. Patients can be further selected based on increased LPA receptor expression in the tissue of interest. LPA receptor expression are determined by methods including, but not limited to, northern blotting, western blotting, quantitative PCR (qPCR), flow cytometry, autoradiography (using a small molecule radioligand or PET ligand). In some embodiments, patients are selected based on the concentration of serum or tissue LPA measured by mass spectrometry. In some embodiments, patients are selected based on a combination of the above markers (increased LPA concentrations and increased LPA receptor expression).
Combination Treatments
[00238] In certain instances, it is appropriate to administer at least one compound of Formula (I) in combination with another therapeutic agent.
[00239] In one specific embodiment, a compound of Formula (I) is co-administered with a second therapeutic agent, wherein the compound of Formula (I) and the second therapeutic agent modulate different aspects of the disease, disorder or condition being treated, thereby providing a greater overall benefit than administration of either therapeutic agent alone.
[00240] For combination therapies described herein, dosages of the co-administered compounds vary depending on the type of co-drug(s) employed, on the specific drug(s) employed, on the disease or condition being treated and so forth. In additional
embodiments, when co-administered with one or more other therapeutic agents, the compound provided herein is administered either simultaneously with the one or more other therapeutic agents, or sequentially.
[00241] If administration is simultaneous, the multiple therapeutic agents are, by way of example only, provided in a single, unified form, or in multiple forms.
[00242] In another embodiment described herein, methods for treatment of proliferative disorders, including cancer, comprises administration to a mammal a compound of Formula
(I) in combination with one or more anti-cancer agents and/or radiation therapy.
[00243] In one aspect, compounds of Formula (I) are to treat or reduce fibrosis in a mammal. In one aspect, compounds of Formula (I) are administered in combination with one or more immunosuppresants. In some embodiments, a compound of Formula (I) is adminsitered with corticosteroids. [00244] In yet another embodiment described herein, methods for treating LPA-dependent or LPA-mediated conditions or diseases, such as the therapy of respiratory disorders (e.g., pulmonary fibrosis, asthma, COPD, rhinitis), comprises administration to a patient compounds, pharmaceutical compositions, or medicaments described herein in combination with at least one agent used in the treatment of respiratory conditions.
[00245] In some embodiments, compounds of Formula (I) are administered to a patient in combination with anti-inflammatory agents.
[00246] In one embodiment, compounds of Formula (I) are administered to a patient in combination with inhaled corticosteroids.
EXAMPLES
[00247] These examples are provided for illustrative purposes only and not to limit the scope of the claims provided herein.
Example 1: Synthesis of l-[4'-(4-Amino-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester
[00248] Step 1: 3-Methylamino-but-2-enoic acid methyl ester: To a solution of methyl acetoacetate (29.4 g, 253 mmol) in MeOH (30 mL) was added methylamine (33 wt% in EtOH; 48 mL, 385 mmol) dropwise at room temperature. The reaction was stirred for 1 hour, and then concentrated and dried to give the title compound as a white crystalline solid.
[00249] Step 2: 2-(4-Bromo-benzoyl)-3-oxo-butyric acid methyl ester: To 3- methylamino-but-2-enoic acid methyl ester (5.0 g, 39.1 mmol) in THF (100 mL) was added pyridine (3.7 mL, 47 mmol). The mixture was cooled to 0°C, and 4-bromobenzoyl chloride (8.55 g, 39.1 mmol) in THF (30 mL) was added dropwise over 2 minutes. The reaction was warmed to room temperature over 1 hour and stirred overnight. Aqueous workup provided the title compound.
[00250] Step 3: 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid methyl ester:
To a mixture of 2-(4-bromo-benzoyl)-3-oxo-butyric acid methyl ester (11 g, 39 mmol) in acetic acid (50 mL) was added hydroxylamine hydrochloride (2.66 g, 39 mmol), and the reaction was stirred at 115 °C for 1 hour. After cooling, aqueous workup provided the title compound, which was used directly in the hydrolysis step.
[00251] Step 4: 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid: 5-(4-Bromo- phenyl)-3-methyl-isoxazole-4-carboxylic acid methyl ester (39 mmol) in MeOH (50 mL) and H20 (10 mL) was treated with lithium hydroxide (2 g, 48 mmol), and the reaction was stirred at 60 °C for 1 hour. The mixture was acidified, and standard workup provided the title compound.
[00252] Step 5: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-carbamic acid tert-butyl ester: 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid (1.6 g, 6.0 mmol), diphenylphosphoryl azide (1.6 g, 6.0 mmol), and triethylamine (1.3 mL, 9.3 mmol) were combined in t-BuOH and refluxed overnight. After cooling, the mixture was concentrated, and the residue was partitioned between EtOAc and H20. The organic layer was separated and concentrated, and the residue was purified by silica gel chromatography (16-18% EtOAc in hexanes) to give the title compound.
[00253] Step 6: l-(4-Bromo-phenyl)-cyclopropanecarbonitrile: Potassium hydroxide (14.3 g, 255 mmol) was dissolved in H20 (5 mL) and toluene (40 mL). 4- Bromophenylacetonitrile (5.0 g, 25.5 mmol) and tetrabutylammonium bromide (0.41 g, 1.3 mmol) was added, followed by 1 ,2-dibromoethane (3.25 mL, 38 mmol) dropwise over 10 minutes. The reaction was stirred at room temperature for 2 hours and then worked-up to give the title compound.
[00254] Step 7: l-(4-Bromo-phenyl)-cyclopropanecarboxylic acid: l-(4-Bromo-phenyl)- cyclopropanecarbonitrile (5 g, 22.5 mmol) and potassium hydroxide (5 g, 89.3 mmol) were combined in ethylene glycol (70 mL), and the reaction was stirred at 180 °C for 4 hours. The mixture was poured into H20, acidified, and filtered to give the title compound.
[00255] Step 8: l-(4-Bromo-phenyl)-cyclopropanecarboxylic acid ethyl ester: l-(4-
Bromo-phenyl)-cyclopropanecarboxylic acid (5 g, 20.7 mmol) in EtOH (50 mL) was treated with sulfuric acid (2 mL), and the reaction was stirred at 75 °C for 1 hour. The mixture was worked up to give the title compound.
[00256] Step 9: l-[4-(4,4,5,5-Tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]- cyclopropanecarboxylic acid ethyl ester: l-(4-Bromo-phenyl)-cyclopropanecarboxylic acid ethyl ester (3.6 g, 13.4 mmol), bis(pinacolato)diboron (3.37 g, 16.1 mmol), and potassium acetate (2.8 g, 29.0 mmol) were combined in 1,4-dioxane (30 mL) under N2 atmosphere. The solution was purged with N2 (g) for 10 minutes, and then (Ι,Γ- bis(diphenylphosphino)ferrocene)-dichloropalladium(II) (0.50 g, 0.65 mmol) was added and the reaction was heated to 80 °C for 2 hours. After aqueous workup, the crude material was purified by silica gel chromatography (0-30% EtOAc in hexanes) to give the title compound. [00257] Step 10: l-[4'-(4-tei"i-Butoxycarbonylamino-3-methyl-isoxazol-5-yl)-biphenyl-4- yl]-cyclopropanecarboxylic acid ethyl ester: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4- yl]-carbamic acid tert-butyl ester (2.0 g, 5.6 mmol), l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester (1.78 g, 5.6 mmol), tetrakis(triphenylphosphine)palladium(0) (0.65 g, 0.56 mmol), and sodium bicarbonate (1.4 g, 16.8 mmol) were combined in DME (30 mL) and H20 (10 mL), and the mixture was purged with N2 (g). The reaction was stirred at 80 °C overnight, and after aqueous workup, the crude material was purified by silica gel chromatography (0-40% EtOAc in hexanes) to give the title compound.
[00258] Step 11: l-[4'-(4-Amino-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester: l-[4'-(4-tert-Butoxycarbonylamino-3-methyl- isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester (1.5 g, 3.2 mmol) in CH2C12 (10 mL) was treated with trifluoroacetic acid (4 mL), and the reaction was stirred for 1 hour. The mixutre was neutralized and worked up to give the title compound.
Example 2: Reductive Amination Procedure
[00259] Amine containing compound (1 equivalent) and ketone compound or aldehyde compound (1-1.5 equivalents) were combined in toluene and stirred at 110 °C for 1 hour. After cooling to room temperature, THF was added, followed by excess sodium
cyanoborohydride ( 2 - 3 equivalents), and the reaction was stirred at room temperature for 2 hours to overnight. The mixture was purified by silica gel chromatography.
Example 3: Hydrolysis of Alkyl Esters
[00260] To cyclopropanecarboxylic acid ethyl ester compound (1 equivalent) in -2: 1 : 1 THF:H20:MeOH was added lithium hydroxide (3 - 10 equivalents), and the reaction was stirred at 70 °C for 2 hours to overnight. After acidic workup, the crude material was purified by preparative HPLC.
Example 4: Suzuki Coupling Raction
[00261] A 4-substituted-5-(4-bromo-phenyl)-3-methyl-isoxazole (1 equivalent), l-[4- (4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester (1.2-2.0 equivalents), tetrakis(triphenylphosphine)palladium(0) (-0.05 - 0.15 equivalents), and sodium bicarbonate (-2.5 equivalents) were combined in -3: 1 DME:H20, and the mixture was purged with N2 (g). The reaction was stirred at 60-80 °C for at least 1 hour to overnight and then cooled and concentrated. The crude material was purified by silica gel chromatography (0-40% EtOAc in hexanes). Example 5: Synthesis of [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl] -methanol and 5- (4-Bromo-phenyl)-3-methyl-isoxazole-4-carbaldehyde
[00262] Step 1: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-methanol: 5-(4-Bromo- phenyl)-3-methyl-isoxazole-4-carboxylic acid methyl ester (5 g, 16.8 mmol) and lithium borohydride (1.85 g, 84.1 mmol) were combined in EtOH and stirred at 60 °C. After aqueous workup, the crude material was purified by silica gel chromatography to give the title compound.
[00263] Step 2: 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carbaldehyde: [5-(4-Bromo- phenyl)-3-methyl-isoxazol-4-yl]-methanol (1.2 g, 4.5 mmol) was treated with 4- methylmorpholine N-oxide (0.786 g, 6.7 mmol) and tetrapropylammonium perruthenate
(catalytic) in CH2CI2. The reaction was monitored by analytical LCMS and when complete it was filtered through Celite then submitted to silica gel chromatography to give the title compound.
Example 6: Synthesis of l-{4'-[3-Methyl-4-(3-phenyl-pyrazol-l-ylmethyl)-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1)
[00264] Step 1: l-[4'-(4-Hydroxymethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 4, using [5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-methanol and l-[4- (4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
[00265] Step 2: l-[4'-(4-Bromomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester: Phosphorus tribromide (0.43 mL, 4.53 mmol) was added to a solution of l-[4'-(4-hydroxymethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester (1.14 g, 3.02 mmol) in DME (30 mL) at 0 °C. The reaction was stirred overnight at room temperature, and then cooled to 0 °C and neutralized with saturated aqueous NaHC03 to pH 7. The mixture was partitioned between CH2CI2 and H20, and the aqueous layer was extracted with CH2CI2. The combined organic layers were dried over MgSC^, filtered, and concentrated, and the residue was purified by silica gel chromatography to give the title compound.
[00266] Step 3: l-{4'-[3-Methyl-4-(3-phenyl-pyrazol-l-ylmethyl)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid: l-[4'-(4-Bromomethyl-3-methyl-isoxazol-5- yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester (0.132 g, 0.3 mmol) and 3- phenyl-lH-pyrazole (0.043 g, 0.3 mmol) were combined in DMF. Sodium hydride (60% in mineral oil; 0.014 g, 0.35 mmol) was added, and the reaction was stirred at room
temperature for 1.5 hours. Once no starting material was seen by analytical LCMS, the mixture was diluted with EtOAc and IN aqueous HC1. The aqueous layer was extracted with EtOAc, and the combined organic layers were washed with H20 and brine, and then dried over Na2S04, filtered, and concentrated. The residue was purified by preparative HPLC to give the title compound.
Example 7: Synthesis of l-{4'-[3-Methyl-4-(4-phenyl-[l,2,3]triazol-l-ylmethyl)- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 2)
[00267] Step 1: l-{4'-[3-Methyl-4-(4-phenyl-[l,2,3]triazol-l-ylmethyl)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 6, Step 3, using l-[4'-(4-bromomethyl-3-methyl-isoxazol- 5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 4-phenyl-lH-l,2,3- triazole.
[00268] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 8: Synthesis of l-{4'-[3-Methyl-4-(5-phenyl-[l,3,4]oxadiazol-2-ylmethyl)- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 3)
[00269] Step 1: 4-Bromomethyl-5-(4-bromo-phenyl)-3-methyl-isoxazole: [5-(4-Bromo- phenyl)-3-methyl-isoxazol-4-yl]-methanol (2.88 g, 10.74 mmol) in DME (23 mL) was treated with phosphorus tribromide (1.5 mL, 16.11 mmol), and the reaction was stirred at room temperature for 1 hour. Aqueous workup provided the title compound.
[00270] Step 2: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-acetonitrile: To 4- bromomethyl-5-(4-bromo-phenyl)-3-methyl-isoxazole (10.74 mmol) in DMF (30 mL) was added potassium cyanide (0.729 g, 10.74 mmol), and the reaction was stirred at 65 °C overnight. After aqueous workup, the crude material was purified by silica gel
chromatography (0-70% EtOAc in hexanes) to give the title compound.
[00271] Step 3: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl] -acetic acid: [5-(4-Bromo- phenyl)-3-methyl-isoxazol-4-yl]-acetonitrile (1.652 g, 5.96 mmol) in EtOH (9 mL) was treated with 4N aqueous NaOH (6 mL, 23.85 mmol), and the reaction was stirred at 75 °C for 3 hours. The mixture was acidified with 2N aqueous HC1 (12 mL) and a precipitate formed as the solution cooled to room temperature. The mixture was filtered, and the solid material was dried to give the title compound. [00272] Step 4: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-acetic acid ethyl ester: To
[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-acetic acid (0.200 g, 0.68 mmol) in EtOH (3 mL) was added thionyl chloride (0.10 mL, 1.35 mmol), and the reaction was stirred for 1 hour. The mixture was quenched with saturated aqueous NH4C1 and diluted with EtOAc and H20. After standard aqueous workup, the crude material was purified by silica gel chromatography to give the title compound.
[00273] Step 5: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-acetic acid hydrazide: To
[5 -(4-bromo-phenyl)-3-methyl-isoxazol-4-yl] -acetic acid ethyl ester (0.114 g, 0.37 mmol) in EtOH (4 mL) was added hydrazine (1M in THF; 2 mL), and the reaction was sealed and stirred at 80 °C overnight. The mixture was poured into brine and extracted with EtOAc. The combined organic layers were washed with H20 and brine, and then dried over MgS04, filtered, and concentrated to give the title compound.
[00274] Step 6: 2-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl]-5-phenyl- [1,3,4] oxadiazole: To [5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-acetic acid hydrazide (0.142 g, 0.46 mmol) in CH2C12 (2.3 mL) at 0 °C was added triethylamine (0.19 mL, 1.37 mmol) and benzoyl chloride (0.05 mL, 0.46 mmol), and the reaction was stirred at room temperature for 3 hours. Toluenesulfonyl chloride (0.088 g, 0.46 mmol) was added, and the reaction was stirred overnight. After aqueous workup, the crude material was purified by silica gel chromatography to give the title compound.
[00275] Step 7: Synthesis of l-{4'-[3-Methyl-4-(5-phenyl-[l,3,4]oxadiazol-2-ylmethyl)- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 4, using 2-[5-(4-bromo-phenyl)-3-methyl- isoxazol-4-ylmethyl]-5-phenyl-[l,3,4]oxadiazole and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
[00276] Step 8: The ester from Step 7 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 9: Synthesis of l-{4'-[4-(4-Benzyl-[l,2,3]triazol-l-ylmethyl)-3-methyl- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 4)
[00277] Step 1: l-[4'-(4-Azidomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester: Sodium nitrile (0.060 g, 0.91 mmol) was dissolved in H20 (0.5 mL). DMF (2 mL) was added, followed by l-[4'-(4-Bromomethyl-3- methyl-isoxazol-5-yl)-biphenyl-4-yl] -cyclopropanecarboxylic acid ethyl ester (0.200 g, 0.45 mmol), and the reaction was stirred overnight. The mixture was diluted with H20 and extracted with EtOAc. The combined organic layers were dried over Na2S04, filtered, and concentrated to give the title compound.
[00278] Step 2: l-{4'-[4-(4-Benzyl-[l,2,3]triazol-l-ylmethyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester: To a solution of l-[4'-(4- azidomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester (0.183 g, 0.45 mmol) in tBuOH (1.5 mL) and H20 (1.5 mL) was added 3-phenyl-l- propyne (0.053 g, 0.45 mmol), followed by sodium ascorbate (0.009 g, 0.045 mmol) and copper(II) sulfate pentahydrate (0.001 g, 0.005 mmol), and the reaction was stirred overnight. After aqueous workup, the crude material was purified by silica gel
chromatography to give the title compound.
[00279] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 10: Synthesis of l-(4'-{4-[3-(4-Bromo-phenyl)-pyrazol-l-ylmethyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 5)
Step 1: l-(4'-{4-[3-(4-Bromo-phenyl)-pyrazol-l-ylmethyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 6, Step 3, using l-[4'-(4-bromomethyl-3-methyl-isoxazol-
5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 3-(4-bromo-phenyl)-lH- pyrazole.
[00280] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 11: Synthesis of l-(4'-{3-Methyl-4-[(5-phenyl-[l,3,4]oxadiazol-2-ylamino)- methyl]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 6)
[00281] Step 1: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl]-(5-phenyl- [l,3,4]oxadiazol-2-yl)-amine: Prepared according to the procedure described in Example 2, using 5-(4-bromo-phenyl)-3-methyl-isoxazole-4-carbaldehyde and 5-phenyl- [l,3,4]oxadiazol-2-ylamine.
[00282] Step 2: l-(4'-{3-Methyl-4-[(5-phenyl-[l,3,4]oxadiazol-2-ylamino)-methyl]- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using [5-(4-bromo-phenyl)-3- methyl-isoxazol-4-ylmethyl]-(5-phenyl-[l,3,4]oxadiazol-2-yl)-amine and l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester. [00283] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 12: Synthesis of l-{4'-[3-Methyl-4-(5-phenyl-[l,2,3]triazol-l-ylmethyl)- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 7)
[00284] Step 1: l-{4'-[3-Methyl-4-(5-phenyl-[l,2,3]triazol-l-ylmethyl)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 6, Step 3, using l-[4'-(4-bromomethyl-3-methyl-isoxazol-
5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 5-phenyl-lH-
[l,2,3]triazole.
[00285] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 13: Synthesis of l-{4'-[3-Methyl-4-(5-phenyl-tetrazol-2-ylmethyl)-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 8)
[00286] Step 1: l-{4'-[3-Methyl-4-(5-phenyl-tetrazol-2-ylmethyl)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 6, Step 3, using l-[4'-(4-bromomethyl-3-methyl-isoxazol- 5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 5-phenyl-2H-tetrazole.
[00287] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 14: Synthesis of l-{4'-[3-Methyl-4-(4-phenyl-pyrazol-l-ylmethyl)-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 9)
[00288] Step 1: l-{4'-[4-(4-Bromo-pyrazol-l-ylmethyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 6, Step 3, using l-[4'-(4-bromomethyl-3-methyl-isoxazol- 5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 4-Bromo-lH-pyrazole.
[00289] Step 2: l-{4'-[3-Methyl-4-(4-phenyl-pyrazol-l-ylmethyl)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester: l-{4'-[4-(4-Bromo-pyrazol-l- ylmethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester (0.062 g, 0.122 mmol), phenylboronic acid (0.018 g, 0.146 mmol), tri(o-tolyl)phosphine (0.004 g, 0.0122 mmol) and sodium bicarbonate (0.041 g, 0.488 mmol) were dissolved in DME (1.5 mL) and H20 (0.5 mL) and N2 (g) was bubbled through the mixture for 10 minutes. Palladium(II) acetate (1 mg, 0.002 mmol) was added and the reaction was heated to 90 °C for 1 hour. The reaction was cooled and purified via silica gel chromatography to afford the title compound.
[00290] Step 3: l-{4'-[3-Methyl-4-(4-phenyl-pyrazol-l-ylmethyl)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid: l-{4'-[3-Methyl-4-(4-phenyl-pyrazol-l- ylmethyl)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester (0.051 g, 0.101 mmol) was dissolved in THF (1 mL) then MeOH (0.5 mL) and NaOH (3N aq., 0.5 mL) was added and the reaction stirred at room temperature. After 8 hours the reaction was acidified with IN aq. HC1 then submitted to standard workup procedures to give the title compound.
Example 15: Synthesis of l-{4'-[4-(5-Benzyl-[l,3,4]oxadiazol-2-yl)-3-methyl-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 10)
[00291] Step 1: 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid hydrazide: 5-
(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid (0.061 g, 2.16 mmol) was dissolved in THF (5 mL) then Ι,Γ-carbonyldiimidazole (0.390 g, 2.38 mmol) was added and the reaction was heated to 70 °C for 40 minutes. The reaction was then cooled to 0 °C and hydrazine monohydrate (0.220 mL, 4.32 mmol) was added. The reaction was then allowed to slowly warm to room temperature and stirred overnight. Standard aqueous workup afforded the title compound, which was brought to the next step without further purification.
Step 2: 2-Benzyl-5-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-[l,3,4]oxadiazole:
Prepared according to the procedure described in Example 8, Step 6, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carboxylic acid hydrazide and phenylacetyl chloride.
[00292] Step 3: l-{4'-[4-(5-Benzyl-[l,3,4]oxadiazol-2-yl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using 2-benzyl-5-[5-(4-bromo-phenyl)-3- methyl-isoxazol-4-yl]-[l,3,4]oxadiazole and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-
2- yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
[00293] Step 4: The ester from Step 3 was hydro lyzed to the acid according to the procedure described in Example 14, Step 3.
Example 16: Synthesis of l-(4'-{4-[(l-Benzyl-lH-[l,2,3]triazol-4-yl)-hydroxy-methyl]-
3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 11)
[00294] Step 1: l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-prop-2-yn-l-ol: 5-(4- Bromo-phenyl)-3-methyl-isoxazole-4-carbaldehyde (0.285 g, 1.07 mmol) was dissolved in THF (8 mL) and the solution was cooled to -78 °C. Ethynylmagnesium bromide (0.5M in THF, 2.6 mL, 1.28 mmol) was added dropwise and the reaction was allowed to warm to room temperature. After 1 hour the reaction was quenched with aqueous ammonium chloride the submitted to standard workup to yield the title compound.
[00295] Step 2: (l-Benzyl-lH-[l,2,3]triazol-4-yl)-[5-(4-bromo-phenyl)-3-methyl- isoxazol-4-yl] -methanol: Prepared according to the procedure described in Example 9, Step 2, using l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-prop-2-yn-l-ol and azidomethyl- benzene.
[00296] Step 3: l-(4'-{4-[(l-Benzyl-lH-[l,2,3]triazol-4-yl)-hydroxy-methyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using ( 1 -benzyl- 1H- [ 1 ,2,3]triazol-4-yl)-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-methanol and 1 -[4- (4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
[00297] Step 4: The ester from Step 3 was hydro lyzed to the acid according to the procedure described in Example 14, Step 3.
Example 17: Synthesis of l-[4'-(4-Formyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester
[00298] Step 1: 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carbaldehyde (0.5 g, 1.88 mmol) was mixed with l-[4-(4,4,5,5-Tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]- cyclopropanecarboxylic acid ethyl ester (0.72 g, 2.07 mmol) and sodium bicarbonate (0.553 g, 6.58 mmol) in DME (5 mL) and H20 (2.5 mL). The reaction was purged with N2 (g) then bis(triphenylphosphine)palladium(II) dichloride (0.066 g, 0.094 mmol) was added and the reaction was heated to 85 °C overnight. After cooling to room temperature the reaction was submitted to standard aqueous workup the purified by silica gel chromatograph (0-20% EtOAc in hexanes) to give the title compound.
Example 18: Synthesis of l-{4'-[4-(5-Benzyl-[l,3,4]oxadiazol-2-ylmethyl)-3-methyl- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 12)
[00299] Step 1: 2-Benzyl-5-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl]- [1,3,4] oxadiazole: Prepared according to the procedure described in Example 8, Step 6, using [5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-acetic acid hydrazide and phenylacetyl chloride. [00300] Step 2: l-{4'-[4-(5-Benzyl-[l,3,4]oxadiazol-2-ylmethyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using 2-benzyl-5-[5-(4-bromo-phenyl)-3- methyl-isoxazol-4-ylmethyl]-[l,3,4]oxadiazole and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
[00301] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 14, Step 3.
Example 19: Synthesis of l-(4'-{4-[(5-Benzyl-[l,3,4]oxadiazol-2-yl)-hydroxy-methyl]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 13)
[00302] Step 1: (5-Benzyl-[l,3,4]oxadiazol-2-yl)-[5-(4-bromo-phenyl)-3-methyl-isoxazol- 4-yl]-methanol: 2-Benzyl-[l,3,4]oxadiazole (0.500 g, 3.12 mmol) was dissolved in THF and cooled to -70 °C then n-butyllithium (1.5M in THF, 2.1 mL, 3.12 mmol) was added and the reaction stirred for 1.5 hours. Magnesium bromide ethyl etherate (0.631 g, 3.43 mmol) was added and the reaction was allowed to warm to -45 °C. After 45 minutes 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carbaldehyde (0.415 g, 1.56 mmol) in THF (2 mL) was added and the reaction was allowed to stir overnight. The reaction was quenched with aqueous ammonium chloride then submitted to standard workup and purification via silica gel chromatography (0-60% EtOAc in hexanes) to give the title compound.
[00303] Step 2: l-(4'-{4-[(5-Benzyl-[l,3,4]oxadiazol-2-yl)-hydroxy-methyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using (5-benzyl- [1, 3, 4]oxadiazol-2-yl)- [5 -(4-bromo-phenyl)-3-methyl-isoxazol-4-yl] -methanol and l-[4- (4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
[00304] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 14, Step 3.
Example 20: Synthesis of l-{4'-[4-(l-Benzyl-lH-[l,2,3]triazol-4-ylmethyl)-3-methyl- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 14)
[00305] Step 1: l-{4'-[4-(l-Benzyl-lH-[l,2,3]triazol-4-ylmethyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester: l-(4'-{4-[(l-Benzyl-lH- [ 1 ,2,3]triazol-4-yl)-hydroxy-methyl]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester (0.123 g, 0.230 mmol) and triethylsilane (0.044 mL, 0.276 mmol) were dissolved in CH2CI2 (0.5 mL) then trifluoromethanesulfonic acid (0.5 mL) was slowly added. After stirring for 1 hour at room temperature, an additional portion of triethylsilane (0.050 mL) was added and the reaction was heated to 50 °C for 3.5 hours. An additional portion of triethylsilane (1 mL) was added and the reaction continued to stir at 50 °C for 1 hour. The reaction mixture was concentrated, dissolved in CH2CI2, and filtered through a plug of silica gel. The crude material was then purified via preparatory HPLC to afford the title compound.
[00306] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 14, Step 3.
Example 21: Synthesis of l-(4'-{4-[(5-Benzyl-[l,3,4]oxadiazol-2-yl)-hydroxy-methyl]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Enantiomer A) (Compound 15)
[00307] Step 1: (5-Benzyl-[l,3,4]oxadiazol-2-yl)-[5-(4-bromo-phenyl)-3-methyl-isoxazol- 4-yl]-methanol: Prepared according to the procedure described in Example 19, Step 1, using 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carbaldehyde and 2-benzyl- [l,3,4]oxadiazole.
[00308] The recovered material was purified by silica gel chromatography (0-60% EtOAc in hexanes) then the by preparatory chiral HPLC (Chiralpak AD column, 95:5 hexanes:EtOH) to give enantiomer A (first to elute) and enantiomer B (second to elute) with undetermined absolute stereochemistry.
[00309] Step 2: l-(4'-{4-[(5-Benzyl-[l,3,4]oxadiazol-2-yl)-hydroxy-methyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester (Enantiomer A):
Prepared according to the procedure described in Example 1, Step 10, using (5-benzyl- [1, 3, 4]oxadiazol-2-yl)- [5 -(4-bromo-phenyl)-3-methyl-isoxazol-4-yl] -methanol (Enantiomer A) and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
[00310] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 14, Step 3.
Example 22: Synthesis of l-(4'-{4-[(5-Benzyl-[l,3,4]oxadiazol-2-yl)-hydroxy-methyl]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Enantiomer B) (Compound 16)
[00311] Step 1: l-(4'-{4-[(5-Benzyl-[l,3,4]oxadiazol-2-yl)-hydroxy-methyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester (Enantiomer B):
Prepared according to the procedure described in Example 1, Step 10, using (5-benzyl- [1, 3, 4]oxadiazol-2-yl)- [5 -(4-bromo-phenyl)-3-methyl-isoxazol-4-yl] -methanol (Enantiomer B) and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
[00312] Step 2: The ester from Step 1 was hydrolyzed to the acid according to the procedure described in Example 14, Step 3.
Example 23: Synthesis of 5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-ylamine
Step 1: 5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-ylamine: Prepared according to the procedure described in Example 1, Step 11, using [5-(4-bromo-phenyl)-3-methyl-isoxazol- 4-yl]-carbamic acid tert-butyl ester.
Example 24: Synthesis of l-(4'-{4-[Hydroxy-(5-phenyl-[l,3,4]oxadiazol-2-yl)-methyl]- 3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 17)
[00313] Step 1: 2-Phenyl-[l,3,4]oxadiazole: Benzoic acid methyl ester (1.01 g, 7.34 mmol) and hydrazine monohydrate (10 mL) were dissolved in EtOH (20 mL) then heated in a sealed tube to 80 °C for 23 hours. The reaction was allowed to cool and then
triethylorthoformate (25 mL) and /?-toluenesulfonic acid (0.100 g, 0.526 mmol) were added, the tube was re-sealed, and the reaction was heated to 120 °C for 26 hours. The reaction mixture was then submitted to standard aqueous workup and purified on silica gel (0-70% EtOAc in hexanes) to afford the title compound.
[00314] Step 2: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-(5-phenyl-[l,3,4]oxadiazol- 2-yl)-methanol: Prepared according to the procedure described in Example 19, Step 1, using 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carbaldehyde and 2-phenyl- [l,3,4]oxadiazole.
[00315] Step 3: l-(4'-{4-[Hydroxy-(5-phenyl-[l,3,4]oxadiazol-2-yl)-methyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 17, Step 1, using [5-(4-bromo-phenyl)-3- methyl-isoxazol-4-yl]-(5-phenyl-[l,3,4]oxadiazol-2-yl)-methanol and l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
[00316] Step 4: The ester from Step 3 was hydrolyzed to the acid according to the procedure described in Example 14, Step 3.
Example 25: Synthesis of l-(4'-{4-[(l-Benzyl-lH-[l,2,3]triazol-4-yl)-hydroxy-methyl]-
3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Enantiomer A)
(Compound 18) [00317] Step 1: l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-prop-2-yn-l-ol: Prepared according to the procedure described in Example 16, Step 1, and after the reaction the material was purified via preparatory chiral HPLC (Chiralcel AD column, 85: 15
hexanes:EtOH) to give enantiomer A (first to elute) and enantiomer B (second to elute) with undetermined absolute stereochemistry.
[00318] Step 2: (l-Benzyl-lH-[l,2,3]triazol-4-yl)-[5-(4-bromo-phenyl)-3-methyl- isoxazol-4-yl] -methanol (Enantiomer A): To a solution of l-[5-(4-Bromo-phenyl)-3- methyl-isoxazol-4-yl]-prop-2-yn-l-ol (Enantiomer A) (0.530 g, 1.81 mmol) in DMSO (4 mL) and H20 (4 mL) was added azidomethyl-benzene (0.242 g, 1.81 mmol), followed by sodium ascorbate (0.036 g, 0.181 mmol) and copper(II) sulfate pentahydrate (0.005 g, 0.018 mmol), and the reaction was stirred overnight. After aqueous workup the crude material was purified by silica gel chromatography (15-100% EtOAc in hexanes) to give the title compound.
[00319] Step 3: l-(4'-{4-[(l-Benzyl-lH-[l,2,3]triazol-4-yl)-hydroxy-methyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester (Enantiomer A):
Prepared according to the procedure described in Example 1, Step 10, using ( 1 -benzyl- 1H- [ 1 ,2,3]triazol-4-yl)-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-methanol (Enantiomer A) and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
[00320] Step 4: The ester from Step 3 was hydro lyzed to the acid according to the procedure described in Example 14, Step 3.
Example 26: Synthesis of l-(4'-{4-[(l-Benzyl-lH-[l,2,3]triazol-4-yl)-hydroxy-methyl]- 3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Enantiomer B) (Compound 19)
[00321] Step 1: (l-Benzyl-lH-[l,2,3]triazol-4-yl)-[5-(4-bromo-phenyl)-3-methyl- isoxazol-4-yl] -methanol (Enantiomer B): Prepared according to the procedure described in Example 25, Step 2, using l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-prop-2-yn-l- ol (Enantiomer B) and azidomethyl-benzene.
[00322] Step 2: l-(4'-{4-[(l-Benzyl-lH-[l,2,3]triazol-4-yl)-hydroxy-methyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester (Enantiomer B):
Prepared according to the procedure described in Example 1, Step 10, using ( 1 -benzyl- 1H- [ 1 ,2,3]triazol-4-yl)-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-methanol (Enantiomer B) and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
[00323] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 14, Step 3.
Example 27: Synthesis of [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[l-(3-phenyl- isoxazol-5-yl)-ethyl] -amine
[00324] Step 1: Prepared according to the procedure described in Example 2, using 5-(4- bromo-phenyl)-3-methyl-isoxazol-4-ylamine and 1 -(3-phenyl-isoxazol-5-yl)-ethanone. Example 28: Synthesis of 1 -[4'-(4- {Hydroxy- [5-(3-trifluoromethyl-benzyl)- [l,3,4]oxadiazol-2-yl]-methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid (Compound 20)
[00325] Step 1: 2-(3-Trifluoromethyl-benzyl)-[l,3,4]oxadiazole: (3-Trifluoromethyl- phenyl)-acetic acid methyl ester (0.720 g, 3.30 mmol) was dissolved in hydrazine (7 mL) and EtOH (15 mL) and heated to 90 °C overnight. Analytical LCMS indicated complete reaction so the mixture was concentrated and azeotroped twice with toluene. The crude material was dissolved in triethylorthoformate and heated to 135 °C for 20 hours then allowed to cool. The reaction mixture was concentrated to afford the title compound.
[00326] Step 2: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[5-(3-trifluoromethyl- benzyl)-[l,3,4]oxadiazol-2-yl]-methanol: Prepared according to the procedure described in Example 19, Step 1, using 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carbaldehyde and 2- (3-trifluoromethyl-benzyl)-[l,3,4]oxadiazole.
[00327] Step 3: l-[4'-(4-{Hydroxy-[5-(3-trifluoromethyl-benzyl)-[l,3,4]oxadiazol-2-yl]- methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using [5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-[5-(3-trifluoromethyl-benzyl)-[l,3,4]oxadiazol-2- yl]-methanol and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]- cyclopropanecarboxylic acid ethyl ester.
[00328] Step 4: The ester from Step 3 was hydro lyzed to the acid according to the procedure described in Example 14, Step 3.
Example 29: Synthesis of 1 -[4'-(4- {Hydroxy- [l-(3-trifluoromethyl-benzyl)-lH- [ 1 ,2,3] triazol-4-yl] -methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl] - cyclopropanecarboxylic acid (Compound 21) [00329] Step 1: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[l-(3-trifluoromethyl- benzyl)-lH-[l,2,3]triazol-4-yl]-methanol: l-Bromomethyl-3-trifluoromethyl-benzene (0.0491 g, 0.205 mmol) and sodium azide (0.0222 g, 0.342 mmol) were combined in DMSO and stirred at room temperature for 2 hours. Then, l-[5-(4-bromo-phenyl)-3- methyl-isoxazol-4-yl]-prop-2-yn-l-ol (0.500 g, 0.171 mmol), copper(II)sulfate pentahydrate (0.0043 g, 0.017 mmol) and sodium ascorbate (0.0034 g, 0.017 mmol) were added and the reaction stirred at room temperature for 2 days. The reaction was submitted to standard aqueous workup and purified on silica gel to afford the title compound.
[00330] Step 2: l-[4'-(4-{Hydroxy-[l-(3-trifluoromethyl-benzyl)-lH-[l,2,3]triazol-4-yl]- methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using [5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-[l-(3-trifluoromethyl-benzyl)-lH-[l,2,3]triazol-4- yl]-methanol and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]- cyclopropanecarboxylic acid ethyl ester.
[00331] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 30: Synthesis of l-{4'-[4-(Biphenyl-3-yl-hydroxy-methyl)-3-methyl-isoxazol-
5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 22)
[00332] Step 1: Biphenyl-3-yl-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-methanol:
Prepared according to the procedure described in Example 16, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carbaldehyde and 3-(biphenyl)magnesium bromide.
[00333] Step 2: l-{4'-[4-(Biphenyl-3-yl-hydroxy-methyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using biphenyl-3-yl-[5-(4-bromo-phenyl)-3- methyl-isoxazol-4-yl] -methanol and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- phenylj-cyclopropanecarboxylic acid ethyl ester. Additionally, (Ι,Γ- bis(diphenylphosphino)ferrocene)-dichloropalladium(II) was used as the catalyst in place of tetrakis(triphenylphosphine)palladium(0)
[00334] Step 3: l-{4'-[4-(Biphenyl-3-yl-hydroxy-methyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid
[00335] 1 - {4'-[4-(biphenyl-3-yl-hydroxy-methyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid ethyl ester (1 equivalent) was dissolved in THF then EtOH and NaOH (3N aq., 3 equivalents) was added and the reaction stirred at 60 °C overnight. The reaction was worked up and purified via preparatory HPLC (0.1% TFA/H20/ACN).
Example 31: Synthesis of l-[4'-(4-{Hydroxy-[l-(l-phenyl-ethyl)-lH-[l,2,3]triazol-4-yl]- methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid
(Compound 23)
[00336] Step 1: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[l-(l-phenyl-ethyl)-lH- [l,2,3]triazol-4-yl]-methanol: Prepared according to the procedure described in Example 29, Step 1, using l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-prop-2-yn-l-ol and (1- bromo-ethyl)-benzene.
[00337] Step 2: l-[4'-(4-{Hydroxy-[l-(l-phenyl-ethyl)-lH-[l,2,3]triazol-4-yl]-methyl}-3- methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using [5-(4-bromo-phenyl)-3- methyl-isoxazol-4-yl]-[l-(l-phenyl-ethyl)-lH-[l,2,3]triazol-4-yl]-methanol and l-[4- (4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
[00338] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 32: Synthesis of 1 -[4'-(4- {Hydroxy- [l-(2-trifluoromethyl-benzyl)-lH- [ 1 ,2,3] triazol-4-yl] -methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl] - cyclopropanecarboxylic acid (Compound 24)
[00339] Step 1: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[l-(2-trifluoromethyl- benzyl)-lH-[l,2,3]triazol-4-yl]-methanol: Prepared according to the procedure described in Example 29, Step 1, using l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-prop-2-yn-l- ol and l-bromomethyl-2-trifluoromethyl-benzene.
[00340] Step 2: l-[4'-(4-{Hydroxy-[l-(2-trifluoromethyl-benzyl)-lH-[l,2,3]triazol-4-yl]- methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using [5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-[l-(2-trifluoromethyl-benzyl)-lH-[l,2,3]triazol-4- yl]-methanol and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]- cyclopropanecarboxylic acid ethyl ester.
[00341] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 3. Example 33: Synthesis of l-[4'-(4-{[l-(3-Chloro-benzyl)-lH-[l,2,3]triazol-4-yl]- hydroxy-methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 25)
[00342] Step 1: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[l-(3-chloro-benzyl)-lH- [l,2,3]triazol-4-yl]-methanol: Prepared according to the procedure described in Example 29, Step 1, using l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-prop-2-yn-l-ol and 1- bromomethyl-3-chloro-benzene.
[00343] Step 2: l-[4'-(4-{[l-(3-Chloro-benzyl)-lH-[l,2,3]triazol-4-yl]-hydroxy-methyl}- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester:
Prepared according to the procedure described in Example 1, Step 10, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-[ 1 -(3-chloro-benzyl)- lH-[ 1 ,2,3]triazol-4-yl]-methanol and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
[00344] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 34: Synthesis of l-(4'-{4-[(3-Benzyl-phenyl)-hydroxy-methyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 26)
[00345] Step 1: (3-Bromo-phenyl)-phenyl-methanol: Prepared according to the procedure described in Example 16, Step 1, using 3-bromobenzaldehyde and phenylmagnesium bromide.
[00346] Step 2: l-Benzyl-3-bromo-benzene: (3-Bromo-phenyl)-phenyl-methanol (from previous step) was dissolved in diethyl ether (10 mL) and the solution was added dropwise to a suspension of lithium aluminum hydride (0.607 g, 16 mmol) and aluminum chloride (2.11 g, 16 mmol) stirring in THF (15 mL). The reaction was heated to 40 °C for 1 hour then cooled to 0 °C, quenched with H20, and submitted to standard aqueous workup. The crude product was purified via silica gel chromatography (0-5% EtOAc in hexanes) to afford the title compound.
[00347] Step 3: (3-Benzyl-phenyl)-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]- methanol: l-Benzyl-3-bromo-benzene (0.811 g, 3.3 mmol) was dissolved in THF (2 mL), cooled to -78 °C and then n-butyllithium (2.0 M in THF, 1.65 mL, 3.3 mmol) was added dropwise. The reaction was stirred for 15 minutes then warmed to 0 °C and 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carbaldehyde (1.05 g, 3.96 mmol) was added. The reaction was allowed to warm to room temperature while stirring for 1 hour. The reaction was quenched with aqueous ammonium chloride then submitted to standard aqueous workup and silica gel chromatography to give the title compound.
[00348] Step 4: l-(4'-{4-[(3-Benzyl-phenyl)-hydroxy-methyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 17, Step 1, using (3-benzyl-phenyl)-[5-(4-bromo-phenyl)-
3 - methyl-isoxazol-4-yl] -methanol and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- phenylj-cyclopropanecarboxylic acid ethyl ester.
[00349] Step 5: The ester from Step 4 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 35: Synthesis of l-(4'-{4-[(5-Benzyl-pyridin-3-yl)-hydroxy-methyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 27)
[00350] Step 1: 3-Benzyl-5-bromo-pyridine: Benzylmagnesium bromide (1.0 M in THF, 20 mL, 20 mmol) was added to a solution of zinc chloride (2.73 g, 20 mmol) in THF (20 mL) and the reaction was heated to 50 °C for 2.5 hours. The solution was then added by canula to a solution of 3,5-dibromo-pyridine (3.07 g, 13 mmol), copper(I) iodide (0.0148 g, 0.78 mmol), and (l, -bis(diphenylphosphino)ferrocene)-dichloropalladium(II) (0.048 g, 0.65 mmol) in THF (20 mL). The reaction was heated to 50 °C for 48 hours then quenched with H20, submitted to standard aqueous workup, and purified via silica gel
chromatography (0-50% EtOAc in hexanes) to give the title compound.
[00351] Step 2: (5-Benzyl-pyridin-3-yl)-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]- methanol: 3-Benzyl-5-bromo-pyridine (0.474 g, 1.91 mmol) was dissolved in THF (10 mL) and cooled to 0 °C. Isopropylmagnesium chloride (2 M in THF, 0.96 mL, 1.91 mmol) was added dropwise and the reaction was allowed to warm to room temperature and stirred for 1 hour. Analytical LCMS indicated no reaction so an additional portion of
isopropylmagnesium chloride (1.91 mmol) was added and the reaction stirred for 1 hour at room temperature. Analytical LCMS still indicated no progress so the reaction was cooled to -78 °C and n-butyllithium (2.5 M in hexanes, 0.764 mL, 1.91 mL) was added. The reaction was allowed to slowly warm to 0 °C then 5-(4-bromo-phenyl)-3-methyl-isoxazole-
4- carbaldehyde (0.610 g, 2.29 mmol) was added and the reaction was allowed to warm to room temperature. The reaction was quenched with H20, submitted to standard aqueous workup and then purified via silica gel chromatography to yield the title compound.
[00352] Step 3: l-(4'-{4-[(5-Benzyl-pyridin-3-yl)-hydroxy-methyl]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 17, Step 1, using (5-benzyl-pyridin-3-yl)-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-methanol and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
[00353] Step 4: The ester from Step 3 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 36: Synthesis of l-[4'-(4-{[l-(2-Chloro-benzyl)-lH-[l,2,3]triazol-4-yl]- hydroxy-methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 28)
[00354] Step 1: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[l-(2-chloro-benzyl)-lH- [l,2,3]triazol-4-yl]-methanol: Prepared according to the procedure described in Example 29, Step 1, using l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-prop-2-yn-l-ol and 1- bromomethyl-2-chloro-benzene.
[00355] Step 2: l-[4'-(4-{[l-(2-Chloro-benzyl)-lH-[l,2,3]triazol-4-yl]-hydroxy-methyl}- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester:
Prepared according to the procedure described in Example 1, Step 10, using [5-(4-Bromo- phenyl)-3-methyl-isoxazol-4-yl]-[ 1 -(2-chloro-benzyl)- lH-[ 1 ,2,3]triazol-4-yl]-methanol and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
[00356] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 37: Synthesis of l-[4'-(4-{[l-(4-Chloro-benzyl)-lH-[l,2,3]triazol-4-yl]- hydroxy-methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 29)
[00357] Step 1: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[l-(4-chloro-benzyl)-lH- [l,2,3]triazol-4-yl]-methanol: Prepared according to the procedure described in Example 29, Step 1, using l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-prop-2-yn-l-ol and 1- bromomethyl-4-chloro-benzene.
[00358] Step 2: l-[4'-(4-{[l-(4-Chloro-benzyl)-lH-[l,2,3]triazol-4-yl]-hydroxy-methyl}- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester:
Prepared according to the procedure described in Example 1, Step 10, using [5-(4-Bromo- phenyl)-3-methyl-isoxazol-4-yl]-[ 1 -(4-chloro-benzyl)- lH-[ 1 ,2,3]triazol-4-yl]-methanol and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester. [00359] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 38: Synthesis of l-[4'-(4-{(R)-[l-(2-Chloro-benzyl)-lH-[l,2,3]triazol-4-yl]- hydroxy-methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 30)
[00360] Step 1: (S)-l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-prop-2-yn-l-ol: Zinc triflate (0.75 g, 2.1 mmol), (I S, 2R)-(+)-N-methylephedrine (0.41 g, 2.3 mmol) and triethylamine (0.23 g, 2.3 mmol) were stirred in toluene (10 mL) at room temperature for 2 hours. (Trimethylsilyl)acetylene (0.32 g, 2.3 mmol) was added and the reaction stirred for 15 minute then 5-(4-bromo-phenyl)-3-methyl-isoxazole-4-carbaldehyde (0.5 g, 1.9 mmol) was added and the reaction stirred at room temperature for 2 weeks. The reaction mixture was purified on by silica gel chromatography (0-20% EtOAc in hexanes) to afford the title product with 97.5% ee as measured by analytical chiral HPLC.
[00361] Step 2: (R)-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[l-(2-chloro-benzyl)- lH-[l,2,3]triazol-4-yl]-methanol: Prepared according to the procedure described in
Example 29, Step 1 , using (S)-l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-prop-2-yn-l- ol and l-bromomethyl-2-chloro-benzene.
[00362] Step 3: l-[4'-(4-{(R)-[l-(2-Chloro-benzyl)-lH-[l,2,3]triazol-4-yl]-hydroxy- methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1 , Step 10, using (R)-[5- (4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-[l-(2-chloro-benzyl)-lH-[l ,2,3]triazol-4-yl]- methanol and l-[4-(4,4,5,5-tetramethyl-[l ,3,2]dioxaborolan-2-yl)-phenyl]- cyclopropanecarboxylic acid ethyl ester.
[00363] Step 4: The ester from Step 3 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 39: Synthesis of l-[4'-(4-{[l-(3,4-Dichloro-benzyl)-lH-[l,2,3]triazol-4-yl]- hydroxy-methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 31)
[00364] Step 1: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[l-(3,4-dichloro-benzyl)- lH-[l,2,3]triazol-4-yl]-methanol: Prepared according to the procedure described in
Example 29, Step 1 , using l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-prop-2-yn-l-ol and 4-bromomethyl-l ,2-dichloro-benzene. [00365] Step 2: l-[4'-(4-{[l-(3,4-Dichloro-benzyl)-lH-[l,2,3]triazol-4-yl]-hydroxy- methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using [5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-[l-(3,4-dichloro-benzyl)-lH-[l,2,3]triazol-4-yl]- methanol and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]- cyclopropanecarboxylic acid ethyl ester.
[00366] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 40: Synthesis of l-[4'-(4-{(R)-Hydroxy-[l-((R)-l-phenyl-ethyl)-lH- [1 ,2,3] triazol-4-yl] -methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl] - cyclopropanecarboxylic acid (Compound 32)
[00367] Step 1: ((S)-l-Bromo-ethyl)-benzene: Bromine (3.2 g, 20.0 mmol) was added to a suspension of triphenylphosphine (5.2 g, 19.8 mmol) stirring in ACN at -15 °C. The reaction was warmed to room temperature and stirred for 50 mintues then cooled to -35 °C and (Pv)-(+)-l-phenylethanol (1.6 g, 13.1 mmol) was added. The reaction was allowed to warm to -10 °C over 70 minutes and was then quenched with H20 and submitted to standard aqueous workup to afford the title compound which was used without further purification.
[00368] Step 2: (R)-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[l-((R)-l-phenyl- ethyl)- lH-[l,2,3]triazol-4-yl]-methanol: Prepared according to the procedure described in Example 29, Step 1, using (S)-l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-prop-2-yn-l- ol and ((R)-l-bromo-ethyl)-benzene.
[00369] Step 3: l-[4'-(4-{(R)-Hydroxy-[l-((R)-l-phenyl-ethyl)-lH-[l,2,3]triazol-4-yl]- methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using (R)-[5- (4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[ 1 -((R)- 1 -phenyl-ethyl)- lH-[ 1 ,2,3]triazol-4-yl]- methanol and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]- cyclopropanecarboxylic acid ethyl ester.
[00370] Step 4: The ester from Step 3 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 41: Synthesis of l-{4'-[3-Methyl-4-(6-phenyl-pyridin-2-ylamino)-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 33) [00371] Step 1: 2-Bromo-6-phenyl-pyridine: 2,6-Dibromo-pyridine (1.2 g, 0.508 mmol), phenylboronic acid (0.620 g, 0.508 mmol) and sodium carbonate (2 M aq., 30 mL) were dissolved in MeOH (10 mL) and toluene (30 mL) and the solution was degassed with bubbling N2 (g). Tetrakis(triphenylphosphine)palladium(0) (0.172 g, 0.149 mmol) was added and the reaction was heated to 100 °C overnight. After cooling the reaction was submitted to standard aqueous workup and purified by silica gel chromatography to give the title compound.
[00372] Step 2: l-{4'-[3-Methyl-4-(6-phenyl-pyridin-2-ylamino)-isoxazol-5-yl]-biphenyl-
4-yl}-cyclopropanecarboxylic acid ethyl ester: l-[4'-(4-Amino-3-methyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester (0.250 g, 0.689 mmol), 2-bromo-6- phenyl-pyridine (0.1457 g, 0.62 mmol), cesium carbonate (0.2694 g, 0.826 mmol) and (±)-
2,2'-bis(diphenylphosphino)-l, -binaphthyl (0.032 g, 0.052 mmol) were dissolved in toluene (3 mL) and the solution was degassed with bubbling N2 (g).
Tris(dibenzylideneacetone)dipalladium(0) (0.0158 g, 0.017 mmol) was added and the reaction was heated to 110 °C for 24 hours. After cooling the reaction was submitted to standard aqueous workup and silica gel chromatography to afford the title compound.
[00373] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 42: Synthesis of l-(4'-{4-[(6-Benzyl-pyridin-2-yl)-hydroxy-methyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 34)
[00374] Step 1: 2-Benzyl-6-bromo-pyridine: 2,6-Dibromopyridine (2.36 g, 1 mmol), benzylzinc bromide (0.9 M in THF, 1.05 mL, 0.95 mmol) and
tetrakis(triphenylphosphine)palladium(0) (0.012 g, 0.01 mmol) were placed in THF (75 mL) and heated to 60 °C for 20 hours. The reaction mixture was cooled, submitted to standard aqueous workup and purified on silica gel to afford the title compound.
[00375] Step 2: (6-Benzyl-pyridin-2-yl)-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]- methanol: Prepared according to the procedure described in Example 34, Step 3, using 5- (4-bromo-phenyl)-3-methyl-isoxazole-4-carbaldehyde and 2-benzyl-6-bromo-pyridine.
[00376] Step 3: l-(4'-{4-[(6-Benzyl-pyridin-2-yl)-hydroxy-methyl]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using (6-benzyl-pyridin-2-yl)-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-methanol and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester. Additionally, (l, -bis(diphenylphosphino)ferrocene)-dichloropalladium(II) was used as the catalyst in place of tetrakis(triphenylphosphine)palladium(0).
[00377] Step 4: The ester from Step 3 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 43: Synthesis of l-[4'-(4-{Hydroxy-[l-(2-methyl-benzyl)-lH-[l,2,3]triazol-4- yl] -methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl] -cyclopropanecarboxylic acid (Compound 35)
[00378] Step 1: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[l-(2-methyl-benzyl)-lH- [l,2,3]triazol-4-yl]-methanol: Prepared according to the procedure described in Example 29, Step 1, using l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-prop-2-yn-l-ol and 1- bromomethyl-2-methyl-benzene.
[00379] Step 2: l-[4'-(4-{Hydroxy-[l-(2-methyl-benzyl)-lH-[l,2,3]triazol-4-yl]-methyl}- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl] -cyclopropanecarboxylic acid ethyl ester:
Prepared according to the procedure described in Example 1, Step 10, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-[ 1 -(2 -methyl-benzyl)- lH-[ 1 ,2,3]triazol-4-yl]-methanol and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
[00380] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 44: Synthesis of l-[4'-(4-{[l-(2-Chloro-6-fluoro-benzyl)-lH-[l,2,3]triazol-4- yl]-hydroxy-methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 36)
[00381] Step 1: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[l-(2-chloro-6-fluoro- benzyl)-lH-[l,2,3]triazol-4-yl]-methanol: Prepared according to the procedure described in Example 29, Step 1, using l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-prop-2-yn-l- ol and 2-bromomethyl-l-chloro-3-fluoro-benzene.
[00382] Step 2: l-[4'-(4-{[l-(2-Chloro-6-fluoro-benzyl)-lH-[l,2,3]triazol-4-yl]-hydroxy- methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using [5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-[l-(2-chloro-6-fluoro-benzyl)-lH-[l,2,3]triazol-4- yl]-methanol and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]- cyclopropanecarboxylic acid ethyl ester. [00383] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 45: Synthesis of l-[4'-(4-{[l-(2,6-Dichloro-benzyl)-lH-[l,2,3]triazol-4-yl]- hydroxy-methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 37)
[00384] Step 1: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[l-(2,6-dichloro-benzyl)- lH-[l,2,3]triazol-4-yl]-methanol: Prepared according to the procedure described in Example 29, Step 1, using l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-prop-2-yn-l-ol and 2-bromomethyl-l ,3-dichloro-benzene.
[00385] Step 2: l-[4'-(4-{[l-(2,6-Dichloro-benzyl)-lH-[l,2,3]triazol-4-yl]-hydroxy- methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using [5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-[ 1 -(2,6-dichloro-benzyl)-lH-[ 1 ,2,3]triazol-4-yl]- methanol and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]- cyclopropanecarboxylic acid ethyl ester.
[00386] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 46: Synthesis of l-{4'-[4-(6-Benzyl-pyridin-2-ylamino)-3-methyl-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 38)
[00387] Step 1: l-{4'-[4-(6-Benzyl-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl- 4-yl}-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)-biphenyl-4- yl] -cyclopropanecarboxylic acid ethyl ester and 2-benzyl-6-bromo-pyridine.
[00388] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 47: Synthesis of l-{4'-[4-(Biphenyl-3-ylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 39)
[00389] Step 1: l-{4'-[4-(Biphenyl-3-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester and 3-bromo-biphenyl.
[00390] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3. Example 48: Synthesis of l-{4'-[4-(Biphenyl-4-ylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 40)
[00391] Step 1: l-{4'-[4-(Biphenyl-4-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester and 4-bromo-biphenyl.
[00392] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 49: Synthesis of l-(4'-{3-Methyl-4-[6-(3-trifluoromethyl-phenyl)-pyridin-2- ylamino]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 41)
[00393] Step 1: 4,4,5,5-Tetramethyl-2-(3-trifluoromethyl-phenyl)-[l,3,2]dioxaborolane:
Prepared according to the procedure described in Example 1, Step 9, using l-bromo-3- trifluoromethyl-benzene and bis(pinacolato)diboron.
[00394] Step 2: 2-Bromo-6-(3-trifluoromethyl-phenyl)-pyridine: Prepared according to the procedure described in Example 1, Step 10, using 4,4,5 ,5-tetramethyl-2-(3- trifluoromethyl-phenyl)-[l,3,2]dioxaborolane and 2,6-dibromo-pyridine. Additionally, (Ι,Γ- bis(diphenylphosphino)ferrocene)-dichloropalladium(II) was used as the catalyst in place of tetrakis(triphenylphosphine)palladium(0).
[00395] Step 3: l-(4'-{3-Methyl-4-[6-(3-trifluoromethyl-phenyl)-pyridin-2-ylamino]- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl- isoxazol-5-yl)-biphenyl-4-yl] -cyclopropanecarboxylic acid ethyl ester and 2-bromo-6-(3- trifluoromethyl-phenyl)-pyridine.
[00396] Step 4: The ester from Step 3 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 50: Synthesis of l-{4'-[3-Methyl-4-(6-phenyl-pyrazin-2-ylamino)-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 42)
[00397] Step 1: 2-Bromo-6-phenyl-pyrazine: Prepared according to the procedure described in Example 1, Step 10, using 2,6-dibromo-pyrazine and phenylboronic acid. Additionally, (l, -bis(diphenylphosphino)ferrocene)-dichloropalladium(II) was used as the catalyst in place of tetrakis(triphenylphosphine)palladium(0).
[00398] Step 2: l-{4'-[3-Methyl-4-(6-phenyl-pyrazin-2-ylamino)-isoxazol-5-yl]-biphenyl- 4-yl}-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)-biphenyl-4- yl]-cyclopropanecarboxylic acid ethyl ester and 2-bromo-6-phenyl-pyrazine.
[00399] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 51: Synthesis of l-{4'-[3-Methyl-4-(5-phenyl-[l,3,4]oxadiazol-2-ylamino)- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 43)
[00400] Step 1: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-(5-phenyl-[l,3,4]oxadiazol- 2-yl)-amine: 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid (1 g, 3.6 mmol), triethylamine (1 mL, 7.2 mmol) and diphenylphosphoryl azide (1.98 g, 7.2 mmol) were placed in toluene (20 mL) and heated to 60 °C for 20 minutes. Benzoic acid hydrazide
(0.98 g, 7.2 mmol) was added in a single portion and the reaction was heated and stirred for 2 hours. The reaction was cooled and submitted to aqueous workup. The crude material was dissolved in dioxane (100 mL), phosphorous(V) oxychloride was added and the reaction was heated to 100 °C overnight. The reaction was cooled and worked up and the residue was purified on silica gel (0-80% EtOAc in hexanes ) to yield the title compound.
[00401] Step 2: l-{4'-[3-Methyl-4-(5-phenyl-[l,3,4]oxadiazol-2-ylamino)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using [5-(4-bromo-phenyl)-3-methyl-isoxazol- 4-yl]-(5-phenyl-[l,3,4]oxadiazol-2-yl)-amine and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester. Additionally, (l, -bis(diphenylphosphino)ferrocene)-dichloropalladium(II) was used as the catalyst in place of tetrakis(triphenylphosphine)palladium(0).
[00402] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 52: Synthesis of l-{4'-[4-(5-Benzyl-[l,3,4]oxadiazol-2-ylamino)-3-methyl- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 44)
[00403] Step 1: Phenyl-acetic acid hydrazide: Phenyl-acetic acid methyl ester (5 g, 33.3 mmol) was dissolved in hydrazine hydrate (25 mL) and EtOH (50 mL) and the reaction was heated in a sealed tube to 80 °C overnight. After cooling the reaction was concentrated to afford the title compound.
[00404] Step 2: (5-Benzyl-[l,3,4]oxadiazol-2-yl)-[5-(4-bromo-phenyl)-3-methyl-isoxazol- 4-yl]-amine: Prepared according to the procedure described in Example 51, Step 1, using 5- (4-bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid and phenyl-acetic acid hydrazide. [00405] Step 3: l-{4'-[4-(5-Benzyl-[l,3,4]oxadiazol-2-ylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using (5-benzyl-[l,3,4]oxadiazol-2-yl)-[5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-amine and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester. Additionally, (l, -bis(diphenylphosphino)ferrocene)-dichloropalladium(II) was used as the catalyst in place of tetrakis(triphenylphosphine)palladium(0).
[00406] Step 4: The ester from Step 4 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 53: Synthesis of l-(4'-{4-[6-(2-Fluoro-benzyl)-pyridin-2-ylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 45)
[00407] Step 1: 2-Fluoro-benzylzinc bromide: 2-Fluoro-benzyl bromide (1 g, 5.29 mmol), zinc (0.380 g, 5.82 mmol) and 1 ,2-dibromoethane (0.050 mL, 0.58 mmol) were mixed in THF (10 ML) and heated to reflux overnight. After cooling a solution of the title compound was obtained that was used directly and immediately in the next step.
[00408] Step 2: 2-Bromo-6-(2-fluoro-benzyl)-pyridine: A solution of 2-fluoro-benzylzinc bromide was added to 2,6-dibromo-pyridine (1.25 g, 5.27 mmol) then
tetrakis(triphenylphosphine)palladium(0) (0.122 g, 0.106 mmol) was added and the reaction was heated to 68 °C for 4 hours. After cooling, silica gel was added to the reaction and it was concentrated to near-dryness. The silica gel was loaded onto a column of silica gel for purification to afford thet title compound.
[00409] Step 3: l-(4'-{4-[6-(2-Fluoro-benzyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 2-bromo-6-(2-fluoro-benzyl)- pyridine.
[00410] Step 4: The ester from Step 3 was hydrolyzed to the acid according to the procedure described in Example 3.
Example 54: Synthesis of l-(4'-{4-[6-(3-Fluoro-benzyl)-pyridin-2-ylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 46)
[00411] Step 1: 3-Fluoro-benzylzinc bromide: Prepared according to the procedure described in Example 53, Step 1, using 3-fluoro-benzyl bromide. [00412] Step 2: 2-Bromo-6-(3-fluoro-benzyl)-pyridine: Prepared according to the procedure described in Example 53, Step 2, using 2,6-dibromo-pyridine and 3-fluoro- benzylzinc bromide.
[00413] Step 3: l-(4'-{4-[6-(3-Fluoro-benzyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 2-bromo-6-(3-fluoro-benzyl)- pyridine.
[00414] Step 4: The ester from Step 3 was hydrolyzed to the acid according to the procedure described in Example 3.
Example 55: Synthesis of l-(4'-{4-[6-(4-Fluoro-benzyl)-pyridin-2-ylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 47)
[00415] Step 1: 4-Fluoro-benzylzinc bromide: Prepared according to the procedure described in Example 53, Step 1, using 4-fluoro-benzyl bromide.
[00416] Step 2: 2-Bromo-6-(4-fluoro-benzyl)-pyridine: Prepared according to the procedure described in Example 53, Step 2, using 2,6-dibromo-pyridine and 4-fluoro- benzylzinc bromide.
[00417] Step 3: l-(4'-{4-[6-(4-Fluoro-benzyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 2-bromo-6-(4-fluoro-benzyl)- pyridine.
[00418] Step 4: The ester from Step 3 was hydrolyzed to the acid according to the procedure described in Example 3.
Example 56: Synthesis of l-(4'-{4-[6-(3-Methoxy-phenyl)-pyridin-2-ylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 48)
Step 1: l-(4'-{4-[6-(3-Methoxy-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using l-{4'-[4-(6-bromo-pyridin-2-ylamino)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 3- methoxyphenylboronic acid.
[00419] Step 2: The ester from Step 1 was hydrolyzed to the acid according to the procedure described in Example 3. Example 57: Synthesis of l-{4'-[4-(3-Benzyl-phenylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 49)
[00420] Step 1: l-{4'-[4-(3-Benzyl-phenylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester and l-benzyl-3-bromo-benzene.
[00421] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 58: Synthesis of l-(4'-{4-[6-(2-Cyano-phenyl)-pyridin-2-ylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 50)
[00422] Step 1: l-(4'-{4-[6-(2-Cyano-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using l-{4'-[4-(6-bromo-pyridin-2-ylamino)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester and 2- cyanophenylboronic acid.
[00423] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 59: Synthesis of l-(4'-{4-[6-(4-Methoxy-phenyl)-pyridin-2-ylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 51)
Step 1: l-(4'-{4-[6-(4-Methoxy-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using l-{4'-[4-(6-bromo-pyridin-2-ylamino)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester and 4- methoxyphenylboronic acid.
[00424] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 60: Synthesis of l-(4'-{4-[6-(3-Fluoro-phenyl)-pyridin-2-ylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 52)
[00425] Step 1: l-(4'-{4-[6-(3-Fluoro-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using l-{4'-[4-(6-bromo-pyridin-2-ylamino)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester and 3- fluorophenylboronic acid. [00426] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 61: Synthesis of l-(4'-{4-[6-(2-Methoxy-phenyl)-pyridin-2-ylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 53)
[00427] Step 1: l-(4'-{4-[6-(2-Methoxy-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 3-(3-bromo-phenyl)-2-methoxy- pyridine.
[00428] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 62: Synthesis of l-(4'-{4-[6-(2-Fluoro-phenyl)-pyridin-2-ylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 54)
[00429] Step 1: l-(4'-{4-[6-(2-Fluoro-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using l-{4'-[4-(6-bromo-pyridin-2-ylamino)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 2-(2- fluoro-phenyl)-4,4,5,5-tetramethyl-[l,3,2]dioxaborolane.
[00430] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 63: Synthesis of l-(4'-{3-methyl-4-[6-(2-trifluoromethyl-phenyl)-pyridin-2- ylamino]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 55) Step 1: l-(4'-{3-Methyl-4-[6-(2-trifluoromethyl-phenyl)-pyridin-2-ylamino]-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using l-{4'-[4-(6-bromo-pyridin-2-ylamino)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 4,4,5,5- tetramethyl-2-(2-trifluoromethyl-phenyl)-[l,3,2]dioxaborolane.
[00431] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 64: Synthesis of l-(4'-{3-Methyl-4-[(2-phenyl-thiazol-5-ylmethyl)-amino]- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 56)
[00432] Step 1: l-(4'-{3-Methyl-4-[(2-phenyl-thiazol-5-ylmethyl)-amino]-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 12, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)- biphenyl-4-yl] -cyclopropanecarboxylic acid ethyl ester and 2-phenyl-thiazole-5- carbaldehyde.
[00433] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 65: Synthesis of l-{4'-[3-Methyl-4-(2'-trifluoromethyl-biphenyl-3-ylamino)- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 57)
[00434] Step 1: l-{4'-[4-(3-Bromo-phenylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester and 1,3-dibromo-benzene.
[00435] Step 2: l-{4'-[3-Methyl-4-(2'-trifluoromethyl-biphenyl-3-ylamino)-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using l-{4'-[4-(3-bromo-phenylamino)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester and 2-
(trifluoromethyl)phenylboronic acid.
[00436] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 66: Synthesis of l-{4'-[3-Methyl-4-(5-phenyl-pyridin-3-ylamino)-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 58)
[00437] Step 1: 3-Bromo-5-phenyl-pyridine: Prepared according to the procedure described in Example 1, Step 10, using 3,5-dibromo-pyridine and phenylboronic acid.
[00438] Step 2: l-{4'-[3-Methyl-4-(5-phenyl-pyridin-3-ylamino)-isoxazol-5-yl]-biphenyl-
4-yl}-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)-biphenyl-4- yl] -cyclopropanecarboxylic acid ethyl ester and 3 -bromo-5 -phenyl-pyridine.
[00439] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 67: Synthesis of l-(4'-{4-[5-(3-Fluoro-phenyl)-pyridin-3-ylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 59)
[00440] Step 1: 3-Bromo-5-(3-fluoro-phenyl)-pyridine: Prepared according to the procedure described in Example 1, Step 10, using 3,5-dibromo-pyridine and 3- flurophenylboronic acid. [00441] Step 2: l-(4'-{4-[5-(3-Fluoro-phenyl)-pyridin-3-ylamino]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 3-bromo-5-(3-fluoro-phenyl)- pyridine.
[00442] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 68: Synthesis of l-(4'-{4-[6-(2-Chloro-phenyl)-pyridin-2-ylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 60)
[00443] Step 1: l-(4'-{4-[6-(2-Chloro-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using l-{4'-[4-(6-bromo-pyridin-2-ylamino)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 2- chlorophenylboronic acid.
[00444] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 69: Synthesis of l-(4'-{4-[Hydroxy-(6-phenyl-pyridin-2-yl)-methyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 61)
[00445] Step 1: l-(4'-{4-[Hydroxy-(6-phenyl-pyridin-2-yl)-methyl]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 34, Step 3, using l-[4'-(4-formyl-3-methyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 2-bromo-6-phenyl-pyridine.
[00446] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 70: Synthesis of l-{4'-[3-Methyl-4-(2-phenyl-pyridin-4-ylamino)-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 62)
[00447] Step 1: l-{4'-[3-Methyl-4-(2-phenyl-pyridin-4-ylamino)-isoxazol-5-yl]-biphenyl- 4-yl}-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)-biphenyl-4- yl]-cyclopropanecarboxylic acid ethyl ester and 4-bromo-2 -phenyl-pyridine.
[00448] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3. Example 71: Synthesis of l-(4'-{4-[2-(3-Fluoro-phenyl)-pyridin-4-ylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 63)
[00449] Step 1: l-(4'-{4-[2-(3-Fluoro-phenyl)-pyridin-4-ylamino]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 4-bromo-2-(3-fluoro-phenyl)- pyridine.
[00450] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 72: Synthesis of l-(4'-{4-[5-(2-Chloro-phenyl)-pyridin-3-ylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 64)
[00451] Step 1: 3-Bromo-5-(2-chloro-phenyl)-pyridine: Prepared according to the procedure described in Example 1, Step 10, using 3,5-dibromo-pyridine and 2- chlorophenylboronic acid.
[00452] Step 2: l-(4'-{4-[5-(2-Chloro-phenyl)-pyridin-3-ylamino]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 3-bromo-5-(2-chloro-phenyl)- pyridine.
[00453] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 73: Synthesis of l-(4'-{4-[2-(2-Chloro-phenyl)-pyridin-4-ylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 65)
[00454] Step 1: 4-Bromo-2-(2-chloro-phenyl)-pyridine: Prepared according to the procedure described in Example 1, Step 10, using 2,4-dibromo-pyridine and 2- chlorophenylboronic acid.
[00455] Step 2: l-(4'-{4-[2-(2-Chloro-phenyl)-pyridin-4-ylamino]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 4-bromo-2-(2-chloro-phenyl)- pyridine.
[00456] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 3. Example 74: Synthesis of l-{4'-[3-Methyl-4-(4-phenyl-pyrimidin-2-ylamino)-isoxazol- 5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 66)
[00457] Step 1: l-{4'-[3-Methyl-4-(4-phenyl-pyrimidin-2-ylamino)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 2-bromo-4-phenyl-pyrimidine.
[00458] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 75: Synthesis of l-{4'-[3-Methyl-4-(4-phenyl-pyridin-2-ylamino)-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 67)
[00459] Step 1: l-{4'-[3-Methyl-4-(4-phenyl-pyridin-2-ylamino)-isoxazol-5-yl]-biphenyl- 4-yl}-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)-biphenyl-4- yl]-cyclopropanecarboxylic acid ethyl ester and 2-bromo-4-phenyl-pyridine.
[00460] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 76: Synthesis of l-(4'-{3-Methyl-4-[5-(3-trifluoromethyl-phenyl)-pyridin-3- ylamino]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 68)
[00461] Step 1: 3-Bromo-5-(3-trifluoromethyl-phenyl)-pyridine: Prepared according to the procedure described in Example 1, Step 10, using 3,5-dibromo-pyridine and 3- (trifluoromethyl)-phenylboronic acid.
[00462] Step 2: l-(4'-{3-Methyl-4-[5-(3-trifluoromethyl-phenyl)-pyridin-3-ylamino]- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl- isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 3-bromo-5-(3- trifluoromethyl-phenyl)-pyridine.
[00463] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 77: Synthesis of l-(4'-{3-Methyl-4-[5-(4-trifluoromethyl-phenyl)-pyridin-3- ylamino]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 69)
[00464] Step 1: 3-Bromo-5-(4-trifluoromethyl-phenyl)-pyridine: Prepared according to the procedure described in Example 1, Step 10, using 3,5-dibromo-pyridine and 4- (trifluoromethyl)-phenylboronic acid. [00465] Step 2: l-(4'-{3-Methyl-4-[5-(4-trifluoromethyl-phenyl)-pyridin-3-ylamino]- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl- isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 3-bromo-5-(4- trifluoromethyl-phenyl)-pyridine.
[00466] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 78: Synthesis of l-{4'-[3-Methyl-4-(6-phenyl-pyridin-2-ylamino)-isoxazol-5- yl]-biphenyl-4-yl}-cyclobutanecarboxylic acid (Compound 70)
[00467] Step 1: l-(4-Bromo-phenyl)-cyclobutanecarboxylic acid ethyl ester: Ethyl 4- bromophenyl acetate (2 g, 8.2 mmol) was dissolved in DMF (20 mL) and cooled to 0 °C under N2 atmosphere. Sodium hydride (60% in mineral oil, 0.72 g, 18.1 mmol) was added and the reaction was allowed to warm to room temperature. After 10 minutes the ice bath was replaced and 1,3-dibromopropane (0.92 mL, 9.0 mmol) was added, and the reaction was again allowed to warm to room temperature. After 30 minutes the reaction was submitted to aqueous workup and purified on silica gel to give the title compound.
[00468] Step 2: l-[4-(4,4,5,5-Tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]- cyclobutanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 9, using l-(4-bromo-phenyl)-cyclobutanecarboxylic acid ethyl ester and bis(pinacolato)diboron.
[00469] Step 3: l-[4'-(4-tei"i-Butoxycarbonylamino-3-methyl-isoxazol-5-yl)-biphenyl-4- yl] -cyclobutanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using [5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-carbamic acid tert-butyl ester and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]- cyclobutanecarboxylic acid ethyl ester. Additionally, (Ι,Γ- bis(diphenylphosphino)ferrocene)-dichloropalladium(II) was used as the catalyst in place of tetrakis(triphenylphosphine)palladium(0).
[00470] Step 4: l-[4'-(4-Amino-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclobutanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 9, using l-[4'-(4-tert-butoxycarbonylamino-3-methyl-isoxazol-5-yl)- biphenyl-4-yl] -cyclobutanecarboxylic acid ethyl ester.
[00471] Step 5: l-{4'-[3-Methyl-4-(6-phenyl-pyridin-2-ylamino)-isoxazol-5-yl]-biphenyl- 4-yl}-cyclobutanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)-biphenyl-4- yl]-cyclobutanecarboxylic acid ethyl ester and 2-bromo-6-phenyl-pyridine.
[00472] Step 6: The ester from Step 5 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 79: Synthesis of l-(4'-{4-[Hydroxy-(5-phenyl-pyridin-3-yl)-methyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 71)
[00473] Step 1: l-(4'-{4-[Hydroxy-(5-phenyl-pyridin-3-yl)-methyl]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 19, Step 1, using l-[4'-(4-formyl-3-methyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 3-bromo-5-phenyl-pyridine.
[00474] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 80: Synthesis of l-[4'-(4-{Hydroxy-[5-(3-trifluoromethyl-phenyl)-pyridin-3- yl] -methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl] -cyclopropanecarboxylic acid (Compound 72)
[00475] Step 1: l-[4'-(4-{Hydroxy-[5-(3-trifluoromethyl-phenyl)-pyridin-3-yl]-methyl}- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl] -cyclopropanecarboxylic acid ethyl ester:
Prepared according to the procedure described in Example 19, Step 1, using l-[4'-(4-formyl- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 3- bromo-5-(3-trifluoromethyl-phenyl)-pyridine.
[00476] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 81: Synthesis of l-{4'-[3-Methyl-4-(6-phenylethynyl-pyridin-2-ylamino)- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 73)
[00477] Step 1: l-{4'-[3-Methyl-4-(6-phenylethynyl-pyridin-2-ylamino)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester: l-{4'-[4-(6-Bromo-pyridin-2- ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester (0.200 g, 0.386 mmol) was dissolved in toluene along with phenylacetylene (0.051 mL, 0.46 mmol), copper(I) iodide (0.367 g, 1.93 mmol), triethylamine (0.269 mL, 1.93 mmol) and bis(triphenylphosphine)palladium(II) dichloride (0.032 g, 0.039 mmol). The reaction was heated to 40 °C for 3 days then cooled, diluted with EtOAc and filtered through a plug of silica gel. The crude material was purified on silica gel to yield the title compound. [00478] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 82: Synthesis of l-(4'-{4-[6-(3-Cyano-phenyl)-pyridin-2-ylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 74)
[00479] Step 1: l-(4'-{4-[6-(3-Cyano-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using l-{4'-[4-(6-bromo-pyridin-2-ylamino)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 3-cyano- phenylboronic acid.
[00480] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 83: Synthesis of l-(4'-{4-[6-(5-Fluoro-2-methoxy-phenyl)-pyridin-2-ylamino]- 3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 75)
[00481] Step 1: l-(4'-{4-[6-(5-Fluoro-2-methoxy-phenyl)-pyridin-2-ylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using l-{4'-[4-(6-bromo- pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 5-fluoro-2-methoxy-phenylboronic acid.
[00482] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 84: Synthesis of l-(4'-{4-[6-(3-Chloro-5-fluoro-phenyl)-pyridin-2-ylamino]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 76)
[00483] Step 1: l-(4'-{4-[6-(3-Chloro-5-fluoro-phenyl)-pyridin-2-ylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using l-{4'-[4-(6-bromo- pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 3-chloro-5-fluorophenylboronic acid.
[00484] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 85: Synthesis of l-(4'-{4-[6-(2,5-Difluoro-phenyl)-pyridin-2-ylamino]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 77)
[00485] Step 1: l-(4'-{4-[6-(2,5-Difluoro-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol- 5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using l-{4'-[4-(6-bromo-pyridin-2-ylamino)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 2,5- difluoro-phenylboronic acid.
[00486] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 86: Synthesis of l-(4'-{4-[6-(2,6-Dichloro-phenyl)-pyridin-2-ylamino]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 78)
[00487] Step 1: l-(4'-{4-[6-(2,6-Dichloro-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol- 5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using l-{4'-[4-(6-bromo-pyridin-2-ylamino)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 2,6- dichloro-phenylboronic acid. Additionally, (l,l'-bis(diphenylphosphino)ferrocene)- dichloropalladium(II) was used as the catalyst in place of
tetrakis(triphenylphosphine)palladium(0).
[00488] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 87: Synthesis of l-(4'-{4-[6-(2-Chloro-5-fluoro-phenyl)-pyridin-2-ylamino]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 79)
[00489] Step 1: l-(4'-{4-[6-(2-Chloro-5-fluoro-phenyl)-pyridin-2-ylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using l-{4'-[4-(6-bromo- pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 2-chloro-5-fluoro-phenylboronic acid. Additionally, (Ι,Γ- bis(diphenylphosphino)ferrocene)-dichloropalladium(II) was used as the catalyst in place of tetrakis(triphenylphosphine)palladium(0).
[00490] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 88: Synthesis of l-(4'-{4-[6-(2,3-Difluoro-phenyl)-pyridin-2-ylamino]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 80)
[00491] Step 1: l-(4'-{4-[6-(2,3-Difluoro-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol- 5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using l-{4'-[4-(6-bromo-pyridin-2-ylamino)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 2,3- difluoro-phenylboronic acid. Additionally, (l, -bis(diphenylphosphino)ferrocene)- dichloropalladium(II) was used as the catalyst in place of
tetrakis(triphenylphosphine)palladium(0).
[00492] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 89: Synthesis of l-(4'-{4-[6-(2-Chloro-3-fluoro-phenyl)-pyridin-2-ylamino]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 81)
[00493] Step 1: l-(4'-{4-[6-(2-Chloro-3-fluoro-phenyl)-pyridin-2-ylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using l-{4'-[4-(6-bromo- pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 2-chloro-3-fluoro-phenylboronic acid. (Ι,Γ- Bis(diphenylphosphino)ferrocene)-dichloropalladium(II) was used in place of
tetrakis(triphenylphosphine)palladium(0).
[00494] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 90: Synthesis of l-(4'-{4-[5-(2-Chloro-3-fluoro-phenyl)-pyridin-3-ylamino]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 82)
[00495] Step 1: 3-Bromo-5-(2-chloro-3-fluoro-phenyl)-pyridine: Prepared according to the procedure described in Example 1, Step 10, using 3,5-dibromo-pyridine and 2-chloro-3- fluoro-phenylboronic acid. (1,1 '-bis(diphenylphosphino)ferrocene)-dichloropalladium(II) was used in place of tetrakis(triphenylphosphine)palladium(0).
[00496] Step 2: l-(4'-{4-[5-(2-Chloro-3-fluoro-phenyl)-pyridin-3-ylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl- isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 3-bromo-5-(2- chloro-3-fluoro-phenyl)-pyridine.
[00497] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 91: Synthesis of l-(4'-{4-[6-(3-Fluoro-2-methyl-phenyl)-pyridin-2-ylamino]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 83)
[00498] Step 1: l-(4'-{4-[6-(3-Fluoro-2-methyl-phenyl)-pyridin-2-ylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1 , Step 10, using l- {4'-[4-(6-bromo- pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 3-fluoro-2-metheyl-phenylboronic acid. Additionally, (Ι ,Γ- bis(diphenylphosphino)ferrocene)-dichloropalladium(II) was used as the catalyst in place of tetrakis(triphenylphosphine)palladium(0).
[00499] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 92: Synthesis of l-(4'-{4-[6-(2-Chloro-3-trifluoromethyl-phenyl)-pyridin-2- ylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid
(Compound 84)
[00500] Step 1: l-(4'-{4-[6-(2-Chloro-3-trifluoromethyl-phenyl)-pyridin-2-ylamino]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1 , Step 10, using l- {4'-[4-(6-bromo- pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 2-chloro-3-(trifluoromethyel)phenylboronic acid. Additionally, (Ι ,Γ- bis(diphenylphosphino)ferrocene)-dichloropalladium(II) was used as the catalyst in place of tetrakis(triphenylphosphine)palladium(0).
[00501] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 93: Synthesis of Synthesis of V-[l-(4'-{4-[(l-Benzyl-lH-[l,2,3]triazol-4-yl)- hydroxy-methyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarbonyl]- methanesulfonamide (Enantiomer B) (Compound 91)
[00502] A solution of l-(4'-{4-[(l-benzyl-lH-[l ,2,3]triazol-4-yl)-hydroxy-methyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Enantiomer B) (0.100 g, 0.197 mmol), carbonyldiimidazole (0.080 g, 0.5 mmol), N,N-dimethylamino pyridine (0.002 g, 0.02 mmol) in THF (2 mL) was stirred at room temperature overnight. Added MeS02NH2 (0.050 g, 0.5 mmol) and DBU (0.100 mL, 0.65 mmol) and the mixture heated to 100°C in a capped vial for 4.5 hours. The solution was poured into sat. aqueous NH4C1, then water and EtOAc was added. The organic layer was separated, dried (Na2S04), concentrated and the resulting reside purified by preparative HPLC to yield the title compound.
Example 94: Synthesis of V-[l-(4'-{4-[(5-Benzyl-[l,3,4]oxadiazol-2-yl)-hydroxy- methyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarbonyl]- methanesulfonamide (Enantiomer A) (Compound 92) [00503] Step 1: N-[l-(4-Bromo-phenyl)-cyclopropanecarbonyl]-methanesulfonamide: 1-
(4-Bromo-phenyl)-cyclopropanecarboxylic acid (22 g, 91.3 mmol) and S0C12 (13.6 mL, 183 mmol) in CH2C12 were heated together for 1.5 hours then evaporated to afford a dark oil. This oil was added via syringe over 30 minutes to a mixture of MeS02NH2 (19 g, 200 mmol) in THF (250 mL) that was pre -treated at room temperature with NaH (60% in oil; 8.0 g, 200 mmol) for 1.5 hours. After a further 20 minutes, the mixture was poured into water, acidified and extracted with CH2C12, washed with water (2x) and evaporated to -100 mL. Hexane (300 mL) was added and the product collected by filtration to yield the title compound (25 g).
[00504] Step 2: V-{l-[4-(4,4,5,5-Tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]- cyclopropanecarbonyl}-methanesulfonamide: N-[l-(4-Bromo-phenyl)- cyclopropanecarbonylj-methanesulfonamide (22 g, 69 mmol), bis(pinacolato)diborane (21.1 g, 83 mmol), KOAc (21.6 g, 220 mmol) in dioxane (300 mL) were degassed with N2 for 30 minutes and then (l, -bis(diphenylphosphino)ferrocene)-dichloropalladium(II) (1.0 g, 1.4 mmol) was added. The mixture was heated at reflux for 2 hours then at 70°C for 16 hours. Then solution was poured into EtOAc/H20, acidified and the organic layer concentrated to give the boronate which was used in the next step without further purification.
[00505] Step 3: V-[l-(4'-{4-[(5-Benzyl-[l,3,4]oxadiazol-2-yl)-hydroxy-methyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarbonyl]-methanesulfonamide
(Enantiomer A): A solution of N-{l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- phenyl]-cyclopropanecarbonyl}-methanesulfonamide (0.045 g, 0.124 mmol), 5-benzyl- [1, 3, 4]oxadiazol-2-yl)- [5 -(4-bromo-phenyl)-3-methyl-isoxazol-4-yl] -methanol (Enantiomer A) (0.053 g, 0.124 mmol), NaHC03 (0.031 g, 0.372 mmol), DME (1.5 mL) and H20 (1 mL) was degassed by bubbling with N2 for 10 minutes.
Tetrakis(triphenylphosphine)palladium(0) (0.007g, 0.006 mmol) was added and the sealed reaction vial was stirred at 80°C for 16 hours. The mixture was poured into EtOAc/H20, washed with IN HCl then aqueous Na2S04 and concentrated. The resulting reside purified by preparative HPLC to yield the title compound.
Example 95: Synthesis of V-{l-[4'-(4-{Hydroxy-[l-(3-trifluoromethyl-benzyl)-lH- [1 ,2,3] triazol-4-yl] -methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl] - cyclopropanecarbonyl}-methanesulfonamide (Compound 93)
[00506] Step 1: Prepared according to the procedure described in Example 94, Step 3, using [5 -(4-bromo-phenyl)-3 -methyl-isoxazol-4-y 1] - [ 1 -(3 -trifluoromethyl-benzyl)- 1H- [l,2,3]triazol-4-yl]-methanol and N-{l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- phenyl]-cyclopropanecarbonyl}-methanesulfonamide.
Example 96: Synthesis of V-(l-{4'-[3-Methyl-4-(5-phenyl-[l,3,4]oxadiazol-2-ylamino)- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarbonyl)-methanesulfonamide (Compound 94)
[00507] Step 1: Prepared according to the procedure described in Example 94, Step 3, using [5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-(5-phenyl-[l,3,4]oxadiazol-2-yl)-amine and N-{l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarbonyl}- methanesulfonamide .
Example 97: Synthesis of V-(l-{4'-[4-(6-Benzyl-pyridin-2-ylamino)-3-methyl-isoxazol- 5-yl]-biphenyl-4-yl}-cyclopropanecarbonyl)-methanesulfonamide (Compound 95)
[00508] Step 1: V-(l-{4'-[4-(6-Benzyl-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarbonyl)-methanesulfonamide: l-{4'-[4-(6-benzyl-pyridin- 2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (sodium salt; 0.050 g, 0.083 mmol), carbonyldiimidazole (0.0676 g, 0.417 mmol), MeS02NH2 (0.0789 g, 0.83 mmol) and DBU (0.0248 mL, 0.166 mmol) were combined in THF (1 mL) and the mixture was heated to 70°C in a capped vial for 25 hours. The mixture was purified by preparative HPLC to yield the title compound.
Example 98: Synthesis of V-(l-{4'-[3-Methyl-4-(6-phenyl-pyridin-2-ylamino)-isoxazol- 5-yl]-biphenyl-4-yl}-cyclopropanecarbonyl)-methanesulfonamide (Compound 96)
[00509] Step 1: {5-[4'-(l-Methanesulfonylaminocarbonyl-cyclopropyl)-biphenyl-4-yl]-3- methyl-isoxazol-4-yl}-carbamic acid tert-buty\ ester: Prepared according to the procedure described in Example 94, Step 3, using [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]- carbamic acid tert-butyl ester and N-{l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- phenyl]-cyclopropanecarbonyl}-methanesulfonamide.
[00510] Step 2: V-{l-[4'-(4-Amino-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarbonyl}-methanesulfonamide: {5-[4'-(l-Methanesulfonylaminocarbonyl- cyclopropyl)-biphenyl-4-yl]-3-methyl-isoxazol-4-yl}-carbamic acid tert-butyl ester (0.25 g, 0.49 mmol)) in CH2C12 (2 mL) and TFA (2 mL) was stirred overnight then poured into EtOAc/NaHC03 (aq). The organic layer was concentrated to yield the title compound that was used directly in the next step.
[00511] Step 3: V-(l-{4'-[3-Methyl-4-(6-phenyl-pyridin-2-ylamino)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarbonyl)-methanesulfonamide: N-{l-[4'-(4-Amino-3- methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarbonyl}-methanesulfonamide (0.103 g, 0.25 mmol), 2-bromo-6-phenylpyridine (0.059 g, 0.25 mmol), potassium carbonate (0.243 g, 0.75 mmol), and BINAP (15 mg, 0.025 mmol) were combined in THF (10 mL) and the solution was degassed with N2 for 10 minutes. Palladium(II)acetate (0.003 g, 0.0125 mmol) was added and degassing was continued for 10 minutes. The reaction mixture was sealed and heated at 65°C overnight then poured into EtO Ac/water. The organic layer was concentrated and purified by silica gel chromatography to give the title compound.
Example 99: l-{4'-[4-(2'-Dimethylaminomethyl-biphenyl-3-ylamino)-3-methyl- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 85)
[00512] Step 1: l-{4'-[4-(2'-Dimethylaminomethyl-biphenyl-3-ylamino)-3-methyl- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1 , Step 10, using l- {4'-[4-(3-bromo- phenylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 2-(N,N-dimethylaminomethyl)-phenylboronic acid. (Ι , Γ- Bis(diphenylphosphino)ferrocene)-dichloropalladium(II) was used in place of
tetrakis(triphenylphosphine)palladium(0).
[00513] Step 2: The ester from Step 1 was hydrolyzed to the acid according to the procedure described in Example 3.
Example 100: Synthesis of l-(4'-{4-[6-(2,3-Dichloro-phenyl)-pyridin-2-ylamino]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 86)
[00514] Step 1: l-(4'-{4-[6-(2,3-Dichloro-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol- 5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1 , Step 10, using l -{4'-[4-(6-bromo-pyridin-2-ylamino)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 2,3- dichlorophenylboronic acid. (1 , 1 '-bis(diphenylphosphino)ferrocene)-dichloropalladium(II) was used in place of tetrakis(triphenylphosphine)palladium(0).
[00515] Step 2: The ester from Step 1 was hydrolyzed to the acid according to the procedure described in Example 3.
Example 101 : Synthesis of l-(4'-{4-[6-(3-Fluoro-2-methoxy-phenyl)-pyridin-2- ylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid
(Compound 87) [00516] Step 1: l-(4'-{4-[6-(3-Fluoro-2-methoxy-phenyl)-pyridin-2-ylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using l-{4'-[4-(6-bromo- pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 3-fluoro-2-methoxyphenylboronic acid. (Ι,Γ- Bis(diphenylphosphino)ferrocene)-dichloropalladium(II) was used in place of
tetrakis(triphenylphosphine)palladium(0).
[00517] Step 2: The ester from Step 1 was hydrolyzed to the acid according to the procedure described in Example 3.
Example 102: Synthesis of l-(4'-{4-[5-(3-Chloro-phenyl)-pyridin-3-ylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 88)
[00518] Step 1: 3-Bromo-5-(3-chloro-phenyl)-pyridine: Prepared according to the procedure described in Example 1, Step 10, using the following starting materials: 3,5- dibromo-pyridine and 3-chlorophenylboronic acid.
[00519] Step 2: l-(4'-{4-[5-(3-Chloro-phenyl)-pyridin-3-ylamino]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 3-bromo-5-(3-chloro-phenyl)- pyridine.
[00520] Step 3: The ester from Step 2 was hydrolyzed to the acid according to the procedure described in Example 3.
Example 103: Synthesis of l-(4'-{4-[5-(2,5-Difluoro-phenyl)-pyridin-3-ylamino]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 89)
[00521] Step 1: 3-Bromo-5-(2,5-difluoro-phenyl)-pyridine: Prepared according to the procedure described in Example 41, Step 1, using 3,5-dibromo-pyridine and 2,5- difluorophenylboronic acid.
[00522] Step 2: l-(4'-{4-[5-(2,5-Difluoro-phenyl)-pyridin-3-ylamino]-3-methyl-isoxazol- 5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-methyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 3-bromo-5-(2,5-difluoro- phenyl)-pyridine.
[00523] Step 3: The ester from Step 2 was hydrolyzed to the acid according to the procedure described in Example 3. Example 104: Synthesis of l-(4'-{4-[6-(3-Chloro-phenyl)-pyridin-2-ylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 90)
[00524] Step 1: l-(4'-{4-[6-(3-Chloro-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using l-{4'-[4-(6-bromo-pyridin-2-ylamino)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 3- chlorophenylboronic acid. (1,1 '-bis(diphenylphosphino)ferrocene)-dichloropalladium(II) was used in place of tetrakis(triphenylphosphine)palladium(0).
[00525] Step 2: The ester from Step 1 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 105: Synthesis of l-{4'-[3-Ethyl-4-(6-phenyl-pyridin-2-ylamino)-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 97)
[00526] Step 1: 3-Methylamino-pent-2-enoic acid methyl ester: Prepared according to the procedure described in Example 1, Step 1, using the following starting materials: 3-oxo- pentanoic acid methyl ester and methylamine.
[00527] Step 2: 2-(4-Bromo-benzoyl)-3-oxo-pentanoic acid methyl ester: Prepared according to the procedure described in Example 1, Step 2, using the following starting materials: 3-methylamino-pent-2-enoic acid methyl ester and 4-bromobenzoyl chloride.
[00528] Step 3: 5-(4-Bromo-phenyl)-3-ethyl-isoxazole-4-carboxylic acid methyl ester: Prepared according to the procedure described in Example 1, Step 3, using the following starting material: 2-(4-bromo-benzoyl)-3-oxo-pentanoic acid methyl ester.
[00529] Step 4: 5-(4-Bromo-phenyl)-3-ethyl-isoxazole-4-carboxylic acid: Prepared according to the procedure described in Example 1, Step 4, using the following starting material: 5-(4-bromo-phenyl)-3-ethyl-isoxazole-4-carboxylic acid methyl ester.
[00530] Step 5: [5-(4-Bromo-phenyl)-3-ethyl-isoxazol-4-yl]-carbamic acid terf -butyl ester: Prepared according to the procedure described in Example 1, Step 5, using the following starting material: 5-(4-bromo-phenyl)-3-ethyl-isoxazole-4-carboxylic acid.
[00531] Step 6: l-[4'-(4-tei"i-Butoxycarbonylamino-3-ethyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using the following starting materials: [5-(4-bromo-phenyl)-3-ethyl- isoxazol-4-yl]-carbamic acid tert-butyl ester and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester. (Ι,Γ- bis(diphenylphosphino)ferrocene)-dichloropalladium(II) was used in place of tetrakis(triphenylphosphine)palladium(0).
[00532] Step 7: l-[4'-(4-Amino-3-ethyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 11, using l-[4'-(4-tert-butoxycarbonylamino-3-ethyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester.
[00533] Step 8: l-{4'-[3-Ethyl-4-(6-phenyl-pyridin-2-ylamino)-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 41, Step 2, using l-[4'-(4-amino-3-ethyl-isoxazol-5-yl)-biphenyl-4- yl]-cyclopropanecarboxylic acid ethyl ester and 2-bromo-6-phenyl-pyridine.
[00534] Step 9: The ester from Step 8 was hydro lyzed to the acid according to the procedure described in Example 3.
Example 106: Synthesis of l-{4'-[3-Ethyl-4-(5-phenyl-[l,3,4]oxadiazol-2-ylamino)- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 98)
[00535] Step 1: [5-(4-Bromo-phenyl)-3-ethyl-isoxazol-4-yl]-(5-phenyl-[l,3,4]oxadiazol-2- yl)-amine: Prepared according to the procedure described in Example 51, Step 1, using 5- (4-bromo-phenyl)-3-ethyl-isoxazole-4-carboxylic acid and benzoic acid hydrazide.
[00536] Step 2: l-{4'-[3-Ethyl-4-(5-phenyl-[l,3,4]oxadiazol-2-ylamino)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester: Prepared according to the procedure described in Example 1, Step 10, using [5-(4-bromo-phenyl)-3-ethyl-isoxazol-4- yl] -(5 -phenyl- [ 1 ,3,4]oxadiazol-2-yl)-amine and 1 -[4-(4,4,5 ,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester. (Ι,Γ- bis(diphenylphosphino)ferrocene)-dichloropalladium(II) was used in place of
tetrakis(triphenylphosphine)palladium(0).
[00537] Step 3: The ester from Step 2 was hydro lyzed to the acid according to the procedure described in Example 3.
[00538] In some embodiments, mass spectrometric data (mass spec, data) is obtained with a Shimadzu LCMS 201 OA.
Example 107: Establishment of a CHO Cell Line Stably Expressing Human LPAi
[00539] A 1.1 kb cDNA encoding the human LPAi receptor was cloned from human lung. Human lung R A (Clontech Laboratories, Inc. USA) was reverse transcribed using the RETROscript kit (Ambion, Inc.) and the full-length cDNA for human LPAi was obtained by PCR of the reverse transcription reaction. The nucleotide sequence of the cloned human LPAi was determined by sequencing and confirmed to be identical to the published human LPAi sequence (An et al. Biochem. Biophys. Res. Commun. 231 :619 (1997). The cDNA was cloned into the pCDNA5/FRT expression plasmid and transfected in CHO cells using lipofectamine 2000 (Invitrogen Corp., USA). Clones stably expressing human LPAi were selected using hygromycin and identified as cells that show Ca-influx in response to LPA. Example 108: Generation of Cells Transiently Expressing Human LPA2
[00540] A vector containing the human LPA2 receptor cDNA was obtained from the
Missouri S&T cDNA Resource Center (www.cdna.org). The full-length cDNA fragment for human LPA2 was obtained by PCR from the vector. The nucleotide sequence of the cloned human LPA2 was determined by sequencing and confirmed to be identical to the published human LPA2 sequence (NCBI accession number NM 004720). The cDNA was cloned into the pCDNA3.1 expression plasmid and transfected into B103 cells (Invitrogen Corp., USA) by seeding cells in a 96-well poly-D-lysine coated plate at 30,000-35,000 cells per well together with 0.2 μΐ lipofectamine 2000 and 0.2 μg of the LPA2 expression vector. Cells were cultured overnight in complete media before being assayed for LPA-induced Ca- influx.
Example 109: Establishment of a CHO Cell Line Stably Expressing Human LPA3
[00541] A vector containing the human LP A3 receptor cDNA was obtained from the
Missouri S&T cDNA Resource Center (www.cdna.org). The full-length cDNA fragment for human LP A3 was obtained by PCR from the vector. The nucleotide sequence of the cloned human LPA3 was determined by sequencing and confirmed to be identical to the published human LP A3 sequence (NCBI accession number NM 012152). The cDNA was cloned into the pCDNA5/FRT expression plasmid and transfected in CHO cells using lipofectamine 2000 (Invitrogen Corp., USA). Clones stably expressing human LPA3 were selected using hygromycin and identified as cells that show Ca-influx in response to LPA.
Example 110: LPAI and LPA3 Calcium Flux Assays.
[00542] Human LPAi or LPA3 expressing CHO cells are seeded at 20,000-45,000 cells per well in a 96-well poly-D-lysine coated plate one or two days before the assay. Prior to the assay, the cells are washed once with PBS and then cultured in serum-free media overnight. On the day of the assay, a calcium indicator dye (Calcium 4, Molecular Devices) in assay buffer (HBSS with Ca2+ and Mg2+ and containing 20 mM Hepes and 0.3% fatty-acid free human serum albumin) is added to each well and incubation continued for 1 hour at 37°C. 10 μΐ of test compounds in 2.5% DMSO are added to the cells and incubation continued at room temperature for 30 minutes. Cells are the stimulated by the addition of 10 nM LPA and intracellular Ca2+ measured using the Flexstation 3 (Molecular Devices). IC50S are determined using Graphpad prism analysis of drug titration curves.
Example 111: LPA2 Calcium Flux Assay.
[00543] Following an overnight culture with lipofectamine 2000 and the LPA2 expression vector, the B103 cells are washed once with PBS then serum starved for 4 hours. A calcium indicator dye (Calcium 4, Molecular Devices) in assay buffer (HBSS with Ca2+ and Mg2+ and containing 20 mM Hepes and 0.3% fatty-acid free human serum albumin) is added to each well and incubation continued for 1 hour at 37°C. 10 μΐ of test compounds in 2.5% DMSO are added to the cells and incubation continued at room temperature for 30 minutes. Cells are the stimulated by the addition of 10 nM LPA and intracellular Ca2+ measured using the Flexstation 3 (Molecular Devices). IC50s are determined using Graphpad prism analysis of drug titration curves.
Example 112: GTPyS Binding Assay
[00544] The ability of a compound to inhibit binding of GTP to LPAi is assessed via a membrane GTPyS assay. CHO cells stably expressing the recombinant human LPAi receptor are resuspended in 10 mM Hepes, 7.4 containing 1 mM DTT, lysed and centrifuged at 75,000 xg to pellet the membranes. The membranes are resuspended in 10 mM Hepes, 7.4 containing 1 mM DTT and 10% glycerol. Membranes (~25 μg per well) are incubated in 96-well plates with 0.1 nM [35S]-GTPyS, 900 nM LPA, 5 μΜ GDP, and test compound in Assay Buffer (50 mM Hepes, pH 7.4, 100 mM NaCl, 10 mM MgCl2 , 50 μg/ml saponin and 0.2% fatty-acid free human serum albumin) for 30 minutes at 30°C. The reactions are terminated by rapid filtration through Whatman GF/B glass fibre filter plates. The filter plates are washed 3 times with 1 ml cold Wash Buffer (50 mM Hepes, 7.5, 100 mM NaCl and 10 mM MgCl2) and dried. Scintillant is then added to the plates and the radioactivity retained on the filters is determined on a Packard TopCount (Perkin Elmer). Specific binding is determined as total radioactive binding minus non-specific binding in the absence of the ligand (900 nM LPA). IC50S were determined using Graphpad prism analysis of drug titration curves.
[00545] Illustrative in vitro biological data for representative compounds of Formula (I) is presented in the Table below. Unless otherwise noted, all the compounds in Table 4 that were tested in this assay had IC50 values of less than 50 μΜ. Table 4.
Figure imgf000096_0001
Compound No. HLPAl Ca Flux IC50
46 A
47 A
48 A
49 A
50 A
51 A
52 A
53 A
54 A
55 A
56 A
57 A
58 A
59 A
60 A
61 A
62 B
63 C
64 A
65 A
66 A
67 A
68 A
69 A
70 A
71 A
72 A
73 A
74 A
75 A
76 A
77 A
78 A
79 A
80 A
81 A
82 A
83 A
84 B
85 A
86 A
87 A
88 A
89 A
90 A
91 A
92 A Compound No. HLPA1 Ca Flux IC50
93 C
94 A
95 A
96 A
97 A
98 A
A = less than 0.3 μΜ; B = greater than 0.3 μΜ and less than 1 μΜ;
C= greater than 1 μΜ and less than 50 μΜ.
Example 113. LPA1 Chemotaxis Assay.
[00546] Chemotaxis of the A2058 human melanoma cells was measured using the
Neuroprobe ChemoTx® System plates (8 μιη pore size, 5.7 mm diameter sites). The filter sites were coated with 0.001% fibronectin (Sigma) in 20 mM Hepes, pH 7.4 and allowed to dry. A2058 cells were serum- starved for 24 hours , then harvested with Cell Stripper and resuspended in DMEM containing 0.1% fatty-acid- free bovine serum albumin (BSA) to a concentration of 1 x 106/ml. Cells were mixed with an equal volume of test compound (2X) in DMEM containing 0.1 %> fatty-acid-free BSA and incubated at 37°C for 15 minutes. LPA (100 nM in DMEM containing 0.1% fatty-acid-free BSA) or vehicle was added to each well of the lower chamber and 50 μΐ of the cell suspension/test compound mix was applied to the upper portion of the ChemoTx plate. Plates were incubated at 37°C for three hours and then the cells removed from the upper portion by rinsing with PBS and scraping. The filter was dried then stained with HEMA 3 Staining System (Fisher Scientific). The absorbance of the filter was read at 590 nM and IC50S were determined using Symyx Assay Explorer.
[00547] In this experiment, compounds 11, 13, 19, 23, 26, 27, 32, 33, 38,39 41, 44, 45, 46, 47, 49, 52, 58, 59, 60, 64, 66, 67, 68, 75, 79, 81, 82, 83, 91, 92, and 95 inhibited LPA- driven chemotaxis (IC50 less than 100 nM) of human A2058 melanoma cells.
Example 114: Bleomycin-induced Lung fibrosis model in mice
[00548] Female C57B1/6 mice (Harlan, 25-30g) are housed 4 per cage, given free access to food and water and allowed to acclimate for at least 7 days prior to test initiation. After the habituation phase, mice are lightly anesthetized with isoflurane (5% in 100% 02) and administered with bleomycin sulfate (0.01-5 U/kg, Henry Schein) via intratracheal instillation (Cuzzocrea S et al. Am J Physiol Lung Cell Mol Physiol. 2007
May;292(5):L1095-104. Epub 2007 Jan 12.). Mice are returned to their cages and monitored daily for the duration of the experiment. Test compound or vehicle is delivered po, ip or sc daily. The route and frequency of dosing is based on previously determined
pharmacokinetic properties. All animals are sacrificed using inhaled isoflurane 3, 7, 14, 21 or 28 days after bleomycin instillation. Following sacrifice, mice are intubated with a 20 gauge angiocatheter attached to a 1 ml syringe. Lungs are lavaged with saline to obtain bronchoalveolar lavage fluid (BALF) and then removed and fixed in 10% neutral buffered formalin for subsequent histopatho logical analysis. BALF is centrifuged for 10 min at 800 x g to pellet the cells and the cell supernatant removed and frozen at -80 °C for subsequent protein analysis using the DC protein assay kit (Biorad, Hercules, CA.) and soluble collagen analysis using Sircol (Biocolor Ltd, UK). BALF is analyzed for concentrations of inflammatory, pro-fibrotic and tissue injury biomarkers including transforming growth factor βΐ, hyaluronic acid, tissue inhibitor of metalloproteinase-1, matrix matelloproteinase- 7, connective tissue growth factor and lactate dehydrogenase activity, using commercially available ELISA. The cell pellet is re-suspended in PBS. Total cell counts are then obtained using a Hemavet hematology system (Drew Scientific, Wayne, PA.) and differential cells counts are determined using Shandon cytospin (Thermo Scientific, Waltham, MA.). Lung tissue is stained using hematoxylin and eosin (H&E) and trichrome and lung fibrosis. is determined by semiquantitative histopatho logical scoring (Ashcroft T. et al. J. Clin. Path. 1988;41;4, 467-470) using light microscopy (lOx magnification) and quantitative, computer-assisted densitometry of collagen in lung tissue sections using light microscopy. The data are plotted using Graphpad prism and statistical differences between groups determined.
[00549] In the acute setting (3 day), Compound 19 significantly reduced total protein and collagen concentrations in broncheoalveolar lavage fluid (BALF).
Example 115: Mouse carbon tetrachloride (CCl4)-induced liver fibrosis model
[00550] Female C57BL/6 mice (Harlan, 20-25 g) housed 4/cage are given free access to food and water and allowed to acclimate for at least 7 days prior to test initiation. After the habituation phase, mice receive CC14 (1.0 ml/kg body weight) diluted in corn oil vehicle (100 volume) via i.p. injection twice a week for 8 weeks. (Higazi, A. A. et al., Clin Exp Immunol. 2008 Apr;152(l): 163-73. Epub 2008 Feb 14.). Control mice receive an equivalent volume of corn oil vehicle only. Test compound or vehicle is delivered po, ip or sc daily. At the end of the study (8 weeks after first i.p. injection of CC14), mice are sacrificed using inhaled isoflurane and blood is drawn via cardiac puncture for subsequent analysis of
ALT/AST levels. The liver is harvested, and one half of the liver is frozen at -80°C and the other half is fixed in 10% neutral buffered formalin for histological assessment of liver fibrosis using light microscopy (lOx magnification). Liver tissue homogenates are analyzed for collagen levels using Sircol (Biocolor Ltd, UK). Fixed Liver tissue is stained using hematoxylin and eosin (H&E) and trichrome and liver fibrosis is determined by
quantitative, computer-assisted densitometry of collagen in liver tissue sections using light microscopy. Plasma and liver tissue lysates are also analyzed for concentrations of inflammatory, pro-fibrotic and tissue injury biomarkers including transforming growth factor βΐ, hyaluronic acid, tissue inhibitor of metalloproteinase-1, matrix matelloproteinase- 7, connective tissue growth factor and lactate dehydrogenase activity, using commercially available ELISA. The resulting data are plotted using Graphpad prism and statistical differences between groups determined.
Example 116: Mouse intravenous LPA-induced histamine release
[00551] A mouse intravenous LPA-induced histamine release model is utilized to determine the in vivo potency of LPAi and LPA3 receptor antagonists. Female CD-I mice (weighing 25 - 35 grams) are administered compound (i.p., s.c. or p.o.) in a volume of lOml/kg 30 minutes to 24 hours prior to intravenous LPA challenge (300 μg/mouse in 0.1% FAF BSA). Immediately following LPA challenge mice are placed into an enclosed Plexiglas chamber and exposed to an isoflurane for a period of 2 minutes. They are removed, decapitated and trunk blood collected into tubes containing EDTA. Blood is then centrifuged at 10,000 X g for 10 minutes at 4°C. Histamine concentrations in the plasma are determined by EI A. Drug concentrations in plasma are determined by mass spectrometry. The dose to achieve 50% inhibition of blood histamine release is calculated by nonlinear regression (Graphpad Prism) and plotted as the ED50. The plasma concentration associated with this dose is plotted as the
Example 117: Mouse unilateral ureteral obstruction kidney fibrosis model
[00552] Female C57BL/6 mice (Harlan, 20-25 g) housed 4/cage will be given free access to food and water and allowed to acclimate for at least 7 days prior to test initiation. After the habituation phase, mice undergo unilateral ureteral obstruction (UUO) surgery or sham to left kidney. Briefly, a longitudinal, upper left incision is performed to expose the left kidney. The renal artery is located and 6/0 silk thread is passed between the artery and the ureter. The thread is looped around the ureter and knotted 3 times insuring full ligation of ureter. The kidney is returned to abdomen, the abdominal muscle is sutured and the skin is stapled closed. Mice are returned to their cages and monitored daily for the duration of the experiment. Test compound or vehicle is delivered po, ip or sc daily. The route and frequency of dosing is based on previously determined pharmacokinetic properties. All animals are sacrificed using inhaled isoflurane 4, 8 or 14 days after UUO surgery.
Following sacrifice blood is drawn via cardiac puncture, the kidneys are harvested and one half of the kidney is frozen at -80°C and the other half is fixed in 10% neutral buffered formalin for histological assessment of kidney fibrosis using light microscopy (lOx magnification). Kidney tissue homogenates are analyzed for collagen levels using Sircol (Biocolor Ltd, UK). Fixed kidney tissue is also stained using hematoxylin and eosin (H&E) and trichrome and kidney fibrosis is determined by quantitative, computer-assisted densitometry of collagen in liver tissue sections using light microscopy and collagen content in kidney lysate. Plasma and kidney tissue lysates are also analyzed for concentrations of inflammatory, pro-fibrotic and tissue injury biomarkers including transforming growth factor βΐ, hyaluronic acid, tissue inhibitor of metalloproteinase-1, and plasminogen activator inhibitor -1, using commercially available ELISA. The resulting data are plotted using Graphpad prism and statistical differences between groups determined.
Example 118: Clinical Trial in Humans with Idiopathic Pulmonary Fibrosis (IPF) Purpose
[00553] The purposes of this study is to assess the efficacy of treatment with a compound of Formula (I) compared with placebo in patients with idiopathic pulmonary fibrosis (IPF) and to assess the safety of treatment with a compound of Formula (I) compared with placebo in patients with IPF.
[00554] The primary outcome variable is the absolute change in percent predicted forced vital capacity (FVC) from baseline to Week 72.
[00555] Secondary outcome measures include: composite outcomes of important IPF-related events; progression- free survival; categorical assessment of absolute change in percent predicted FVC from baseline to Week 72; change in Shortness-of-Breath from baseline to Week 72; change in percent predicted hemoglobin (Hb)-corrected carbon monoxide diffusing capacity (DLco) of the lungs from baseline to Week 72; change in oxygen saturation during the 6 minute walk test (6MWT) from baseline to Week 72; change in high-resolution computed tomography (HRCT) assessment from baseline to Week 72; change in distance walked in the 6MWT from baseline to Week 72.
Criteria
[00556] Patients eligible for this study include those patients that satisfy the following inclusion criteria: diagnosis of IPF; 40 to 80 years of age; FVC > 50% predicted value; DLco > 35%) predicted value; either FVC or DLco < 90%> predicted value; no improvement in past year; able to walk 150 meters in 6 minutes and maintain saturation > 83% while on no more than 6 L/min supplemental oxygen.
[00557] Patients are excluded from this study if they satisfy any of the following criteria: unable to undergo pulmonary function testing; evidence of significant obstructive lung disease or airway hyper-responsiveness; in the clinical opinion of the investigator, the patient is expected to need and be eligible for a lung transplant within 72 weeks of randomization; active infection; liver disease; cancer or other medical condition likely to result in death within 2 years; diabetes; pregnancy or lactation; substance abuse; personal or family history of long QT syndrome; other IPF treatment; unable to take study medication; withdrawal from other IPF trials.
[00558] Patients are orally dosed with either placebo or an amount of compound of Formula (I) (1 mg/day - 1000 mg/day). The primary outcome variable will be the absolute change in percent predicted FVC from Baseline to Week 72. Patients will receive blinded study treatment from the time of randomization until the last patient randomized has been treated for 72 weeks. A Data Monitoring Committee (DMC) will periodically review safety and efficacy data to ensure patient safety.
[00559] After week 72, patients who meet the Progression of Disease (POD) definition, which is a > 10%> absolute decrease in percent predicted FVC or a > 15% absolute decrease in percent predicted DLco, will be eligible to receive permitted IPF therapies in addition to their blinded study drug. Permitted IPF therapies include corticosteroids, azathioprine, cyclophosphamide and N-acetyl-cysteine.
Example 119: Parenteral Pharmaceutical Composition
[00560] To prepare a parenteral pharmaceutical composition suitable for administration by injection (subcutaneous, intravenous, and the like), 100 mg of a water-soluble salt of a compound of Formula (I) is dissolved in sterile water and then mixed with 10 mL of 0.9% sterile saline. The mixture is incorporated into a dosage unit form suitable for administration by injection
[00561] In another embodiment, the following ingredients are mixed to form an injectable formulation: 1.2 g of a compound of Formulas (I), 2.0 mL of sodium acetate buffer solution (0.4 M), HC1 (1 N) or NaOH (1 M) (q.s. to suitable pH), water (distilled, sterile) (q.s.to 20 mL). All of the above ingredients, except water, are combined and stirred and if necessary, with slight heating if necessary. A sufficient quantity of water is then added. Example 120: Oral Pharmaceutical Composition
[00562] To prepare a pharmaceutical composition for oral delivery, 100 mg of a compound of Formula (I) is mixed with 750 mg of starch. The mixture is incorporated into an oral dosage unit for, such as a hard gelatin capsule, which is suitable for oral administration. Example 121: Sublingual (Hard Lozenge) Pharmaceutical Composition
[00563] To prepare a pharmaceutical composition for buccal delivery, such as a hard lozenge, mix 100 mg of a compound of Formula (I) with 420 mg of powdered sugar mixed, with 1.6 mL of light corn syrup, 2.4 mL distilled water, and 0.42 mL mint extract. The mixture is gently blended and poured into a mold to form a lozenge suitable for buccal administration.
Example 122: Fast-Disintegrating Sublingual Tablet
[00564] A fast-disintegrating sublingual tablet is prepared by mixing 48.5% by weigh of a compound of Formula (I), 44.5%> by weight of microcrystalline cellulose (KG-802), 5%> by weight of low-substituted hydroxypropyl cellulose (50 μιη), and 2%> by weight of magnesium stearate. Tablets are prepared by direct compression (AAPS PharmSciTech. 2006;7(2):E41). The total weight of the compressed tablets is maintained at 150 mg. The formulation is prepared by mixing the amount of compound of Formula (I) with the total quantity of microcrystalline cellulose (MCC) and two-thirds of the quantity of low- substituted hydroxypropyl cellulose (L-HPC) by using a three dimensional manual mixer (lnversina ®, Bioengineering AG, Switzerland) for 4.5 minutes. All of the magnesium stearate (MS) and the remaining one-third of the quantity of L-HPC are added 30 seconds before the end of mixing.
Example 123: Inhalation Pharmaceutical Composition
[00565] To prepare a pharmaceutical composition for inhalation delivery, 20 mg of a compound of Formula (I) is mixed with 50 mg of anhydrous citric acid and 100 mL of 0.9% sodium chloride solution. The mixture is incorporated into an inhalation delivery unit, such as a nebulizer, which is suitable for inhalation administration.
Example 124: Rectal Gel Pharmaceutical Composition
[00566] To prepare a pharmaceutical composition for rectal delivery, 100 mg of a compound of Formula (I) is mixed with 2.5 g of methylcelluose (1500 mPa), 100 mg of
methylparapen, 5 g of glycerin and 100 mL of purified water. The resulting gel mixture is then incorporated into rectal delivery units, such as syringes, which are suitable for rectal administration. Example 125: Topical Gel Pharmaceutical Composition
[00567] To prepare a pharmaceutical topical gel composition, 100 mg of a compound of Formula (I) is mixed with 1.75 g of hydroxypropyl celluose, 10 mL of propylene glycol, 10 mL of isopropyl myristate and 100 mL of purified alcohol USP. The resulting gel mixture is then incorporated into containers, such as tubes, which are suitable for topicl administration. Example 126: Ophthalmic Solution
[00568] To prepare a pharmaceutical opthalmic solution composition, 100 mg of a compound of Formula (I) is mixed with 0.9 g of NaCl in 100 mL of purified water and filterd using a 0.2 micron filter. The resulting isotonic solution is then incorporated into ophthalmic delivery units, such as eye drop containers, which are suitable for ophthalmic administration.
Example 127: Nasal spray solution
[00569] To prepare a pharmaceutical nasal spray solution, 10 g of a compound of Formula (I) is mixed with 30 mL of a 0.05M phosphate buffer solution (pH 4.4). The solution is placed in a nasal administrator designed to deliver 100 μΐ of spray for each application.
[00570] The examples and embodiments described herein are for illustrative purposes only and various modifications or changes suggested to persons skilled in the art are to be included within the spirit and purview of this application and scope of the appended claims.

Claims

WHAT IS CLAIMED IS:
1. A compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof:
Figure imgf000105_0001
Formula (I)
wherein,
R1 is -C02RD, -C(=0)NHS02RE, -C(=0)N(RD)2, -CN, or tetrazolyl;
RD is H or Ci-C6 alkyl;
REis Ci-C6 alkyl or a substituted or unsubstituted phenyl;
L2 is absent, -C(=0)-, -N(RD)-, substituted or unsubstituted C1-C4 alkylene, or
substituted or unsubstituted Ci-C4heteroalkylene, where if L2 is substituted, then L2 is substituted with R12, where R12 is F, Ci-C4alkyl, -OH, or -ORD; ring A is a substituted or unsubstituted phenyl, or a substituted or unsubstituted monocyclic Ci-Csheteroarylene, where if ring A is substituted, then ring A is substituted with 1 or 2 R14, each R14 is independently selected from halogen, - CN, -OH, Ci-C4alkyl, Ci-C4fluoroalkyl, Ci-C4fluoroalkoxy, Ci-C4alkoxy, and Ci-C4heteroalkyl;
L4 is absent, or a substituted or unsubstituted C1-C4 alkylene, where if L4 is
substituted then L4 is substituted with R13, where R13 is F, Ci-C4alkyl, -OH, or -ORD;
R5 is H or C C4 alkyl;
each RA is independently selected from halogen, -CN, -OH, Ci-C4alkyl, Ci- C4fluoroalkyl, Ci-C4fluoroalkoxy, Ci-C4alkoxy, and Ci-C4heteroalkyl;
each RB is independently selected from halogen, -CN, -OH, Ci-C4alkyl, Ci- C4fluoroalkyl, Ci-C4fluoroalkoxy, Ci-C4alkoxy, and Ci-C4heteroalkyl;
each R is independently selected from halogen, -CN, -OH, Ci-C4alkyl, Ci- C4fluoroalkyl, Ci-C4fluoroalkoxy, Ci-C4alkoxy, and Ci-C4heteroalkyl;
m is 0, 1 or 2; n is 0, 1 or 2; p is 0, 1 or 2; r is 1, 2, 3, or 4.
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein: R1 is -C02RD, or -C(=0)NHS02RE;
L2 is absent, -C(=0)-, -NH-, -N(CH3)-, -CH2-, -CH2CH2-, -CH(CH3)-, -
CH2CH(CH3)-, -CH(CH3)CH2-, -CH(OH)-, -CH(ORD)-, -CH2CH(OH)-, - CH2CH(ORD)-, -CH(OH)CH2-, -CH(ORD)CH2-, -CH2NH-, -CH(CH3)NH-, - NHCH2- or -NHCH(CH3)-;
L4 is absent, -CH2-, -CH(CH3)-, -CH(OH)-, -CH2CH2-, -CH2CH(CH3)-, - CH(CH3)CH2-, -CH2CH(OH)-, or -CH(OH)CH2-;
R5 is -H, -CH3 or -CH2CH3;
m is 0 or 1 ;
n is 0 or 1 ;
r is 1 , 2, or 3.
3. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein:
L2 is -NH-, -CH2-, -CH2CH2-, -CH(CH3)-, -CH2CH(CH3)-, -CH(CH3)CH2-, -
CH(OH)-, -CH2CH(OH)-, -CH(OH)CH2-, -CH2NH-, -CH(CH3)NH-, -NHCH2- or -NHCH(CH3)-;
ring A is a substituted or unsubstituted phenyl, or a substituted or unsubstituted monocyclic Ci-Csheteroarylene containing 1-4 N atoms, 0 or 1 O atoms and 0 or 1 S atoms, where if ring A is substituted, then ring A is substituted with 1 or 2
R14;
L4 is absent, -CH2-, or -CH(CH3)-;
R5 is -CH3;
r is 1.
4. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein: ring A is a substituted or unsubstituted phenyl, where if ring A is substituted, then ring A is substituted with 1 or 2 R14.
5. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein: ring A is a substituted or unsubstituted monocyclic Ci-Csheteroarylene containing 1-
4 N atoms, 0 or 1 O atoms and 0 or 1 S atoms, where if ring A is substituted, then ring A is substituted with 1 or 2 R14.
6. The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein: ring A is a substituted or unsubstituted 5-membered monocyclic Ci-C4heteroarylene containing 1-4 N atoms, 0 or 1 O atoms and 0 or 1 S atoms, where if ring A is substituted, then ring A is substituted with 1 or 2 R14.
The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein: ring A is a substituted or unsubstituted furanyl, a substituted or unsubstituted
thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted pyrazolyl, substituted or unsubstituted triazolyl, substituted or unsubstituted tetrazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted isothiazolyl, substituted or unsubstituted oxadiazolyl, or substituted or unsubstituted thiadiazolyl, where if ring A is substituted, then ring A is substituted with 1 or 2 R14.
The com ound of claim 6, or a pharmaceutically acceptable salt thereof, wherein:
Figure imgf000107_0001
N Γ¾/ N- , t 'N~* , r N -N * , I N H , or i¾ N <N"*
The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein: ring A is a substituted or unsubstituted 6-membered monocyclic Cs-Csheteroarylene containing 1-3 N atoms, where if ring A is substituted, then ring A is substituted with 1 or 2 R14. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein:
Figure imgf000108_0001
11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) has the structure of Formula (II):
Figure imgf000108_0002
Formula (II).
The compound of claim 11, or a pharmaceutically acceptable salt thereof, wherein: R1 is -C02RD, or -C(=0)NHS02RE;
RD is H or Ci-C4 alkyl;
RE is Ci-C4 alkyl;
L2 is -CH2-, -CH(CH3)-, or -CH(OH)-;
ring A is a substituted or unsubstituted 5-membered monocyclic Ci-C4heteroarylene containing 1-4 N atoms and 0 or 1 O atoms, where if ring A is substituted, then ring A is substituted with R14;
L4 is -CH2- or -CH(CH3)-;
p is 0 or 1.
The compound of claim 11, or a pharmaceutically acceptable salt thereof, wherein: R1 is -C02RD, or -C(=0)NHS02RE; Ru is H or Ci-C4alkyl;
RE is Ci-C4alkyl;
L2 is -NH-, -CH2-, -CH(CH3)-, -CH(OH)-, -NHCH2- or -NHCH(CH3)-;
ring A is a substituted or unsubstituted pyridinylene, where if ring A is substituted, then ring A is substituted with R14;
L4 is absent, -CH2-, or -CH(CH3)-;
p is 0 or 1.
14. The compound of claim 1, wherein the compound is:
1 - {4'-[3-Methyl-4-(3-phenyl-pyrazol- 1 -ylmethyl)-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 1);
1 - {4'-[3-Methyl-4-(4-phenyl-[l ,2,3]triazol- 1 -ylmethyl)-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 2);
1 - {4'-[3-Methyl-4-(5-phenyl-[ 1 ,3,4]oxadiazol-2-ylmethyl)-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 3);
1 - {4'-[4-(4-Benzyl-[ 1 ,2,3]triazol-l -ylmethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 4);
1 -(4'- {4-[3-(4-Bromo-phenyl)-pyrazol- 1 -ylmethyl]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 5);
1 -(4'- {3-Methyl-4-[(5-phenyl-[ 1 ,3,4]oxadiazol-2-ylamino)-methyl]-isoxazol-5-yl} - biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 6);
1 - {4 - [3 -Methyl-4-(5 -phenyl- [1 ,2,3 ]triazol- 1 -ylmethyl)-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 7);
1 - {4'-[3-Methyl-4-(5-phenyl-tetrazol-2-ylmethyl)-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 8);
1 - {4'-[3-Methyl-4-(4-phenyl-pyrazol- 1 -ylmethyl)-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 9);
l-{4'-[4-(5-Benzyl-[l,3,4]oxadiazol-2-yl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 10);
l-(4'-{4-[(l-Benzyl-lH-[l,2,3]triazol-4-yl)-hydroxy-methyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 11);
1 - {4 - [4-(5 -Benzyl-[ 1 ,3 ,4]oxadiazol-2-ylmethyl)-3 -methyl-isoxazol-5 -yl] -biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 12); l-(4'-{4-[(5-Benzyl-[l,3,4]oxadiazol-2-yl)-hydroxy-methyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 13);
l-{4'-[4-(l-Benzyl-lH-[l,2,3]triazol-4-ylmethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 14);
l-(4'-{4-[(S)-(5-Benzyl-[l,3,4]oxadiazol-2-yl)-hydroxy-methyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 15);
1 -(4'- {4-[(R)-(5-Benzyl-[ 1 ,3,4]oxadiazol-2-yl)-hydroxy-methyl]-3-methyl-isoxazol-5-yl} - biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 16);
1 -(4'- {4- [Hydroxy-(5 -phenyl- [ 1 ,3,4]oxadiazol-2-yl)-methyl]-3-methyl-isoxazol-5-yl} - biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 17);
l-(4'-{4-[(S)-(l-Benzyl-lH-[l,2,3]triazol-4-yl)-hydroxy-methyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 18);
1 -(4'- {4- [(R)-(l -Benzyl- 1H-[1 ,2,3]triazol-4-yl)-hydroxy-methyl]-3-methyl-isoxazol-5-yl} - biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 19);
1 -[4'-(4- {Hydroxy-[5-(3-trifluoromethyl-benzyl)-[ 1 ,3,4]oxadiazol-2-yl]-methyl} -3-methyl- isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 20);
1 -[4'-(4- {Hydroxy-[ 1 -(3-trifluoromethyl-benzyl)-lH-[ 1 ,2,3]triazol-4-yl]-methyl} -3- methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 21);
1 - {4'-[4-(Biphenyl-3-yl-hydroxy-methyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 22);
1 -[4'-(4- {Hydroxy-[l -(1 -phenyl-ethyl)-lH-[ 1 ,2,3]triazol-4-yl]-methyl} -3-methyl-isoxazol- 5 -yl)-biphenyl-4-yl] -cyclopropanecarboxylic acid (Compound 23);
1 -[4'-(4- {Hydroxy-[ 1 -(2-trifluoromethyl-benzyl)- lH-[ 1 ,2,3]triazol-4-yl]-methyl} -3-methyl- isoxazol-5-yl)-biphenyl-4-yl] -cyclopropanecarboxylic acid (Compound 24);
1 -[4'-(4- {[ 1 -(3-Chloro-benzyl)- 1H-[1 ,2,3]triazol-4-yl]-hydroxy-methyl} -3-methyl-isoxazol-
5 -yl)-biphenyl-4-yl] -cyclopropanecarboxylic acid (Compound 25);
1 -(4'- {4-[(3-Benzyl-phenyl)-hydroxy-methyl]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 26);
l-(4'-{4-[(5-Benzyl-pyridin-3-yl)-hydroxy-methyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 27);
1 -[4'-(4- {[ 1 -(2-Chloro-benzyl)- 1H-[1 ,2,3]triazol-4-yl]-hydroxy-methyl} -3-methyl-isoxazol- 5 -yl)-biphenyl-4-yl] -cyclopropanecarboxylic acid (Compound 28); 1 -[4'-(4- {[ 1 -(4-Chloro-benzyl)- 1H-[1 ,2,3]triazol-4-yl]-hydroxy-methyl} -3-methyl-isoxazol-
5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 29);
l-[4*-(4-{(R)-[l-(2-Chloro-benzyl)-lH-[l,2,3]triazol-4-yl]-hydroxy-methyl}-3-methyl- isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 30);
1 -[4*-(4- {[ 1 -(3,4-Dichloro-benzyl)- lH-[ 1 ,2,3]triazol-4-yl]-hydroxy-methyl} -3-methyl- isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 31);
1 -[4*-(4- {(R)-Hydroxy-[l-((R)- 1 -phenyl-ethyl)- lH-[ 1 ,2,3]triazol-4-yl]-methyl} -3-methyl- isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 32);
1 - {4'-[3-Methyl-4-(6-phenyl-pyridin-2-ylamino)-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 33);
l-(4'-{4-[(6-Benzyl-pyridin-2-yl)-hydroxy-methyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 34);
1 -[4'-(4- {Hydroxy- [ 1 -(2-methyl-benzyl)- lH-[ 1 ,2,3]triazol-4-yl]-methyl} -3-methyl- isoxazol-5-yl)-biphenyl-4-yl] -cyclopropanecarboxylic acid (Compound 35);
1 -[4'-(4- {[ 1 -(2-Chloro-6-fluoro-benzyl)- lH-[ 1 ,2,3]triazol-4-yl]-hydroxy-methyl} -3-methyl- isoxazol-5-yl)-biphenyl-4-yl] -cyclopropanecarboxylic acid (Compound 36);
1 -[4'-(4- {[ 1 -(2,6-Dichloro-benzyl)- lH-[ 1 ,2,3]triazol-4-yl]-hydroxy-methyl} -3-methyl- isoxazol-5-yl)-biphenyl-4-yl] -cyclopropanecarboxylic acid (Compound 37);
1 - {4'-[4-(6-Benzyl-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 38);
1 - {4'-[4-(Biphenyl-3-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 39);
1 - {4'-[4-(Biphenyl-4-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 40);
1 -(4'- {3-Methyl-4-[6-(3-trifluoromethyl-phenyl)-pyridin-2-ylamino]-isoxazol-5-yl} - biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 41);
1 - {4'-[3-Methyl-4-(6-phenyl-pyrazin-2-ylamino)-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 42);
1 - {4'-[3-Methyl-4-(5-phenyl-[ 1 ,3,4]oxadiazol-2-ylamino)-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 43);
l-{4'-[4-(5-Benzyl-[l,3,4]oxadiazol-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 44); 1 -(4'- {4-[6-(2-Fluoro-benzyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 45);
1 -(4'- {4-[6-(3-Fluoro-benzyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 46);
1 -(4'- {4-[6-(4-Fluoro-benzyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 47);
1 -(4'- {4-[6-(3-Methoxy-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4- yl)-cyclopropanecarboxylic acid (Compound 48);
1 - {4'-[4-(3-Benzyl-phenylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 49);
1 -(4'- {4-[6-(2-Cyano-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 50);
1 -(4'- {4-[6-(4-Methoxy-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4- yl)-cyclopropanecarboxylic acid (Compound 51);
1 -(4'- {4-[6-(3-Fluoro-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 52);
1 -(4'- {4-[6-(2-Methoxy-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4- yl)-cyclopropanecarboxylic acid (Compound 53);
1 -(4'- {4-[6-(2-Fluoro-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl) cyclopropanecarboxylic acid (Compound 54);
1 -(4'- {3-Methyl-4-[6-(2-trifluoromethyl-phenyl)-pyridin-2-ylamino]-isoxazol-5-yl} - biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 55);
1 -(4'- {3-Methyl-4-[(2-phenyl-thiazol-5-ylmethyl)-amino]-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 56);
1 - {4'-[3-Methyl-4-(2'-trifluoromethyl-biphenyl-3-ylamino)-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 57);
1 - {4'-[3-Methyl-4-(5-phenyl-pyridin-3-ylamino)-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 58);
1 -(4'- {4-[5-(3-Fluoro-phenyl)-pyridin-3-ylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl) cyclopropanecarboxylic acid (Compound 59);
1 -(4'- {4-[6-(2-Chloro-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl) cyclopropanecarboxylic acid (Compound 60); 1 -(4'- {4-[Hydroxy-(6-phenyl-pyridin-2-yl)-methyl]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl) cyclopropanecarboxylic acid (Compound 61);
1 - {4'-[3-Methyl-4-(2-phenyl-pyridin-4-ylamino)-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 62);
1 -(4'- {4-[2-(3-Fluoro-phenyl)-pyridin-4-ylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 63);
1 -(4'- {4-[5-(2-Chloro-phenyl)-pyridin-3-ylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 64);
1 -(4'- {4-[2-(2-Chloro-phenyl)-pyridin-4-ylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 65);
1 - {4'-[3-Methyl-4-(4-phenyl-pyrimidin-2-ylamino)-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 66);
1 - {4'-[3-Methyl-4-(4-phenyl-pyridin-2-ylamino)-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 67);
1 -(4'- {3-Methyl-4-[5-(3-trifluoromethyl-phenyl)-pyridin-3-ylamino]-isoxazol-5-yl} - biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 68);
1 -(4'- {3-Methyl-4-[5-(4-trifluoromethyl-phenyl)-pyridin-3-ylamino]-isoxazol-5-yl} - biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 69);
1 - {4'-[3-Methyl-4-(6-phenyl-pyridin-2-ylamino)-isoxazol-5-yl]-biphenyl-4-yl} - cyclobutanecarboxylic acid (Compound 70);
1 -(4'- {4-[Hydroxy-(5-phenyl-pyridin-3-yl)-methyl]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl) cyclopropanecarboxylic acid (Compound 71);
1 -[4'-(4- {Hydroxy-[5-(3-trifluoromethyl-phenyl)-pyridin-3-yl]-methyl} -3-methyl-isoxazol- 5 -yl)-biphenyl-4-yl] -cyclopropanecarboxylic acid (Compound 72);
1 - {4'-[3-Methyl-4-(6-phenylethynyl-pyridin-2-ylamino)-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 73);
1 -(4'- {4-[6-(3-Cyano-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 74);
1 -(4'- {4-[6-(5-Fluoro-2-methoxy-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl} - biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 75);
1 -(4'- {4-[6-(3-Chloro-5-fluoro-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl} - biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 76);
- I l l - 1 -(4'- {4-[6-(2,5-Difluoro-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4- yl)-cyclopropanecarboxylic acid (Compound 77);
1 -(4'- {4-[6-(2,6-Dichloro-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4 yl)-cyclopropanecarboxylic acid (Compound 78);
1 -(4'- {4-[6-(2-Chloro-5-fluoro-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl} - biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 79);
1 -(4'- {4-[6-(2,3-Difluoro-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4- yl)-cyclopropanecarboxylic acid (Compound 80);
1 -(4'- {4-[6-(2-Chloro-3-fluoro-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl} - biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 81);
1 -(4'- {4-[5-(2-Chloro-3-fluoro-phenyl)-pyridin-3-ylamino]-3-methyl-isoxazol-5-yl} - biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 82);
1 -(4'- {4-[6-(3-Fluoro-2-methyl-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl} - biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 83);
l-(4'-{4-[6-(2-Chloro-3-trifluoromethyl-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 84);
l-{4'-[4-(2'-Dimethylaminomethyl-biphenyl-3-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl 4-yl}-cyclopropanecarboxylic acid (Compound 85);
1 -(4'- {4-[6-(2,3-Dichloro-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4 yl)-cyclopropanecarboxylic acid (Compound 86);
1 -(4'- {4-[6-(3-Fluoro-2-methoxy-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl} - biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 87);
1 -(4'- {4-[5-(3-Chloro-phenyl)-pyridin-3-ylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 88);
1 -(4'- {4-[5-(2,5-Difluoro-phenyl)-pyridin-3-ylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4- yl)-cyclopropanecarboxylic acid (Compound 89);
1 -(4'- {4-[6-(3-Chloro-phenyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 90);
N-[ 1 -(4'- {4- [(1 -Benzyl- lH-[ 1 ,2,3]triazol-4-yl)-hydroxy-methyl]-3-methyl-isoxazol-5-yl} - biphenyl-4-yl)-cyclopropanecarbonyl]-methanesulfonamide (Enantiomer B) (Compound 91); N-[ 1 -(4'- {4-[(5-Benzyl-[ 1 ,3,4]oxadiazol-2-yl)-hydroxy-methyl]-3-methyl-isoxazol-5-yl} - biphenyl-4-yl)-cyclopropanecarbonyl]-methanesulfonamide (Enantiomer A) (Compound 92);
N- { 1 -[4*-(4- {Hydroxy-[ 1 -(3-trifluoromethyl-benzyl)-lH-[ 1 ,2,3]triazol-4-yl]-methyl} -3- methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarbonyl}-methanesulfonamide
(Compound 93);
N-(l-{4'-[3-Methyl-4-(5-phenyl-[l,3,4]oxadiazol-2-ylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarbonyl)-methanesulfonamide (Compound 94);
N-(l-{4'-[4-(6-Benzyl-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarbonyl)-methanesulfonamide (Compound 95);
N-(l-{4'-[3-Methyl-4-(6-phenyl-pyridin-2-ylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarbonyl)-methanesulfonamide (Compound 96);
1 - {4'-[3-Ethyl-4-(6-phenyl-pyridin-2-ylamino)-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 97);
l-{4'-[3-Ethyl-4-(5-phenyl-[l,3,4]oxadiazol-2-ylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 98);
or a pharmaceutically acceptable salt thereof.
15. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claims 1-14, or a pharmaceutically acceptable salt thereof.
16. The pharmaceutical composition of claim 15, wherein the pharmaceutical
composition is formulated for intravenous injection, subcutaneous injection, oral administration, inhalation, nasal administration, topical administration, ophthalmic administration or otic administration.
17. The pharmaceutical composition of claim 15, wherein the pharmaceutical
composition is a tablet, a pill, a capsule, a liquid, an inhalant, a nasal spray solution, a suppository, a suspension, a gel, a colloid, a dispersion, a suspension, a solution, an emulsion, an ointment, a lotion, an eye drop or an ear drop.
18. A method of treating cancer in a mammal comprising administering a
therapeutically effective amount of a compound according to any one of claims 1-14 or a pharmaceutically acceptable salt thereof to the mammal in need thereof.
19. A method of treating or preventing fibrosis in a mammal comprising administering a therapeutically effective amount of a compound according to any one of claims 1-14 or a pharmaceutically acceptable salt thereof to the mammal in need thereof. A method of treating or preventing lung fibrosis, asthma, chronic obstructive pulmonary disease (COPD), renal fibrosis, acute kidney injury, chronic kidney disease, liver fibrosis, skin fibrosis, fibrosis of the gut, breast cancer, pancreatic cancer, ovarian cancer, prostate cancer, glioblastoma, bone cancer, colon cancer, bowel cancer, head and neck cancer, melanoma, multiple myeloma, chronic lymphocytic leukemia, cancer pain, tumor metastasis, transplant organ rejection, scleroderma, ocular fibrosis, age related macular degeneration (AMD), diabetic retinopathy, collagen vascular disease, atherosclerosis, Raynaud's phenomenom, or neuropathic pain in a mammal comprising administering a therapeutically effective amount of a compound according to any one of claims 1-14 or a pharmaceutically acceptable salt thereof to the mammal in need thereof.
PCT/US2010/050786 2009-10-01 2010-09-29 Polycyclic compounds as lysophosphatidic acid receptor antagonists WO2011041461A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU2010300594A AU2010300594A1 (en) 2009-10-01 2010-09-29 Polycyclic compounds as lysophosphatidic acid receptor antagonists
EP10821201.0A EP2483269A4 (en) 2009-10-01 2010-09-29 Polycyclic compounds as lysophosphatidic acid receptor antagonists
EA201270467A EA201270467A1 (en) 2009-10-01 2010-09-29 POLYCYCLIC CONNECTIONS AS ANTAGONISTS OF LYSOPHOSPHATID ACID RECEPTORS
BR112012007102A BR112012007102A2 (en) 2009-10-01 2010-09-29 polycyclic compounds as lysophosphatpidic acid receptor antagonists
JP2012532286A JP2013506679A (en) 2009-10-01 2010-09-29 Polycyclic compounds as lysophosphatidic acid receptor antagonists
CN201080054537.6A CN102656168B (en) 2009-10-01 2010-09-29 Polycyclic compounds as lysophosphatidic acid receptor antagonists
CA2776779A CA2776779A1 (en) 2009-10-01 2010-09-29 Polycyclic compounds as lysophosphatidic acid receptor antagonists
MX2012003723A MX2012003723A (en) 2009-10-01 2010-09-29 Polycyclic compounds as lysophosphatidic acid receptor antagonists.
IN2702DEN2012 IN2012DN02702A (en) 2009-10-01 2010-09-29
TNP2012000126A TN2012000126A1 (en) 2009-10-01 2012-03-21 Polycyclic compounds as lysophosphatidic acid receptor antagonists
IL218962A IL218962A0 (en) 2009-10-01 2012-03-29 Polycyclic compounds as lysophosphatidic acid receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24787709P 2009-10-01 2009-10-01
US61/247,877 2009-10-01

Publications (2)

Publication Number Publication Date
WO2011041461A2 true WO2011041461A2 (en) 2011-04-07
WO2011041461A3 WO2011041461A3 (en) 2011-08-25

Family

ID=43128100

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2010/050786 WO2011041461A2 (en) 2009-10-01 2010-09-29 Polycyclic compounds as lysophosphatidic acid receptor antagonists
PCT/US2010/050787 WO2011041462A2 (en) 2009-10-01 2010-09-29 Polycyclic compounds as lysophosphatidic acid receptor antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2010/050787 WO2011041462A2 (en) 2009-10-01 2010-09-29 Polycyclic compounds as lysophosphatidic acid receptor antagonists

Country Status (20)

Country Link
US (3) US8778983B2 (en)
EP (2) EP2483269A4 (en)
JP (2) JP2013506680A (en)
KR (1) KR20120097490A (en)
CN (2) CN102770415B (en)
AR (1) AR078495A1 (en)
AU (1) AU2010300594A1 (en)
BR (1) BR112012007102A2 (en)
CA (1) CA2776779A1 (en)
CL (1) CL2012000812A1 (en)
EA (1) EA201270467A1 (en)
GB (1) GB2474748B (en)
IL (1) IL218962A0 (en)
IN (2) IN2012DN02730A (en)
MX (1) MX2012003723A (en)
PE (1) PE20120997A1 (en)
TN (1) TN2012000126A1 (en)
TW (1) TWI415849B (en)
UY (1) UY32923A (en)
WO (2) WO2011041461A2 (en)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011041729A2 (en) 2009-10-01 2011-04-07 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
US8048902B2 (en) 2008-12-15 2011-11-01 Amira Pharmaceuticals, Inc. Antagonists of lysophosphatidic acid receptors
US8058300B2 (en) 2009-06-03 2011-11-15 Amira Pharmaceuticals, Inc. Polycyclic antagonists of lysophosphatidic acid receptors
WO2013070879A1 (en) 2011-11-10 2013-05-16 Bristol-Myers Squibb Company Methods for treating spinal cord injury with lpa receptor antagonists
WO2013078283A1 (en) 2011-11-22 2013-05-30 Intermune, Inc. Methods of diagnosing and treating idiopathic pulmonary fibrosis
US8455499B2 (en) 2008-12-11 2013-06-04 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
US8541587B2 (en) 2011-04-05 2013-09-24 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists
US8592402B2 (en) 2009-08-04 2013-11-26 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
US8664220B2 (en) 2009-10-01 2014-03-04 Amira Pharmaceuticals, Inc. Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2014104372A1 (en) 2012-12-28 2014-07-03 宇部興産株式会社 Halogen-substituted heterocyclic compound
WO2016197009A1 (en) 2015-06-05 2016-12-08 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
KR20170016988A (en) 2014-06-27 2017-02-14 우베 고산 가부시키가이샤 Salt of halogen-substituted heterocyclic compound
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2019126087A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as lpa antagonists
US10576062B2 (en) 2016-06-21 2020-03-03 Bristol-Myers Squibb Company Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists
US10647705B2 (en) 2017-11-14 2020-05-12 Merck Sharp & Dohme Corp. Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
US10662172B2 (en) 2017-12-19 2020-05-26 Bristol-Myers Squibb Company Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
US11180488B2 (en) 2017-12-19 2021-11-23 Bristol-Myers Squibb Company Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists
US11261174B2 (en) 2017-12-19 2022-03-01 Bristol-Myers Squibb Company Pyrazole O-linked carbamoyl cyclohexyl acids as LPA antagonists
US11267800B2 (en) 2017-12-19 2022-03-08 Bristol-Myers Squibb Company Cyclohexyl acid triazole azines as LPA antagonists
US11312706B2 (en) 2017-12-19 2022-04-26 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azines as LPA antagonists
US11319315B2 (en) 2017-12-19 2022-05-03 Bristol-Myers Squibb Company Cyclohexyl acid triazole azoles as LPA antagonists
US11319309B2 (en) 2017-12-19 2022-05-03 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as LPA antagonists
US11352345B2 (en) 2017-12-19 2022-06-07 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azoles as LPA antagonists
US11384067B2 (en) 2017-12-19 2022-07-12 Bristol-Myers Squibb Company Pyrazole n-linked carbamoyl cyclohexyl acids as LPA antagonists
US11447475B2 (en) 2017-12-19 2022-09-20 Bristol-Myers Squibb Company Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
US11498904B2 (en) 2017-11-14 2022-11-15 Merck Sharp & Dohme Llc Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
US11548871B2 (en) 2019-11-15 2023-01-10 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
US11572353B2 (en) 2016-09-19 2023-02-07 Beijing Innocare Pharma Tech Co., Ltd. Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof
US11584738B2 (en) 2020-06-03 2023-02-21 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
US11884627B2 (en) 2022-02-25 2024-01-30 Lhotse Bio, Inc. Compounds and compositions for treating conditions associated with LPA receptor activity
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
RU2818246C2 (en) * 2018-06-18 2024-04-26 Эпиджен Байосайенсиз, Инк. Heterocyclic compounds used in treating disease
US11980609B2 (en) 2021-05-11 2024-05-14 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3240281A1 (en) 2010-06-03 2011-12-08 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
CN103002896A (en) 2010-06-16 2013-03-27 布鲁斯·钱德勒·梅 Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
WO2012100436A1 (en) 2011-01-30 2012-08-02 Curegenix Inc. Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
KR101369584B1 (en) 2011-04-19 2014-03-06 일양약품주식회사 Phenyl-isoxazol derivatives and preparation process thereof
US20150164874A1 (en) * 2011-05-25 2015-06-18 Intermune, Inc. Pirfenidone and anti-fibrotic therapy in selected patients
JP5978302B2 (en) * 2011-08-08 2016-08-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ (N-Benzimidazol-2-yl) -cyclopropanecarboxamide as a lysophosphatidic acid antagonist
WO2013025733A1 (en) 2011-08-15 2013-02-21 Intermune, Inc. Lysophosphatidic acid receptor antagonists
GB2493914A (en) * 2011-08-19 2013-02-27 Univ Jw Goethe Frankfurt Main Flurbiprofen and related compounds for the treatment of skin diseases
WO2013085824A1 (en) * 2011-12-04 2013-06-13 Angion Biomedica Corp. Small molecule anti-fibrotic compounds and uses thereof
KR20150021057A (en) * 2012-06-20 2015-02-27 에프. 호프만-라 로슈 아게 N-alkyltriazole compounds as lpar antagonists
EP2877598A1 (en) 2012-07-24 2015-06-03 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
CN103965664B (en) * 2013-01-25 2015-07-22 中国石油化工股份有限公司 Carbon black particle dispersing agent, preparation method and application thereof
CA2901421A1 (en) 2013-03-13 2014-10-09 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of autoimmune disorders
CN105517631A (en) 2013-03-13 2016-04-20 炎症反应研究公司 Use of levocetirizine and montelukast in the treatment of traumatic injury
RU2015134422A (en) 2013-03-13 2017-04-18 Инфламматори Респонс Ресёрч, Инк. APPLICATION OF LEVOCYTHIRIZINE AND MONTELUKAST IN THE TREATMENT OF VASCULITIS
DK2988743T3 (en) 2013-03-15 2021-03-01 Epigen Biosciences Inc HETEROCYCLIC COMPOUNDS WHICH MAY BE USED FOR DISEASE TREATMENT
WO2015013579A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
GB201314926D0 (en) * 2013-08-20 2013-10-02 Takeda Pharmaceutical Novel Compounds
US9981942B2 (en) * 2013-12-20 2018-05-29 Laboratorios Del Dr. Esteve S.A. Piperidine derivatives having multimodal activity against pain
JP2017078022A (en) * 2014-02-28 2017-04-27 クミアイ化学工業株式会社 Isoxazole derivative, and agricultural and horticultural plant disease control agent prepared therewith
JP2017526728A (en) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド Levocetirizine and montelukast in the treatment of inflammation-mediated conditions
AU2015369665A1 (en) * 2014-12-23 2017-06-29 Pharmacyclics Llc BTK inhibitor combinations and dosing regimen
US9729562B2 (en) 2015-03-02 2017-08-08 Harris Corporation Cross-layer correlation in secure cognitive network
WO2019041340A1 (en) * 2017-09-04 2019-03-07 Eli Lilly And Company Lysophosphatidic acid receptor 1 (lpar1) inhibitor compounds
CN109776351B (en) * 2017-11-15 2021-11-09 江苏优士化学有限公司 Diazoacetic ester continuous synthesis method
CN108379275B (en) * 2018-05-29 2020-05-22 中国医学科学院阜外医院 Lysophosphatidic acid, lysophosphatidic acid receptor 3, and use of lysophosphatidic acid receptor 3 agonist
WO2020060915A1 (en) 2018-09-18 2020-03-26 Bristol-Myers Squibb Company Cyclopentyl acids as lpa antagonists
CN114599641A (en) 2019-06-18 2022-06-07 百时美施贵宝公司 Cyclobutylcarboxylic acids as LPA antagonists
WO2020257138A1 (en) 2019-06-18 2020-12-24 Bristol-Myers Squibb Company Isoxazole carboxylic acids as lpa antagonists
US11091447B2 (en) 2020-01-03 2021-08-17 Berg Llc UBE2K modulators and methods for their use
JP2023519892A (en) 2020-03-27 2023-05-15 ランドス バイオファーマ インコーポレイテッド PLXDC2 ligand
CN114907282B (en) * 2022-05-24 2023-08-22 华南理工大学 Method for synthesizing 4-phenyl alkenyl isoxazole derivative

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
AU6645998A (en) 1996-12-23 1998-07-17 Du Pont Pharmaceuticals Company Oxygen or sulfur containing heteroaromatics as factor xa inhibitors
JP3237608B2 (en) 1997-04-21 2001-12-10 住友製薬株式会社 Isoxazole derivative
DE60003025T2 (en) 1999-04-02 2004-03-18 Bristol-Myers Squibb Pharma Co. ARYLSULFONYLE AS FACTOR XA INHIBITORS
WO2001060819A1 (en) 2000-02-18 2001-08-23 Kirin Beer Kabushiki Kaisha Novel isoxazole and thiazole compounds and use thereof as drugs
AU4456601A (en) * 2000-03-28 2001-10-08 Nippon Soda Co., Ltd. Oxa(thia)zolidine derivative and anti-inflammatory drug
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
EP1340749A4 (en) 2000-11-17 2007-09-05 Takeda Pharmaceutical Isoxazole derivatives
JP4396808B2 (en) * 2001-02-08 2010-01-13 小野薬品工業株式会社 Urological disease therapeutic agent comprising LPA receptor modulator
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
EP1415667B1 (en) 2001-07-17 2008-09-03 Ono Pharmaceutical Co., Ltd. Pancreatic juice secretion regulators comprising lpa receptor controller
MY151199A (en) * 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
JP4569106B2 (en) * 2001-12-25 2010-10-27 味の素株式会社 Organ fibrosis inhibitor
JP2003261545A (en) 2001-12-28 2003-09-19 Takeda Chem Ind Ltd Neurotrophic factor production/secretion accelerator
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
US20050261298A1 (en) * 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
WO2003062392A2 (en) 2002-01-18 2003-07-31 Ceretek Llc Methods of treating conditions associated with an edg receptor
US20050101518A1 (en) * 2002-01-18 2005-05-12 David Solow-Cordero Methods of treating conditions associated with an EDG-2 receptor
JP4547912B2 (en) * 2002-03-05 2010-09-22 小野薬品工業株式会社 8-Azaprostaglandin derivative compound and drug containing the compound as an active ingredient
US20040014662A1 (en) * 2002-05-08 2004-01-22 Per Lindquist Modulation of neural stem cells and neural progenitor cells
CA2484233A1 (en) * 2002-05-13 2003-11-27 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
WO2003099765A1 (en) * 2002-05-28 2003-12-04 Ono Pharmaceutical Co., Ltd. β-ALANINE DERIVATIVE AND USE THEREOF
TW200400930A (en) 2002-06-26 2004-01-16 Ono Pharmaceutical Co Therapeutic agent for chronic disease
WO2004031118A1 (en) 2002-10-03 2004-04-15 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonists
US20040171037A1 (en) 2002-11-19 2004-09-02 Jing Li Amplified genes involved in cancer
US20040192739A1 (en) 2003-01-16 2004-09-30 David Solow-Cordero Methods of treating conditions associated with an Edg-2 receptor
US20040167132A1 (en) 2003-01-16 2004-08-26 Geetha Shankar Methods of treating conditions associted with an Edg-2 receptor
US20050065194A1 (en) * 2003-01-16 2005-03-24 Geetha Shankar Methods of treating conditions associated with an Edg-2 receptor
US7135469B2 (en) * 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
AU2004229467B2 (en) 2003-04-11 2007-01-25 The University Of Tennessee Research Foundation Lysophosphatidic acid analogs and inhibition of neointima formation
WO2004099164A1 (en) 2003-05-02 2004-11-18 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating hcv infection
SI1638551T1 (en) 2003-05-19 2012-04-30 Irm Llc Immunosuppressant compounds and compositions
JP4692281B2 (en) * 2003-08-05 2011-06-01 味の素株式会社 New azole compounds
JP5048333B2 (en) 2003-10-09 2012-10-17 ユニバーシティ オブ テネシー リサーチ ファウンデーション LPA receptor agonists and antagonists and methods of use
WO2005058790A1 (en) 2003-12-19 2005-06-30 Ono Pharmaceutical Co., Ltd. Compounds having lysophosphatidic acid receptor antagonism and uses thereof
DE10360369A1 (en) 2003-12-22 2005-07-14 Bayer Cropscience Ag amides
WO2005123671A1 (en) * 2004-06-22 2005-12-29 Taisho Pharmaceutical Co., Ltd. Pyrrole derivative
JP2006096712A (en) 2004-09-30 2006-04-13 Senju Pharmaceut Co Ltd Corneal sensitivity improver containing lpa receptor antagonist
CA2610310A1 (en) 2005-06-08 2006-12-14 Novartis Ag Polycyclic oxadiazoles or isoxazoles and their use as s1p receptor ligands
WO2007007588A1 (en) 2005-07-08 2007-01-18 Ono Pharmaceutical Co., Ltd. Compound having cyclic group with planarity as core
CA2619101A1 (en) 2005-08-23 2007-03-01 Irm Llc Immunosuppressant compounds and compositions
CA2643670A1 (en) 2006-02-27 2007-08-30 Sterix Limited Diaryl compounds as non-steroidal inhibitors of 17-beta hydroxysteroid dehydrogenase and/or steroid sulphatase for the treatment of oestrogen-related diseases such as hormone dependent breast cancer
WO2007139946A2 (en) 2006-05-25 2007-12-06 University Of Tennessee Research Foundation Gpcr ligands identified by computational modeling
EP2054424A1 (en) 2006-07-24 2009-05-06 University Of Virginia Patent Foundation Vinyl phosphonate lysophosphatidic acid receptor antagonists
US20080051372A1 (en) 2006-08-24 2008-02-28 The Scripps Research Institute Methods utilizing cell-signaling lysophospholipids
WO2008024979A2 (en) 2006-08-24 2008-02-28 The Scripps Research Institute Methods utilizing cell-signaling lysophospholipids
US20100143381A1 (en) 2007-03-12 2010-06-10 Andrew Tager Lysophosphatidic acid receptor targeting for lung disease
US9163091B2 (en) 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
AU2009243756B2 (en) 2008-05-05 2013-06-27 Sanofi-Aventis Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
JP4933512B2 (en) 2008-10-09 2012-05-16 住友化学株式会社 Light guide plate
WO2010068775A2 (en) 2008-12-11 2010-06-17 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
WO2011017350A2 (en) 2009-08-04 2011-02-10 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011041551A1 (en) 2009-10-01 2011-04-07 Intermune, Inc. Therapeutic antiviral peptides
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
KR101628737B1 (en) * 2010-01-06 2016-06-13 애플 인크. Device, method, and graphical user interface for mapping directions between search results

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None
See also references of EP2483269A4

Cited By (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455499B2 (en) 2008-12-11 2013-06-04 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
US8048902B2 (en) 2008-12-15 2011-11-01 Amira Pharmaceuticals, Inc. Antagonists of lysophosphatidic acid receptors
US8440707B2 (en) 2008-12-15 2013-05-14 Amira Pharmaceuticals, Inc. Antagonists of lysophosphatidic acid receptors
US8273780B2 (en) 2009-06-03 2012-09-25 Amira Pharmaceuticals, Inc. Polycyclic antagonists of lysophosphatidic acid receptors
US8058300B2 (en) 2009-06-03 2011-11-15 Amira Pharmaceuticals, Inc. Polycyclic antagonists of lysophosphatidic acid receptors
US8592402B2 (en) 2009-08-04 2013-11-26 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
EP2483253A4 (en) * 2009-10-01 2013-04-03 Amira Pharmaceuticals Inc Compounds as lysophosphatidic acid receptor antagonists
US8778983B2 (en) 2009-10-01 2014-07-15 Amira Pharmaceuticals, Inc. Polycyclic compounds as lysophosphatidic acid receptor antagonists
EP2483252A4 (en) * 2009-10-01 2013-04-03 Amira Pharmaceuticals Inc Compounds as lysophosphatidic acid receptor antagonists
EP2483253A2 (en) * 2009-10-01 2012-08-08 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
US10000456B2 (en) 2009-10-01 2018-06-19 Amira Pharmaceuticals, Inc. Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011041729A2 (en) 2009-10-01 2011-04-07 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
EP2483252A2 (en) * 2009-10-01 2012-08-08 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
US9624182B2 (en) 2009-10-01 2017-04-18 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
US8217066B2 (en) 2009-10-01 2012-07-10 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
US8664220B2 (en) 2009-10-01 2014-03-04 Amira Pharmaceuticals, Inc. Polycyclic compounds as lysophosphatidic acid receptor antagonists
US9090573B2 (en) 2009-10-01 2015-07-28 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
US8541587B2 (en) 2011-04-05 2013-09-24 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists
WO2013070879A1 (en) 2011-11-10 2013-05-16 Bristol-Myers Squibb Company Methods for treating spinal cord injury with lpa receptor antagonists
WO2013078283A1 (en) 2011-11-22 2013-05-30 Intermune, Inc. Methods of diagnosing and treating idiopathic pulmonary fibrosis
WO2014104372A1 (en) 2012-12-28 2014-07-03 宇部興産株式会社 Halogen-substituted heterocyclic compound
KR20150100756A (en) 2012-12-28 2015-09-02 우베 고산 가부시키가이샤 Halogen-substituted heterocyclic compound
US10597375B2 (en) 2012-12-28 2020-03-24 Ube Industries, Ltd. Halogen-substituted heterocyclic compound
EP3360869A1 (en) 2012-12-28 2018-08-15 Ube Industries, Ltd. Halogen-substituted heterocyclic compound useful for the treatment of diseases caused by lpa
US10000463B2 (en) 2012-12-28 2018-06-19 Ube Industries, Ltd. Halogen-substituted heterocyclic compound
US10023554B2 (en) 2014-06-27 2018-07-17 Ube Industries, Ltd. Halogen-substituted heterocyclic compound salt
KR20170016988A (en) 2014-06-27 2017-02-14 우베 고산 가부시키가이샤 Salt of halogen-substituted heterocyclic compound
WO2016197009A1 (en) 2015-06-05 2016-12-08 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
US10576062B2 (en) 2016-06-21 2020-03-03 Bristol-Myers Squibb Company Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists
USRE49352E1 (en) 2016-06-21 2023-01-03 Bristol-Myers Squibb Company Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists
US11007180B2 (en) 2016-06-21 2021-05-18 Bristol-Myers Squibb Company Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists
US11572353B2 (en) 2016-09-19 2023-02-07 Beijing Innocare Pharma Tech Co., Ltd. Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
US10647705B2 (en) 2017-11-14 2020-05-12 Merck Sharp & Dohme Corp. Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
US10995085B2 (en) 2017-11-14 2021-05-04 Merck Sharp & Dohme Corp. Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
US11498904B2 (en) 2017-11-14 2022-11-15 Merck Sharp & Dohme Llc Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
US11352345B2 (en) 2017-12-19 2022-06-07 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azoles as LPA antagonists
US10662172B2 (en) 2017-12-19 2020-05-26 Bristol-Myers Squibb Company Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
US11261180B2 (en) 2017-12-19 2022-03-01 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as LPA antagonists
US11267800B2 (en) 2017-12-19 2022-03-08 Bristol-Myers Squibb Company Cyclohexyl acid triazole azines as LPA antagonists
US11312706B2 (en) 2017-12-19 2022-04-26 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azines as LPA antagonists
US11319315B2 (en) 2017-12-19 2022-05-03 Bristol-Myers Squibb Company Cyclohexyl acid triazole azoles as LPA antagonists
US11319309B2 (en) 2017-12-19 2022-05-03 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as LPA antagonists
US11180488B2 (en) 2017-12-19 2021-11-23 Bristol-Myers Squibb Company Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists
US11384067B2 (en) 2017-12-19 2022-07-12 Bristol-Myers Squibb Company Pyrazole n-linked carbamoyl cyclohexyl acids as LPA antagonists
US11447475B2 (en) 2017-12-19 2022-09-20 Bristol-Myers Squibb Company Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
US11008300B2 (en) 2017-12-19 2021-05-18 Bristol-Myers Squibb Company Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists
US11261174B2 (en) 2017-12-19 2022-03-01 Bristol-Myers Squibb Company Pyrazole O-linked carbamoyl cyclohexyl acids as LPA antagonists
US11697646B2 (en) 2017-12-19 2023-07-11 Bristol-Myers Squibb Company Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
WO2019126087A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as lpa antagonists
RU2818246C2 (en) * 2018-06-18 2024-04-26 Эпиджен Байосайенсиз, Инк. Heterocyclic compounds used in treating disease
US11548871B2 (en) 2019-11-15 2023-01-10 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
US11999717B2 (en) 2019-11-15 2024-06-04 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
US11584738B2 (en) 2020-06-03 2023-02-21 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
US11912686B2 (en) 2020-06-03 2024-02-27 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
US11980609B2 (en) 2021-05-11 2024-05-14 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
US11884627B2 (en) 2022-02-25 2024-01-30 Lhotse Bio, Inc. Compounds and compositions for treating conditions associated with LPA receptor activity

Also Published As

Publication number Publication date
GB2474748B (en) 2011-10-12
AU2010300594A1 (en) 2012-05-17
US8778983B2 (en) 2014-07-15
US20110082164A1 (en) 2011-04-07
CN102770415A (en) 2012-11-07
MX2012003723A (en) 2012-05-08
IN2012DN02730A (en) 2015-09-11
EP2483269A2 (en) 2012-08-08
UY32923A (en) 2010-11-30
WO2011041462A3 (en) 2011-08-11
WO2011041462A2 (en) 2011-04-07
CN102770415B (en) 2014-09-24
AR078495A1 (en) 2011-11-09
BR112012007102A2 (en) 2016-04-26
US20140256744A1 (en) 2014-09-11
CN102656168A (en) 2012-09-05
JP2013506679A (en) 2013-02-28
EP2483251A4 (en) 2013-05-01
PE20120997A1 (en) 2012-08-01
WO2011041461A3 (en) 2011-08-25
CL2012000812A1 (en) 2012-09-07
CN102656168B (en) 2015-04-01
US8664220B2 (en) 2014-03-04
CA2776779A1 (en) 2011-04-07
GB201016312D0 (en) 2010-11-10
EP2483251A2 (en) 2012-08-08
JP2013506680A (en) 2013-02-28
EP2483251B1 (en) 2016-10-26
TN2012000126A1 (en) 2013-09-19
TWI415849B (en) 2013-11-21
EP2483269A4 (en) 2013-05-01
US20130072490A1 (en) 2013-03-21
KR20120097490A (en) 2012-09-04
IL218962A0 (en) 2012-07-31
US10000456B2 (en) 2018-06-19
IN2012DN02702A (en) 2015-09-04
TW201125862A (en) 2011-08-01
GB2474748A (en) 2011-04-27
EA201270467A1 (en) 2012-09-28

Similar Documents

Publication Publication Date Title
US8778983B2 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
EP2438048B1 (en) Polycyclic antagonists of lysophosphatidic acid receptors
US8217066B2 (en) Compounds as lysophosphatidic acid receptor antagonists
KR101323054B1 (en) Antagonists of lysophosphatidic acid receptors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080054537.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10821201

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12012500572

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2702/DELNP/2012

Country of ref document: IN

Ref document number: MX/A/2012/003723

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 218962

Country of ref document: IL

Ref document number: 12053559

Country of ref document: CO

Ref document number: 000410-2012

Country of ref document: PE

ENP Entry into the national phase

Ref document number: 20127008251

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2776779

Country of ref document: CA

Ref document number: 2012532286

Country of ref document: JP

Ref document number: 2010821201

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1201001438

Country of ref document: TH

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012000812

Country of ref document: CL

WWE Wipo information: entry into national phase

Ref document number: 2010300594

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 201270467

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2010300594

Country of ref document: AU

Date of ref document: 20100929

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012007102

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012007102

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120329